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CHAPTER I
INTRODUCTION
Background
Chronic kidney disease (CKD) has emerged as one of the major public health issues worldwide.
In the United States, it has been estimated that 14% of the adult population suffers from CKD
(defined by an estimated glomerular filtration rate of <60ml/min/1.73m2) [1]. Moreover, 580,
741 patients in the US are already reaching the end stage of renal disease (ESRD) (1752 per
million population) and an additional 200,000 people will develop ESRD in the next 10 years
[2]. Once diagnosed with ESRD, one needs to undergo renal replacement therapy (RRT) as a
life-saving treatment. The most common RRT modality in the United States is hemodialysis
(HD) which account for 98% of total ESRD patients on dialysis [1].
ESRD patients experience alarmingly high rates of cardiovascular complications.
Cardiovascular diseases (CVD) account for 50% of mortality in ESRD patients which is 15-30
times higher than the age-matched general population [3-5]. Pathophysiology of CVD in this
population is complex as it involves traditional CVD risk factors as well as non-traditional risk
factors specific to the uremic population. It is well known that dialysis patients experience
chronic inflammation due to various dialysis and non-dialysis factors. Because the dialysis
procedure forces one’s blood through a dialyzer membrane, blood contact with a
nonbiocompatible membrane or with non-sterile dialysate solutions and an impure dialysate
triggers the inflammatory process [6]. However, dialysis factors themselves may not be the
major factors for instigating the inflammatory process, because CKD patients not yet on dialysis
also have high a incidence of inflammation [6-8].
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In addition, another comorbid condition that is highly prevalent in ESRD patients is
protein-energy wasting (PEW), which is by far the strongest predictor for adverse outcome and
mortality [9]. PEW is characterized by a loss of muscle mass, unintentional weight loss and a
significant decline in nutritional parameters such as albumin and prealbumin [10]. Low serum
albumin (hypoalbuminemia) in this population is partly due to inadequate energy and protein
intake, loss of amino acid/protein during dialysis, and/or volume overload as a result of noncompliance to fluid restriction. Because albumin contains thiol moieties, which is the most
important antioxidant in the plasma, low plasma albumin correlates with diminished plasma total
antioxidant capacity which provides a pathophysiological link to cardiovascular mortality in
ESRD patients with hypoalbuminemia [11]. Furthermore, PEW and inflammation often occur
concomitantly in HD patients (referred together as the malnutrition-inflammation complex
syndrome, MICS). As a matter of fact, persistent inflammation is responsible for a cascade of
reactions that causes an increase in resting energy expenditure, loss of muscle mass and
oxidation [12] which eventually exacerbates PEW.
Oxidative stress, defined as an imbalance between the pro- and anti-oxidant system, is
highly elevated in HD patients as compared to healthy-matched control [11, 13, 14]. Impaired
oxidative balance in HD patients is partly attributed to increased reactive oxygen species
production, reduced clearance, and a poor antioxidant defense system [14]. Oxidative stress is
linked to CVD because of its involvement in oxidative modification of low-density lipoprotein
(LDL). Oxidized LDL instigates a cascade of reactions including adhesion of circulating
monocytes on endothelial cells, migration of monocytes into the arterial intima and platelet
activation, and expression of tissue factor by endothelial cells [14].
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Furthermore, advanced CKD patients including ESRD on dialysis also develop
dyslipidemia characterized by impaired synthesis and activity of high-density lipoprotein (HDL)
and delayed catabolism of triglyceride-rich apo B containing lipoprotein, which subsequently
leads to elevated triacylglycerols (TAG) and low plasma HDL cholesterol (HDLC) [15].
Accumulating evidence indicates that the concentration of plasma apo-A1 and lecithincholesterol acyl-transferase (LCAT) are decreased [16, 17] which in turn impedes HDLmediated reverse cholesterol transport [18], a process for disposing excessive cholesterol from
extra hepatic tissues and blood vessel walls. As oxidative stress is highly prevalent in ESRD
patients, byproducts of oxidation reactions can be involved in oxidative modification of
lipoproteins which consequently can disrupt the protective effects of HDL against atherosclerosis
[18]. Taken together, a combination of MICS coupled with oxidative stress and dyslipidemia is
highly conducive to exacerbating atherosclerosis in the HD population.
Rationale for the current project
Although much knowledge have been gained in understanding the complex pathophysiology of
CVD in this population, multifaceted clinical interventions aimed at improving CVD outcome in
HD patients have been marginally successful. This is evident with from the fact that two thirds of
dialysis patients die within five years of commencing dialysis predominantly related to CVD
[19] despite substantial improvement in dialysis therapy. In fact, mortality rates in ESRD
patients in the US (>20% per year), is worse than many fatal cancers [1, 20]. Some major clinical
trials that failed to demonstrate beneficial results of improving mortality and CVD outcomes
include AURORA [21], 4D trials [22] (both studies used lipid lowering therapy approach) and
HEMO trial (increased dialysis dose)[23, 24]. Interestingly, two clinical trials that used ‘dietary
intervention’ as a mean to improve cardiovascular outcome showed promising results. Off the
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two, one study – ‘Secondary Prevention with Antioxidants of Cardiovascular Disease in End
Stage Renal Disease (SPACE)’ demonstrated that supplementation with 800IU of vitamin E per
day resulted in reduction of overall mortality and morbidity based on composite cardiovascular
end points [25]. Additionally, a recent observational study in 1046 diabetic hemodialysis patients
demonstrated that patients with the lowest tertiles of plasma α-tocopherol had a 79% higher risk
of stroke and 31% higher risk of all-cause mortality compared to those with the highest tertiles
[26], which exemplifies the role of maintaining adequate dietary vitamin E/antioxidant intake.
Taken together, from the nutritional stand point, an effective yet a safe therapeutic approach is
needed to reduce comorbid conditions in this population. Nevertheless, dietary strategies to
correct these problems have been inconclusive.
Recommendation for Omega-3 fatty acids studies in HD population stemmed from the
fact that these nutrients have been shown to possess anti-inflammatory, anti-oxidative and lipid
altering properties in vivo, in vitro and also in a clinical setting [27-30]. Furthermore, the fact
that HD patients have lower plasma and erythrocytes levels of omega-3, (among the lowest as
compared to the other clinical population [31]) related to dietary monotony [32] and a high
inflammatory and oxidative milieu, exemplify the needs for dietary intervention studies.
However, current level of evidence is still controversial to mandate incorporation of this nutrient
into standard nutritional care of HD patients as a mean to prevent CVD.
Similarly, vitamin E tocotrienols (TT) recently have received great scrutiny due to their
superior biological activity and therapeutic benefits as compared to tocopherols (TP) [33-35].
TT have been reported to confer antioxidant protection from oxidative damage [36], have antiinflammatory properties [37] and are potentially cardioprotective due to their lipid altering
properties [38]. Taken together, the fact that ESRD patients undergoing HD are at high risk for
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cardiac mortality related to widely prevalent malnutrition, inflammation, heightened oxidative
stress and dyslipidemia, therefore, dietary intervention to evaluate the effectiveness of these
nutrients to reduce the aforementioned co-morbid conditions is recommended [6].
However, the global impact of such dietary intervention in a diverse clinical population is
difficult to interpret, partly due to 1) inter-individual variation in the response against dietary
intervention; 2) the existence of various confounding factors such as the difference in underlying
comorbidities, medication profile, genetic makeup and socioeconomic disparities; 3) lack of
effective approach to accurately account for compliance/non-compliance towards the
intervention and 4) the nature of traditional biomarkers that are unable to provide a complete
picture to reflect the effect of such intervention. With the emergence of ‘omics’ technology, a
comprehensive systematic and simultaneous profiling of the complete set of metabolites is now
possible [39, 40]. Given that, metabolomics approach has been used in various fields including
investigating the postdose drug effects vs predose metabolic profiles [41], studying drug toxicity
and gene function [42], evaluating the progression of disease [43] and determining changes in
metabolite excretion profiles following dietary changes [39], we therefore sought to apply
metabolomics to understand a broader spectrum regarding the effects of these nutrients in HD
patients.
Specific aims of the current project
The objective of this study was to investigate the effects of supplementation with nutrients
having anti-inflammatory and antioxidant properties on nutritional, lipids, inflammatory and
oxidative status. The central hypothesis of the present study was that supplementation with
protein as an anabolic nutrient; omega-3 fatty acids and tocotrienol rich fraction (TRF) as anti-

	
  

6
	
  

inflammatory and antioxidant nutrients; will improve nutritional status, lipid profiles, as well as
inflammatory and oxidative stress markers. The rationale for the proposed studies was that once
the effects of these nutrients are established, larger clinical trials can be performed to establish
clinical evidence in order to accommodate incorporation of these nutrients into dietary regimen
of HD patients as an adjunct therapy to attenuate co-morbid conditions in these patients.
Accordingly, the following specific aims were established;

Specific aim 1: To document the global effects of protein and omega-3 supplementation on
nutritional status and inflammatory markers in chronic hemodialysis patients.

Specific aim 2: To document the global effects of TRF supplementation on nutritional indices,
inflammatory markers, oxidative status and lipid profiles in chronic hemodialysis patients.

Specific aim 3: To determine changes in metabolomics profiles following TRF supplementation.
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CHAPTER II
REVIEW OF LITERATURE
Overview of kidney structures and functions
The kidneys are a pair of bean shape organs located retroperitoneally between the transverse
process of T12-L3 vertebrae, with the left kidney located on a slightly superior position than the
right kidney. Each kidney weighs ~ 150g and 135g in males and females, respectively. Despite
representing less than 1% of total body weight, the kidneys receive approximately 20% of the
cardiac output, which is the highest blood flow of all the larger organs in the body, filtering ~
1600 L of blood/day. The blood supplies for the kidneys originate from the paired renal arteries
at the level L2 of the vertebrae. Each kidney comprised of more than a million functional units –
called nephrons. Each nephron consists of different functional segments with a typical cellular
appearance; the renal corpuscle (glomerulus and bowman capsule), proximal convoluted tubule,
descending loop of Henle, ascending limb, distal convoluted tubule and the collecting duct [44,
45].
The kidneys serve important functions, including maintaining homeostatic balance with
regards to fluids, electrolytes, organic solutes and acid-base balance. In the renal corpuscle,
perfusion pressure of the glomerulus forces molecules smaller than 6500Da to pass through
semipermeable membrane of the glomerulus into Bowman capsule as filtrate. About 80% of the
blood entering glomerulus returns to the blood stream while the remaining 20% become filtrate.
However, 99% of the filtrate will be reabsorbed via renal tubules and only 1% of the filtrate is
excreted as urine. This process is achieved via a unique structure of renal tubules with varying

	
  

8
	
  

permeability between segments and hormonal regulation allowing the kidney to produce a final
urine with diverse concentration of electrolytes, osmolality, pH and volume [45].
Kidneys also play substantial roles (not related to excretion) as in the regulation of blood
pressure that is achieved via renin-angiotensin mechanism. Granular cells of the juxtaglomerular
apparatus in the kidneys secrete renin which catalyzes the formation of angiotensin I from a
plasma globulin, angiotensinogen. Angiotensin I is further converted into angiotensin II, a strong
vasoconstrictor causing constriction of the blood vessels and subsequently increased blood
pressure. Angiotensin II also contributes to the increase in blood volume by increasing water and
sodium reabsorption via stimulation of aldosterone hormone [44, 46].
Moreover, renal corticointerstitial cells of the kidneys produce erythropoietin (EPO),
which plays a vital role in maturation of erythrocytes in the bone marrow and other nonhomopoietic roles such as a neuroprotective agent in the response to neuronal injury in the brain
[47] and in the wound healing process mainly by improving vascular perfusion [48]. Another
function of the kidney includes the maintenance of calcium-phosphorus homeostasis. This is
achieved via a complex interplay of various effector organs (the guts, kidney and bone) and
hormones (parathyroid hormone, calcitonin and active vitamin D) – the kidney role in this
process includes activation of vitamin D and excretion of phosphorus and calcium [45]. The
diverse role of kidney is summarized in Table 2-1.
Chronic kidney disease and end-stage renal disease
Definition
Chronic kidney disease (CKD) is defined as progressive, irreversible abnormalities in kidney
structure and function, present for more than three months which has implication for health [49].
Based on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical guidelines, CKD is
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classified based on cause, glomerular filtration rate (GFR) category and albuminuria category
[49]. Given the difficulties to accurately measures GFR in clinical settings, it is often estimated
using mathematical calculation based on serum creatinine levels, demographic and
anthropometric parameters [50]. Based on the estimated GFR (eGFR) patients with CKD are
classified from G1 (normal/reduced kidney functions) to G5 (kidney failure). However, it should
be noted that decrease in GFR alone is not an absolute criterion for kidney damage diagnosis but
rather should be manifested by either pathological abnormalities or markers of kidney damage
such as abnormalities in imaging test and composition of the blood and urine [49, 51]. Among
individuals with CKD, one is typically considered as end-stage renal disease (ESRD) when GFR
is severely reduced to <15ml/min/1.73 m2 (Table 2-2) and this is accompanied with clinical
symptoms mandating the need for lifelong renal replacement therapy (RRT) to maintain survival.
Incidence and Prevalence
In the United States incident of end-stage kidney disease rose steadily since 1980 to 2001, but
has leveled off since then to approximately 350 people per million population (pmp) [1]. When
these data are compared to other well developed nations, ESRD incidents in the US range from
twice to thrice as much of those in the United Kingdom, France, Denmark, Russia, New Zealand,
Australia and most European countries (Figure 2-1).
In term of ESRD prevalence, United States continues to report one of the highest rates
(1870 pmp), just behind Taiwan (2584 pmp) and Japan (2260 pmp). In contrast, other affluent
countries such as the United Kingdom, Sweden, France and Australia have reported prevalences
rate twice as low as in the US [1].
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Etiology
Uncontrolled underlying chronic diseases such as Diabetes Mellitus (DM) and hypertension are
the most common causes of ESRD. Based on the United States Renal Data System, 41% of
incident ESRD cases are due to DM (718 cases pmp), follow by hypertension (477 cases pmp),
glomerulonephritis (274 cases pmp) and polycystic kidney diseases (92 cases pmp).
Internationally DM is reported as a primary cause of ESRD in more than 60% of the new ESRD
patients in Mexico, Singapore and Malaysia, while Russia, the Netherland, Norway and Romania
reported rates below 20% [1]. Other rare causes include autoimmune disease (especially
systemic lupus erythematous associated nephritis), tubular interstitial nephritis, drug toxicity and
glomerular diseases caused by hepatitis B, C and HIV viruses.
Uncontrolled DM contributes to functional changes in glomeruli including hyperfiltration
and hyperfusion, subsequently leading to histological alteration of the nephron, increasing
capillary permeability to macromolecules characterized by micro and macroalbuminuria
(>300mg/day). This is accompanied by structural changes including glomerular basement
thickening and hypertrophy, as well as mesangial expansion leading to glumerolosclerosis and
tubulointerstitial fibrosis. Metabolic processes such as hyperglycemia and hormonal mediators
including glucagon and growth hormones are implicated in diabetic nephropathy, over time,
leading to overt proteinuria, azotemia and culminating in ESRD [52].
Treatment Modalities
Patients with advanced CKD (stage G4/5) may eventually deteriorate to the degree that the
remaining kidney functions are unable to keep them off from significant kidney failure
symptoms. Some of the severe symptoms include excessive fluid overload leading to congestive
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heart failure, severe nausea, vomiting, confusion/decrease alertness and seizures. Moreover,
certain electrolytes such as sodium, potassium or bicarbonate could be dangerously elevated,
affecting functionality of the organ. This is commonly occurring when eGFR is
<15ml/min/1.73m2, however some patients might be more symptomatic at a higher eGFR [46].
Therefore, RRT is needed at this point to limit clinical symptoms and to maintain their survival.
There are several options of RRT available including different forms of dialysis (e.g.
hemodialysis, peritoneal dialysis) and kidney transplantation. In-center hemodialysis (HD) is the
most common type of treatment modality in the US accounting for 98% of the total dialysis
patient population [1].
In HD procedure, patient’s blood is pump through semipermeable membrane dialyzer in
the extracorporeal circuit, while dialysate (solution containing sterilized mineral ions,
bicarbonate and glucose [53]) is flowing in the opposite direction of the blood flow (Figure 2-2B). Removal of waste solutes and fluid is achieved by the principle of hydrostatic pressure and
diffusion across the concentration gradient. Because HD required permanent access to blood
stream during each treatment, vascular access either via an arteriovenous fistula, arteriovenous
graft or intravenous catheter has to be created. Patients undergoing in-center chronic HD
treatment typically attend the clinic for three times a week for three to four hours per treatment.
During HD procedure, blood is drawn out from the access route at a rate of 200-400 mL/min
while patient is closely monitored for changes in blood pressure.
Meanwhile, peritoneal dialysis use similar principle as HD, except the fact that it uses
the patient’s own peritoneum membrane to remove waste solute and fluids (Figure 2-2-A). In
this process, a dialysate fluid is introduced into the abdominal cavity through a permanent
catheter implanted in the abdomen. This dialysate fluid (containing sterile mineral ions,
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bicarbonate and glucose) remains in the patient’s abdominal cavity (4-6 hours) to allow waste
solutes to exchange across the concentration gradient before removal and replacement with new
ones. This process is repeated at least four times a day for patients undergoing continuousambulatory peritoneal dialysis treatment.
Kidney transplantation (Figure 2-2-C) offers a better prospect as compared to dialysis
provided that the transplanted kidney functions successfully. However, RRT is still dominated by
HD in large due to shortage of donor kidneys [54]. In this procedure, a compatible kidney from
living/deceased donor is transplanted into the patient’s pelvis and connection is made into the
artery and vein, including surgical incision of the transplanted ureter into the bladder. Patient
receiving a kidney transplant needs to also rely on immunosuppression drugs to avoid rejection.
Complications
In CKD, as GFR is decreased the capacity to respond to the intake of minerals, water and other
solutes become less flexible due to reduced number of functional nephrons, leading to the
accumulation of solutes and water in the body. Compounds that are normally being excreted
such as phosphates, sulfates, uric acids and hydrogen ions are subsequently retained in the body
as the disease progresses. Retention of hydrogen ions results in metabolic acidosis, a clinical
disturbance characterized by increased plasma acidity that could lead to disturbance of several
organs system. In addition, toxic compounds such as phenols, guanidine, organic acids, indols,
polyamines β2-microglobulin and some other trace elements will accumulate leading to
hormonal deficiency and the inability to respond to stimuli (e.g. insulin resistance,
eryhthropoietin resistance) [46].
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Accumulation of blood urea and other toxic compounds that normally are being excreted
by the kidney could leads to uremia. Uremia is a clinical syndrome due to imbalance of body
fluids, electrolytes, hormones and metabolic abnormalities that occur following dysfunctional
kidneys [46]. Some common signs and symptoms of uremia includes neural and muscular
manifestation (e.g. fatigue, peripheral neuropathy, decrease mental acuity, anorexia and nausea,
restless legs, cramps, decrease sense of smell and taste), endocrine and metabolic affects
(amenorrhea, reduce body temperature, increased protein-muscle catabolism), while severe
untreated uremia could lead to seizures, coma and cardiac arrest	
   [54]. Uremia could also lead to
oxidative stress and oxidation of macromolecules as evident by increased levels of reactiveoxygen species (ROS), oxidized plasma proteins and lipids [55].
Anemia (as defined by hemoglobin levels ≤ 13g/dL for men and ≤ 12 g/dL for women
[32]) is another common complication of ESRD. Hemoglobin <11 g/dL are often associated with
lower quality of life and increased cardiovascular mortality and morbidity [56]. Anemia in CKD
and ESRD patients has multifactorial physiopathology but it is generally accepted that it may
occurs due to the decreased in erythropoietin production as result of the loss of functioning renal
tubular mass. In dialysis patients, protein-energy malnutrition and chronic infection lead to
erythropoietin resistance and anemia [57]. Inflammation could also affect mucosal absorption of
ferum and trigger gastric bleeding which further exacerbates anemia in ESRD [58]. Anemic
condition leads to prolonged fatigue, decreased immune functions and increased workload of the
heart resulting in ventricular hyperthrophy, a risk factor for CVD[59]. Chronic anemic patients
also experience fluid and sodium retention, high cardiac output and reduced oxygen carriage in
the circulation [60]. Moreover, anemia could also induce a series of cardiovascular and
neurohormonal compensations including increased plasma norephineprine, renin activity,
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aldosterone, growth hormone and arterial natriuretic peptide that could have injurious
cardiovascular complications in long-term [60].
Furthermore, ESRD patients often experience bone and mineral disorders characterized
by hyperphosphatemia, hyperparathyroidism and systemic deficit in activation of vitamin D. A
cascade of changes in the metabolism of calcium, phosphorus and vitamin D occurs following
reduction of GFR leading to these disorders. As GFR is reduced, activity of 1α-hydroxylase
enzyme declines, causing impaired conversion of vitamin D into its active form and subsequently
limiting calcium absorption from the intestinal tracts. On the other hand, phosphorus levels in the
blood are increased due to decreased renal tubular functions. Because vitamin D is also needed in
suppression of the production of parathyroid hormones (PTH), reduced vitamin D levels (the
active form) together with reduced serum calcium lead to overproduction of PTH in a
counteregulatory action to release calcium from the bones store [61]. Ironically, increased in
serum phosphorus levels (hyperphosphatemia) further exacerbate PTH production leading to
hyperparathyroidism.
Although dialysis is an effective treatment to alleviate the adverse effect of uremia, some
residual uremic toxins remain [62]. This is evidenced by high mortality rate, poor quality of life
and high hospitalization rates in patients undergoing dialysis despite advancement in dialysis
technology.

It has been estimated that more than 20% of ESRD patients undergoing HD

treatment die due to uremia and treatment complications [20].
ESRD main complication: cardiovascular diseases
Cardiovascular disease (CVD) is a major complication affecting CKD and ESRD population. It
has been estimated that cardiovascular death accounts for more than 50% of mortality in ESRD
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patients undergoing HD treatment [19]. Common forms of CVD occurring in this population
include acute myocardial infarction and several forms of atherosclerotic vascular diseases (e.g.
chronic coronary artery disease, stroke and transient ischemic attacks)	
  [5].
Atherosclerosis is an inflammatory process initiated by several factors including
accumulation of LDLs in the artery wall [63, 64]. When plasma LDL levels exceeds certain
threshold, they enter artery faster than they can be removed leading to their accumulation [63].
Because accumulated LDLs are prone to oxidation, the oxidative stress milieu in ESRD patients
exaggerates the acceleration of atherosclerosis in part by modification/oxidation of LDLs [64].
The modified LDLs trigger endothelial cells to express a protein known as monocyte
chemotactic protein-1 (MCP-1), which in turn attracts monocytes into the arterial wall and
promotes their differentiation to macrophages. Macrophages engulf oxidized LDLs via their
scavenger receptor and express several cytokines including tumor necrosis factor alpha (TNF-α),
interleukin-1 (IL-1) which activates endothelial cells to express adhesion molecules (e.g. Eselection, VCAM-1 and ICAM-1). Formation of lipid-filled foam cells following macrophages’
ingestion of LDLs and the binding of monocytes to the endothelium by adhesion proteins marks
the beginning phase of atherosclerosis [63].
Evidence from autopsy and clinical investigation has demonstrated that coronary artery
plaques are highly prevalent in patients with advanced kidney disease [64, 65]. Figure 2-3
summarizes the atherogenesis/ coronary artery plaque development processes. As reviewed by
Stenvinkel et al [64], during the early phase of atheroma, prolonged inflammatory conditions and
persistent dyslipidemia result in increased susceptibility to oxidation of lipids and other
macromolecules. Fatty streak is developed following recruitment of inflammatory cells and the
accumulation of foam cells. Degradation of extracellular matrix occurs when the activated
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leukocytes secreted proteinase, and proinflammatory cytokines stimulated T helper cell type 1
(Th1) which could limit the synthesis of new collagen, thinning the fibrous cap and making it
susceptible to rupture. When the rupture occurs, coagulation of the blood on the plaque caused
the formation of thrombus and manifested as an acute coronary syndrome [64].
Various factors have been postulated to be involved in the increased cardiovascular
burden in ESRD as illustrated in Figure 2-4. Briefly, ESRD patients undergoing chronic HD are
exposed to various conditions that increase the cardiovascular diseases burden including 1)
underlying co-morbid conditions such as diabetes; 2) uremic residuals which triggers
inflammatory modulation, heightened oxidative stress and influences appetite and food intake; 3)
dialysis technique related factors that could worsen inflammatory responses and nutrient losses;
4) undesirable outcome of dietary restrictions (e.g. limited intake of antioxidants due to
restriction of certain fruits and vegetables) and 5) genetic factors and racial disparities (as
reviewed by Kalantar-Zadeh & Balakrishnan [66]).
Dyslipidemia
A number of factors contribute to the accelerated atherosclerosis in ESRD population. One of
them is dyslipidemia which in some studies reported the prevalence rate as high as 80% [67, 68].
Dysregulation of lipid metabolism in this population is characterized by hypertriglyceridemia,
elevated very low-density lipoprotein (VLDL) and reduced plasma HDLC. Interestingly, plasma
levels of total cholesterol and LDLC are usually within normal limits [15].
In normal metabolism, liver secretes TAG rich VLDL into the circulation. Lipoprotein
lipase (LPL), an endothelial enzyme, converts TAG in VLDL into free fatty acid, allowing
uptake and utilization by peripheral tissue. As VLDL loses its TAG content, it becomes
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intermediate density lipoprotein (IDL) and eventually LDL that is rich in cholesterol. LDL
delivers cholesterol to extrahepatic tissue for synthesis and maintenance of cell membrane. HDL
on the other hand is involved in reverse-cholesterol transport system, by removing excess
cholesterol from extrahepatic cells via several mechanisms. HDL acquires lipids by: 1) action of
ATP binding cassette transporter A-1 (ABCA1) that mediate the transfer of phospholipids and
some unesterified cholesterol; 2) lecithin cholesterol acyltransferase (LCAT) that converts free
cholesterol on the surface of nascent HDL into cholesteryl ester before sequestering it into the
core of HDL particle - this step is important to ensure maximum uptake of cholesterol from
extrahepatic tissue and maturation of HDL particle. HDL can unload its cholesterol either
through binding with SR-B1 for liver uptake/excretion in bile or by transferring it to VLDL/LDL
in exchange of TAG, mediated by cholesteryl ester transfer protein (CETP) [63]. However, the
indirect pathway (i.e. through CETP) is believed to be pro-atherogenic due to the transfer of
cholesterol from HDL to the pro-atherogenic VLDL/IDL [63].
In ESRD patients, despite having normal or even subnormal plasma total cholesterol,
they are at high risk of atherosclerotic vascular diseases [69]. This is partly contributed by a
delayed TAG rich lipoprotein catabolism which is illustrated in Figure 2-5. ESRD induced
deficiencies of LPL that is responsible for removal of two-third of fatty acids content on VLDL
for uptake by extrahepatic tissues [70]. This lead to accumulation of ApoB-containing
lipoproteins (TAG rich) which are highly atherogenic because they are readily oxidizable and
taken up by macrophages leading to formation of foam cells in the artery walls [69].
Vaziri et al [18, 69] reviewed evidences to explain lower HDL particle and its cholesterol
contents in ESRD. Based on these evidences, it is summarize that: 1) hepatic expression and
production of ApoA1, which is the principal protein component of HDL particle is decreased; 2)
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expression of acyl-CoA:cholesterol acyltransferase-1 (ACAT) is increased – this cause retention
of cholesterol within the cells due to entrapment of free cholesterol from HDL uptake; 3) hepatic
production and activity of LCAT is reduced; and 4) HDL uptake by the liver for removal and
degradation occurs via HDL endocytic receptor (irreversible) instead of SRB1 (reversible).
Several lines of evidence also indicate that activity of CETP is increased in this population [71].
CETP mediates the transfer of cholesterol ester from HDL to VLDL remnants in exchange for
TAG. In summary, CKD/ESRD induces dyslipidemia which causes increased influx, impaired
efflux leading to accumulation of lipids in the artery walls which is believed to accelerate
atherosclerosis in this population.
Malnutrition, inflammation, oxidative stress and their relation to CVD
Malnutrition, inflammation and oxidative stress interlink has been recognized as the ‘evil axis’
for poor survival rates in dialysis patients [20]. This is based on the fact that up to two third of
dialysis patients show evidence of protein energy malnutrition, chronic inflammation and
increased oxidative stress. In fact, nutritional and inflammatory markers such as serum albumin,
CRP and IL-6 have been identified as the strongest predictor for mortality and morbidity in this
population [72, 73]. It is believed that there is overlap between malnutrition and inflammation in
term of their mechanism and their relation to CVD in this population [74]. A brief discussion on
each of these components follows:
Malnutrition
Malnutrition is highly prevalent in ESRD population. It has been reported that, malnutrition
present in 18-70% of ESRD patients undergoing hemodialysis [75]. Various terms have been
used to describe a syndrome of adverse changes in body composition, inadequate nutritional
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intake, and loss of protein/energy stores in this population. These terms include malnutrition,
protein-energy-malnutrition, malnutrition-inflammation-atherosclerosis syndrome, and uremic
cachexia [75]. However, the International Society of Renal Nutrition and Metabolism (ISRNM)
suggests the use of the term - protein energy wasting (PEW) - to describe concurrent losses in
protein and energy stores and facilitate the diagnosis and identification of this condition [12].
Based on the consensus statement by ISRNM, the etiology of PEW in this population is
multifactorial and not limited to insufficient dietary intake alone [12]. In fact, uremic milieu is
speculated to be responsible for alteration in appetite-regulating hormone such as ghrelin,
resulting in chronic anorexia [76]. Moreover, HD patients also experience 12 to 20% increase in
resting energy expenditure related to HD procedure [77], or the presence of comorbidities.
Hypercatabolism in this population is also linked to persistent inflammation. Inflammation
contributes to PEW by several mechanisms: 1) increase resting energy expenditure that triggers
starvation response even in well-fed individuals [12, 78]; 2) pro-inflammatory cytokines such as
tumor necrosis factor (TNF) and interleukin (IL) cause muscle protein breakdown [79] and act
on the central nervous system to decrease appetite leading to anorexia [80]; and 3) the increase in
positive acute phase protein (i.e. CRP) leads to decreases in visceral protein stores (e.g. by
reducing synthesis and half-life of serum albumin) [81]. In addition, dialysis procedure itself is
also catabolic in nature, contributing to PEW by causing nutrient losses, triggering inflammatory
response and leading to loss of residual renal function [12]. Potential causes of PEW are listed in
Table 2-3.
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Inflammation
Inflammation can be defined as a complex body response to injury [82], destruction of tissue or
harmful stimuli characterized by production of cytokines (e.g. interleukins and tumor necrosis
factor) which in turn stimulate secretion of acute phase protein (C-reactive protein). The initial
reaction in response to damaging stimuli is normal; however, persistent inflammation is harmful
as it may result in organ and vascular damage.
In ESRD population, inflammation is relatively an old problem that has been reported
since 1980s [6]. However, only recently has chronic inflammation been recognized as an
established risk factor that plays a central role in various co-morbidities especially CVD, PEW
and is an independent predictor for mortality [6]. Pathophysiology of chronic inflammation in
ESRD patients is complex due to its inter-twined relation with PEW, however each contributes
independently to mortality risk [11]. Common causes of chronic inflammation that are
traditionally reported include foreign body exposure (e.g. arteriovenous graft and dialyser),
depletion of antioxidant, oxidative stress, and pre-existing co-morbid diseases [74, 83]. Some
other causes include intercurrent clinical events (e.g. periodontal diseases) and dialysis related
causes (e.g. infection of dialysis access and volume overload) as presented in Figure 2-6.
Pro-inflammatory cytokines have been postulated to induce and mediate the lean body
mass catabolism in dialysis patients, however their exact role is not completely understood. One
of the mechanisms proposed is through impairment of insulin signaling activity (e.g. suppression
of insulin receptor-1-associated phosphatidylinositol 3-kinase activity) which subsequently leads
to stimulation of ubiquitin-proteasome proteolytic system and activation of caspase-3 [84, 85].
Similarly, pro-inflammatory cytokines also suppress the expression and function of insulin-like
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growth factor-1, which is an anabolic growth factor [86]. Moreover, IL-1 and TNF-α also have
been shown to cause anorexia by acting on central satiety center, leading to suppressed food
intake [85]. Taken together, pronounced catabolic effects of pro-inflammatory cytokines on
muscle catabolism is due to combined suppression of food intake and increased protein
breakdown which subsequently leads to overall poor nutritional status [85].
Oxidative stress – the missing link
Oxidative stress (OS) is defined as a state of imbalance between oxidant production and their
degradation by antioxidant system which leads to accumulation of free radicals such as reactive
oxygen species (ROS) and reactive nitrogen species (RNS). Over 90% of free radical production
occurs during normal process of metabolism such as during metabolism of oxygen in
mitochondria when oxygen that is being passing down the electron transport chain leaks away
and turns into superoxide anion [87]. Additionally, ROS could be synthesized in phagocytic
cells, at the vascular walls, and other tissues following exposure to a stimulus such as the
presence of foreign particle or during inflammatory processes [14, 87]. When OS occurs, it
results in oxidation of various macromolecules such as DNA, lipids and protein [11]. Oxidative
modifications of lipoprotein particles especially LDL is thought to be an important step in the
initiation of atherogenesis [63, 69].
In HD patients, OS has been recognized as an important factor that serves as a missing
link between malnutrition and inflammation. OS is highly elevated in HD patients when
compared to healthy-matched controls [88]. Impaired oxidative balance in HD patients is partly
attributed to increased ROS production, reduced clearance, and poor antioxidant defense system
[14]. Several lines of evidence support the notion that OS is linked to CVD based on the fact that
oxidative modification of LDL, is the initial steps that triggers immune response. Oxidized LDL
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instigates cascade of reactions including adhesion of circulating monocytes on endothelial cells,
migration of monocytes into arterial intima and platelet activation, cytokines release and
expression of tissue factor and by endothelial cells [14].
There are several factors that contribute to the impaired oxidative balance in HD patients.
These include the underlying disease itself, HD procedures, poor dietary antioxidant intake
related to malnutrition and persistent inflammation. Evidence indicates that residual uremic
solutes such as β2m, and homocysteine can become substrate for oxidative modification, thus
potentiating their pathogenicity	
   [11]. HD procedure on the other hand causes solute loss
including enzymatic antioxidants. Furthermore, malnutrition condition, characterized by
hypoalbuminemia also contribute to OS. This is because albumin molecules contain thiol groups
that act as antioxidant in order to maintain plasma milieu in a reduced form. Therefore,
diminished plasma albumin reduces overall plasma antioxidant capacity. Taken together,
inflammation and malnutrition condition will have a synergistic effect on the risk of oxidative
injury in this population	
  [11].
Standard of care for nutrition in HD patients
Patients undergoing chronic HD require a comprehensive nutritional care given the fact that high
prevalence of protein energy malnutrition (PEM) is largely contributed by inadequate nutritional
intake [51]. The goal of the nutritional management for these patients is to maintain a good
nutritional status through adequate energy, protein, vitamin and mineral intake while minimizing
complications associated with uremia by maintaining blood chemistry within normal ranges [45].
It is also crucial to ensure patient’s adherence on fluid restriction, potassium and sodium intake
in order to control edema and electrolytes imbalance, given the limited capacity of HD to
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completely remove fluid and minerals. Often, nutritional management also considers long term
complications of HD such as bone mineral diseases (renal osteodystrophy) by monitoring
phosphorus, calcium and vitamin D intake. All of these are achieved through carefully planned
dietary regimens and periodic counseling from a renal dietitian.
Continuous monitoring of patient’s nutritional status is crucial in order to achieve these
goals. This process includes assessment of visceral protein status, body composition and
nutritional intake. The widely used clinical indicator for assessment of visceral protein store in
HD patients is serum albumin. This is due to the fact that it is readily available and has been
identified as an independent predictor for hospitalization and mortality [85]. Beside that, serum
transferrin and prealbumin levels are also frequently used in monitoring nutritional status. It is
important to note that serum albumin and prealbumin level can fluctuate based upon hydration
status, infection, inflammation and trauma while ferritin can be influenced by changes in iron
stores or the presence of inflammation. Since albumin and prealbumin are negative acute-phase
reactants, it is common to measure C-reactive protein (an acute phase reactant) when their levels
are low. Beside biochemical profiles, simple anthropometric measurements such as weight and
BMI along with diet records are also used to monitor changes in body composition and
nutritional status over time. Furthermore, the use of composite indices comprised of diagnostic
measures of body composition and dietary intake coupled with subjective assessment of overall
well-being is also recommended [85]. One of the commonly used composite indices is
Malnutrition-Inflammation Score (MIS). MIS is a quantitative scoring system that incorporates
components relating nutritional status (BMI, serum albumin, serum total iron binding capacity,
appetite and gastro-intestinal symptoms), functional status and comorbidity [89].
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Standard dietary recommendation for HD patients include energy intake of 35 kcal/kg
body weight (for adult patients <60 years old) and 30-35 kcal/kg body weight for older adults
(>60 years old), while protein intake should be at least 1.2 g/kg body weight with 50% of the
protein being of high biological value. This is the maneuver to prevent protein-energy
malnutrition and to meet the increase in requirement due to the catabolic nature of the HD
treatment. Moreover, controlling mineral intake particularly sodium (<2.0 g /day), calcium (2.0
g/day) and phosphorus (0.8-1.0 g/day) should also be emphasized in order to prevent acute
complications and comorbidities. Standard of care for nutrition in HD patients is summarized in
Table 2-4.
Strategies to reduce CVD
As discussed earlier, inflammation plays a central role in various comorbidities associated with
ESRD including CVD. Carrero and Stenvinkel [6], have outlined treatment strategies in order to
control inflammation and reduce the associated comorbidities (Figure 2-6). These multi-modal
treatment approaches include medical, pharmacological, nutritional and life style interventions.
First and foremost, comorbidities and potential dialysis related causes should be addressed and
treated if possible. These include assessment and treatment for intercurrent illnesses such as
periodontal disease and infectious complications of HD access.
When all of the medical issues have been addressed, it is recommended that various antiinflammatory strategies in the forms of pharmacological, physical and nutritional intervention be
considered. Some of the pharmaceutical products reported to have immunomodulating properties
include statins, pentoxifylline (a nonspecific phosphodiesterase inhibitor with anti-inflammatory
properties) and angiotensin-converting enzyme inhibitor. Furthermore, given that majority of
dialysis patients are physically inactive, resistance training and aerobic exercise could also be
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introduced as several studies indicate beneficial results on inflammation [82, 90, 91]. From the
nutritional standpoints, there are several nutrients that merit further investigation based on
evidence from animal and human studies. These nutrients include omega-3 fatty acids, vitamin
E, and soy isoflavones and genistein. The following discussion will focusing on the two nutrients
that form the basis of this dissertation project, namely, omega-3 fatty acids and vitamin E
tocotrienols.
Potential nutritional agents to reduce co-morbid conditions:
Omega-3 fatty acids
Several different system of nomenclature exists for fatty acids. One of the commonly used is n-x
system (also known as omega-x), which is based on the location of the first double bonds
counted from the methyl therminus. Thus a fatty acid that comprised of two or more double
bonds, one of which is located three or six carbon positions from methyl terminus is called
omega-3 or omega-6, respectively (Figure 2.3). In general, omega-3 fatty acids can be elongated
from α-linolenic acid (C18:3) (ALA) to the longer chain fatty acids [eicosapentanoic acid (EPA)
(C20:5)].

EPA can be further elongated into docosahexanoic acid (DHA) (C22:6) in the

peroxisomes via several complex steps. Because enzymatic conversion of ALA into EPA and
DHA is limited in human, this necessitate reliance on dietary sources in order to maintain
adequate levels of EPA and DHA [92].
Dietary sources and dietary intake recommendation
In the US, average dietary intake of omega-3 fatty acids is about 1.6 g/day or equivalent to 0.7%
of total energy intake [93]. Major dietary source of omega-3 ALA include vegetable oils such as
soybean, rapeseed, flaxseed and also walnuts. EPA and DHA are predominantly from cold-water
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fish with varying concentration among species depending on environmental factors and whether
the fish is farm-raised or wild. Some of the rich sources of EPA and DHA include sardines,
Atlantic salmon, and pacific herring which provide more than 1g per serving size (3 oz.) [94].
Currently, there is no reference for normative range for blood and tissue concentration of
omega-3 fatty acid. Nevertheless, American Heart Association has established evidence-based
guidelines which recommends individuals with documented heart disease to consume about 1g/d
of EHA+DPA [32, 92].

In the nephrology practice, there is no consensus renal dietary

recommendation for omega-3 fatty acid intake, however the recent NKF KDOQI guidelines
recommend for further study to identify the essential fatty acid status in CKD patients [95].
Absorption and transportation
Absorption and transportation of omega-3 fatty acids follow the same route as other long-chain
fatty acids. Upon absorption by intestinal cells, they are resembled into TAG and packaged into
chylomicrons, which are then transported into the thoracic duct via the lymphatic system and
subsequently enter the blood stream for distribution to tissue and finally to be taken up by the
liver.
Epidemiology and observational studies in general population
Earlier epidemiological studies from various population such as Greenlandic Eskimos [96] and
Japanese coastal fishing village residents [97] indicate that higher fish intake were associated
with lower risk for cardiovascular diseases. In the Nurses Health Study, fish intake and omega-3
fatty acids have been reported to have an inverse association with coronary heart disease (CHD).
Women who consumed fish 1 to 3 times per month, once per week, 2 to 4 times per week and >5
times per week had lower risk of CHD death (21%, 29%, 31% and 34%, respectively) when
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compared with women who rarely ate fish

(less than once per month) [98]. Some

epidemiological studies however failed to demonstrate any beneficial association of fish
consumption and CHD / cardiac mortality including Health Professional Follow-up Study
[99]and the US Physician Health Study [100]. It is speculated that the different in the outcome of
these studies are due to differences in experimental design, dietary intake estimation, study
population and variability in the end point studied [94]. It is however beyond the scope of this
dissertation to discuss literature in the non-kidney disease population. Therefore, the following
discussion is streamlined towards omega-3 research in dialysis population.
Omega-3 fatty acids status in dialysis patients
Recommendation for omega-3 fatty acids supplementation in dialysis patients is stemmed from
the fact that omega-3 intake in dialysis population is much lower as compared to healthy control,
partly due to monotony of their diet [32, 92] and non-palatable in taste because of uremia
associated taste alteration	
   [92, 101]. This is also supported by the fact that levels of omega-3
PUFA plasma and cell membranes of HD patients is significantly lower as compared to healthy
subjects	
  [31, 102]. Furthermore, HD patients who are fish eaters have been shown to have much
lower mortality as compared to their counterpart	
   [92]. In term of its cardiovascular effects,
omega-3 has been shown to possess lipid altering properties (especially in reducing TAG),
improved inflammatory markers and improve endothelial function related to its anti-thrombotic
properties	
  [103, 104].
Therapeutic effects of omega-3 fatty acids: lipid altering
The mechanisms involved for the observed effects of omega-3 fatty acids with regards to cardio
vascular health is not clearly understood [94]. The potential mechanism by which omega-3
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confers cardio-protective effects is summarized in Table 2-5. The most established effect of the
omega-3 fatty acids is as a hypotriglyceridemic agent. Majority of the studies reviewed in this
dissertation reported somewhat effects of omega-3 on lipid profiles with supraphysiologic
omega-3 supplementation [29, 105, 106] (Table 2-6). In a longitudinal study by Schmitz and
colleague, 4g daily of fish oil (80% of which containing omega-3 fatty acids) supplementation
resulted in 53% reduction in TAG after 3 months of the supplementation [105]. In another study,
Khajehdehi and colleagues reported that supplementation with 2g omega-3 per day in HD
patients resulted in significant improvement in TC/HDLC, LDLC/HDLC and TAG/HDLC ratios
[29]. Taken together, in hemodialysis patients, there is consistent evidence indicating the
effectiveness of omega-3 supplementation on lipid profiles. This is also in concert with a
comprehensive review of human studies showing that the supplementation of ~ 4g/d of omega-3
fatty acids from fish oil reduced TAG by 25 to 30 percent [104] .
Based on the mechanistic study, it is reported that omega-3 fatty acids can modulate two
important component in lipid homeostasis, namely peroxisome proliferator-activated receptors
(PPARs) and sterol regulatory binding protein (SREBP) [107]. This is partly explained due to
omega-3’s ability to inhibit SREBP conversion from its inactive to active form, affect cellular
composition of the membrane, and bind to PPAR-α and –γ which promote β-oxidation and
adipogenesis [107].
Therapeutic effects of omega-3 fatty acids: anti-inflammatory
Inflammation plays a central role in the accelerated atherosclerosis in HD patients. Friedman and
Moe [92] reviewed several literatures available with regards to omega-3 fatty acids effects in HD
patients, including on inflammatory markers – some of these studies are presented in Table 2-6.
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In a case-control study involving 42 HD patients and 16 age-, gender-matched healthy control,
supplementation with 2.4 g omega-3 fatty acids resulted in reduction of the inflammatory
markers (TNFα and IL-6) [106].

Similarly, Saifullah and colleagues demonstrated that

administration of omega-3 fatty acid with modest dose (1.3 g/day) resulted in 24% reduction in
CRP, a surrogate marker for CVD [108]. In fact, reduction in CRP levels has been found to be
independent of TAG reduction after 6 month of fish oil supplementation using 2 g fish oil daily
(containing 1.6 g omega-3 fatty acids) [109]. However, in a systematic review of all fish
oil/omega-3 fatty acid supplementation in human, it appears that omega-3 fatty acids is
ineffective in reducing inflammatory markers [110]. This however has been criticized due to the
inclusion of studies with relatively small number of subjects in healthy population [108], while it
is generally accepted that the effect of supplementation would be more apparent in population
with heightened inflammatory response such as in HD patients.
Mechanistic explanation of the anti-inflammatory effects of omega-3 fatty acids is
illustrated in Figure 2-8. It is known that arachidonic acid (omega-6 fatty acid) can be converted
into eicosanoid products (e.g. prostaglandins, leukotrienes, thromboxanes, lipoxins and
epoxyeicosatrienoates) via cyclooxygenase, lipoxygenase, or cytochrome P450 arachidonic acid
monooxygenase. Some of these arachidonic acid-derived eicosanoids promote platelet
aggregation, vascular permeability, vasoconstriction and cytokines release; hence their proinflammatory and pro-thrombotic properties are implicated in the pathogenesis of CVD [92].
Because omega-3 fatty acids can incorporate into cell membrane phospholipids, this results in
reduced content of arachidonic acid in the cells. As arachidonic acid is reduced, there is limited
amount of substrate available for the synthesis of pro-inflammatory eicosanoids. In other words,
omega-3 fatty acids exert their anti-inflammatory effects by competing with omega-6 fatty acids
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for the incorporation into the cells and for the enzymes involved in the eicosanoids synthesis
[92]. Moreover, in HD patients, there is a line of evident indicating that the metabolism of
arachidonic acid is shifted from cyclooxygenase pathway to the lipooxygenase pathway, leading
to producing a relatively more pro-inflammatory leukotrines [111]. Therefore, higher levels of
omega-3 fatty acids particularly EPA and DHA could block the lipooxygenase pathway of
eicosanoid production leading to less inflammatory eicosanoids [106, 111]. Reduced proinflammatory eicosanoids may alleviate inflammation by decreasing production of
proinflammatory cytokines, and cell surface molecules such as intercellular cell adhesion
molecules (ICAM) and vascular adhesion molecules (VCAM) that play a critical step in foam
cell formation in the atherogenesis process [92, 112]. In summary, the molecular aspect of
omega-3 fatty acids action on inflammatory response is well understood, however, this is yet to
be translated into a positive outcome in clinical population.
Potential nutritional agents to reduce co-morbid conditions:
Vitamin E tocotrienol
Vitamin E is a group of compounds that possess a chromanol ring with a long chain attached to
its 2-position. There are eight known naturally occurring vitamin E isomers namely α-, β-, δ-, γtocopherol (TT) and tocotrienols (TP) that differ in the number and position of methyl group in
the chromanol ring (three methyl groups in α- isoforms; two methyl groups in β- and γ- isoforms;
one methyl group in δ- isoforms). Vitamin E is a generic term used to describe all TT and TP
isomers that qualitatively exhibit the biological activity of α-tocopherol. TT and TP exhibit
similar chemical structures except the fact that TT possess a farnesyl (unsaturated chain) rather
than a saturated isoprenoid C16 chain [113], characterized by the presence of three trans double
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bonds (Figure 2-4). This explained the fact that TT has greater fluidity and superior cell
accessibility thus confers a distinct biological activity than TP [34, 114].
Dietary Sources
Natural sources of vitamin E are lipid-rich plant products and vegetable oils. The plants
accumulate vitamin E in oily seeds and fruits to prevent lipid peroxidation and protect from
oxygen toxicity [113]. TP are widely available at high concentration in many type of fruits and
vegetable (>0.5mg/100mg edible portions) while TT are limited to certain fruits and vegetable at
a level that usually less than 0.1mg/100mg edible portion [115]. A good sources of TT can be
found in cereal grains such as oat, barley and rye, while the richest natural sources of TT are
found in annatto, palm and rice bran oil [33, 34, 116] (Figure 2-10). Given that, TP particularly
γ-TP is the most abundant vitamin E in the US diet [117].
Absorption and transportation of vitamin E
Absorption mechanism of all vitamin E isomers are fundamentally similar as in other lipid
molecules (reviewed in Rigotti 2007 [118]). Upon digestion, vitamin E is incorporated into
mixed micelles and taken up by enterocytes. The uptake of vitamin E from the mixed micelles is
hypothesized to occur via a simple passive diffusion as well as through intestinal scavenger
receptor class B type I (SR-B1) [118]. However, the detailed cellular mechanism for intracellular
trafficking of vitamin E is remained to be elucidated [118]. Once in the enterocytes, vitamin E is
packed into chylomicron and secreted into the lymphatic system. Several studies indicate that
there is no selective preferential between TP and TT forms – they are absorbed and secreted into
chylomicrons in similar proportion of those occurring in the diet [118, 119]. Anwar and
colleague [120] demonstrated that, an alternative pathways of intestinal vitamin E absorption
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exist – this is occur through HDL-dependent mechanism in which vitamin E is directly secreted
by intestinal epithelial cells into HDL. It is important to note that there is interindividual
variability in intestinal absorption of vitamin E which range from 20 to 80%. This is partly due to
intrinsic differences in expression and activity of SR-B1 and ABCA1, and influenced by the
amount and quality of dietary fat in a meal [118, 121, 122]. Lipoproteins are the major
transporter of lipid soluble antioxidants including vitamin E. Following a meal, chylomicrons
deliver vitamin E to the liver parenchymal cells, while LDL and HDL transport most of vitamin
E under fasting condition for hepatic uptake [118].
Regulation of vitamin E concentration
Biological half-life of TT is relatively shorter than TP (by 4.5 to 8.7 fold); α-, γ-, δ-TT have 2.3,
4.4 and 4.3 hours, respectively vs 20 hours for α-TP [33, 123]. This is explained by the fact that
following hepatic uptake of vitamin E, there is selective preferential for α-TP to being resecreted into the plasma due to differential affinity for various vitamin E forms in α-Tocopherol
Transfer Protein in the following order: α-TP (100%) > α-TT (12%) > γ-TP (9%) > δ-TP (2%)
[124, 125].
Since TP discovery some decades ago by Evans & Katherine Bishop, a vast majority of
studies have been focusing on the therapeutic role of TP [33]. The other forms of vitamin E
compound is remained poorly understood in part due to the abundance of α-TP in human plasma
and lack of bioavailability of the other vitamin E isomers [113]. However, TT have recently
gained increasing scientific attention as current research indicates that they possess a different
therapeutic role than TP due to their eminent anti-oxidative, neuroprotective, antihypercholestrolemic and confers a distinct molecular target [33, 34, 113]. The following
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discussion will be emphasizing on TT. Potential therapeutic effects of TT are summarized in
Table 2-7. It should be noted that, a vast majority of the literature pertaining to the clinical
intervention of vitamin E in HD population are in the form of TP supplementation – this is
summarized in Table 2-8.
Therapeutic effects of tocotrienol: Antioxidant
Imbalance between the generation of reactive species and antioxidant defense system lead to
oxidative stress and subsequently macromolecules damage including DNA, lipids and protein
[11]. Oxidative stress has been shown to involve in the pathogenesis of various chronic diseases
such as cancer and atherosclerosis. As reviewed earlier in this chapter, oxidized LDL play an
important role in the development of atherosclerosis, by attracting accumulation and
differentiation of monocytes, followed by massive deposition of cholesterol and formation of
lipid-filled foam cells on the artery wall. The differentiated monocytes (i.e. macrophages) in turn
express various cytokines which trigger the inflammatory response. Therefore, it is postulated
that antioxidant including vitamin E tocotrienol can prevent DNA damage and lipid peroxidation
by neutralizing free radical and halt further propagation of atherosclerosis [34].
It is well established that, TT, as TP, exhibit antioxidant activity due to phenolic group in
the chromane ring which neutralizes peroxyl radicals by conversion to relatively stable phenoxyl
radicals [126, 127]. These less reactive radicals can be reduced back to its original form by
vitamin C or other thiol antioxidants [116].

However, Yu et al [128] reported that

polyunsaturated phytol side chain of TT also exhibit antioxidative activity. Furthermore, TT also
has a higher recycling efficiency from chromanoxyl radicals due to its position closer to the
membrane surface area as demonstrated in the study using nuclear magnetic resonance
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spectroscopy [129]. This is consistent with other reported publication that TT have a superior
antioxidant activity when compared to TP [36, 129, 130]. For example, in vitro experiment
demonstrated that that α-TT is 40 times more effective against lipid peroxidation in rat liver
microsomal membranes and is 6.5 times more efficient in protecting cytochrome P-450 from
oxidative damage when compared to α-TP [34, 36]. In vivo, TT has been shown to be at least as
equally effective as TP considering physiological processes (e.g. absorption, distribution,
metabolism and excretion) that may limit its antioxidative properties [116]. Recent study using
type-2 diabetic rats supplemented with tocotrienol-rich fractions (TRF) showed that the activity
of antioxidant enzymes (i.e. superoxide dismutase, glutathione peroxidase) were restored and
malondiadehyde (MDA), an oxidative stress marker, were reduced when compared to the
untreated group. The antioxidant activity of TT has been postulated to confer protection against
diabetic nephropathy in these rats [131].
In human, data on the antioxidative role of tocotrienols in chronic diseases is scarce. In a
study by Chin and colleagues, supplementation with 160 mg of TRF for 6 months in healthy
adults failed to improve erythrocyte antioxidant enzymes (i.e. superoxide dismutase and
glutathione peroxidase) and MDA levels [132]. In summary, despite a clear anti-oxidative effect
of TT has been shown in cell and animal studies, this has yet to be demonstrated in clinical
population.
Therapeutic effects of tocotrienol: Anti-inflammatory properties
As discussed earlier, inflammatory mediator such as cytokines are implicated in the development
of atherosclerosis in part by promoting expression of cell adhesion molecules and generation of
free radicals [11, 64]. Therefore, dietary compound possessing anti-inflammatory properties such
as TT has received a greater scrutiny recently. TT has been shown to reduce arachidonic acid, a
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primary substrate for the synthesis of pro-inflammatory eicosanoids, in hereditary
hypercholestrolemic swine [133]. In a recent systematic review by Frank and colleagues, they
illustrated that TT could alleviate pro-inflammatory eicosanoids from arachidonic acid based on
two pathway; 1) through inhibition of glutame-induced production of phospholipase A2, which
is the enzyme that catalyzes production of arachidonic acid from the cell membrane
phospholipids, and 2) through inhibition of cyclooxygenase-2 and c-Src kinase resulting in
reduced production of pro-inflammatory eicosanoids (Figure 2-11) [116]. This is also consistent
with the lowering of the ‘end-point’ of the eicosanoid products such as TNFα, and interleukins in
lipopolysacharides-induced human monocytic cells following incubation with TRF [37].
Moreover, several lines of evidence suggest that TT could block activation of NFκB [37, 134], a
family of transcription factors that plays a central role in regulation of genes critical for
inflammation and immunity. Interestingly, such effects were not seen with TP [134].
In hemodialysis population however, there is no study on TT as yet. Nevertheless, several
studies in general population indicate a positive effect on inflammatory markers. In a study by
Heng et al [135], subjects were recruited based on two different age group (young adults with
average age of 32 and old adults with average age of 52), and TRF was administered for 6
months. They found that TRF supplementation in older adults resulted in lower CRP levels,
which has been regarded as a prognostic indicator for cardiovascular events and mortality in
ESRD patients [6, 7].
Therapeutic effects of tocotrienol: Lipid altering properties
TTs have been consistently demonstrated in the literature to possess lipid altering effects
especially in cell and animal studies. In a study using chicken, TC and LDL-C levels were
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reduced by 22% and 52%, while HDLC-LDLC ratios were improved by 123-150% in the animal
that were fed a small doses of tocotrienol-rich fraction for four weeks [136]. Furthermore, the
same authors also indicate that each of the TT isomer has variable impact on the serum lipids,
with γ- and δ-TT considered as the most potent. In the experimentally induced hyperlipidemic
rats, supplementation with a range of TRF concentration resulted in decreased in lipid parameters
(TAG, LDLC) in dose-dependent manner with the optimum dose identified at 8mg TRF/kg/day
[137].
It is generally accepted that the hypocholestrolemic effect of TRF can be explained by
suppression of mevalonate pathway that serves as the basis for cholesterol biosynthesis. Sterolinhibitory activity of TT is contributed by the side-chain unsaturation with ability to increase
cellular farnesol which signals the proteolytic degradation of HMG-CoA reductase (HMGR), a
rate-limiting enzyme of the cholesterol biosynthetic pathway [34, 138]. Therefore this lipid
altering properties is unique for TT but not TP. Furthermore, in cell study, Song & Debose-Boyd
[139] mechanistically explained that δ-TT suppressed cholesterol biosynthesis by stimulating
ubiquitination and degradation of HMGR, and blocks processing of sterol regulatory elementbinding protein (SREBPs), the transcription factors that involved in synthesis of enzyme
involved in sterol biosynthesis. They also showed that TP neither accelerate HMGR degradation
nor block SREBPs processing, in concert with the notion that lipid-altering effect is the unique
properties of TT. Another mechanistic study from HepG2 liver cell line, hycholesterolemia
induced-mice and borderline hypercholestrolemic patients summarized that the lipid lowering
effect of TT, particular γ- and δ- are due to: 1) suppression of the upstream regulators of lipid
homeostasis genes (i.e. ApoB100, SREBP, HMGCR and diaclyglycerol O-acyltransferase 2)
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resulting in reduced TAG, cholesterol and VLDL biosynthesis; and 2) enhancement of LDL
efflux via induction of LDL receptor expression [140].
However, the effects of TT particularly in lipids in human are rather ambiguous. In a
double-blind,

cross-over

clinical

study,

Qureshi

and

colleagues

demonstrated

that

supplementation with TRF in hypercholestrolemic human subject resulted in 31% decreased in
serum cholesterol during 4 week period when they were given 200mg γ-TT/day as compared to
the time when the same subjects were given 300mg corn oil/day [141]. Furthermore, the same
authors demonstrated that TTs supplementation in patients who took statins reduced statinsrelated side effects [142]. On the other hand, Mensink et al [143] provided TRF supplementation
(140mg TT, 80mg TP per day) to 20 men for 42 days showed no improvement in lipoprotein
profiles despite changes in plasma TP and TT concentration. Similarly, administration of 200mg
TT/day for 28 days in healthy hypercholestrolemic volunteers failed to show any effects on
blood lipids [144]. In a dose escalation study involving 32 normal healthy men, supplementation
with variable doses of TRF ranged from 80mg/day to 320mg/day also did not showed any
changes in lipid profiles [145]. Taken together, the lack of consistency in human results may be
due to: 1) variability in absorption of TT (e.g. with meal/ without meal); 2) different in doses;
and 3) different clinical population [35]. Table 2-9 summarized studies reporting the global
effects of TT supplementation (lipids, inflammation and anti-oxidative effects) in healthy
volunteer. As of now, there is no study reporting the effects of TT supplementation in HD
patients.
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Applying metabolomics for nutrition research in ESRD population
Metabolomics definition
‘Omics’ is a general term referring to interdisciplinary system biology to denote studies on a
large-genome wide scale including genomics, transcriptomics, proteomics, and metabolomics.
The ‘omics’ science has emerged since several decades ago, much attention has been focused on
sequencing the human genome and annotating the human proteome; however, the current focus
is on its application in finding a novel insight to understand the processes in cellular metabolism
in relation to health and diseases [146, 147].
Metabolomics is the latest of the omic sciences that utilized cutting edge analytical
instruments to quantitatively measures metabolites and detect their changes in biological fluids
and tissues in conjunction with pattern recognition approach and bioinformatics [147]. In other
words, metabolomics approach in human scrutinize the human metabolome – that is the
complete collection of human metabolites comprising of a diverse small molecules chemical
entities such as peptides, amino acids, nucleic acids, carbohydrates, vitamins, drugs and organic
acids that are part of biochemical and cellular processes or can be ingested by humans [146].
Because of a diverse role of metabolites in serving as building block of various macromolecules,
fueling all cellular processes, and acting as messengers and buffers in intracellular/extracellular
events following environmental insults, they together with genome and proteome define what
and who we are [146].
However, in contrast to the genome and proteome, metabolome is not well defined due to
the fact that it does not dictate by the genome alone because it can be affected by various factors
such as environmental insults (exogenous factor) or even the indigenous microflora in the gut
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(endogenous factor) [146, 148]. For example, a disease process altered biochemical imbalance in
the body that is transpires in peculiar metabolites that can be measured in biological fluids and
tissues. On the other hand, organism’s genome is constant while the change in transcriptome and
proteome does not always translate as phenotypic alteration. Given that, compared to the other
omics platform, metabolomics has a greater potential to impact clinical health practices due to
the fact that metabolites represent integrative information of the phenotype in response to genetic
and environmental changes [149]. Taken together, a comparative analysis of metabolite profile in
disease vs non-disease states enable disease etiology, stages of progression and diagnostic
biomarkes to be ascertained [149], exemplifies its application in clinical medicine for prognostic
or predictive interpretation of the disease status. It is important to note that despite a number of
advantages offer by metabolomics over conventional analyses, our knowledge on the
composition of the metabolome is currently incomplete [150], thus may limit overall application
in understanding the disease pathophysiology, diagnosis and treatment.
Metabolomics methodology
Metabolomics comprised of two generalized experimental strategies namely: 1) non-targeted
metabolic profiling and 2) targeted metabolic profiling [150]. Non-targeted metabolites profiling
is referring to a holistic study, an unbiased approach of data analysis without prior knowledge
about the data set/ the represented metabolites. This approach usually leads to discovery of new
ideas on the disease process, hypothesis-generating and a potential new ways of diagnosis [146,
150].
However, potential issues arise with the non-targeted metabolite profiling / pattern
recognition is the fact that metabolic profile may not be specific to a disease condition while
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confounders may not be accounted for, leading to problems in understanding the overall disease
process [151, 152]. Therefore, a second strategy, a targeted metabolite profiling is often used to
focus on quantitative changes of metabolite of interest with priori knowledge pertaining to their
involvement in the disease process. This closed profiling approach is also being used to validate
a biomarker after it is being discovered [152].
One of the common multivariate data analysis uses for metabolomics is a principle
component analysis (PCA). In PCA, a new smaller set of uncorrelated variables, known as
principle component (PC) is formed from a large set of related variables (e.g. NMR spectra from
the plasma of HD patients), which represent the largest variation from the original data set.
Using a multidimensional space, each of this PC is compared on a score plot, in which one score
representing one observation (i.e. NMR spectrum from the respective individual). The
contribution of each variable to the PC can also be calculated and visualized as a loading plot.
Loading plot indicates variables (i.e. a part of the NMR spectrum) that responsible for the
clustering and separation that correspond to the score plot [153]. Other statistical algorithm such
as partial least square (PLS) is also commonly used when analyzing human metabolome. Unlike
PCA, PLS is a supervised method of analyses which is an extension of PCA in which Y variables
are added to connect with the information provided by X variables. Y variables represent
additional information of the data set such as different group of intervention (intervention vs
placebo) or different time of measurement (e.g. baseline vs end of study), biochemistry or
clinical data [154]. In other words, PLS method helps to identify correlation between the
measured bioassay (y-axis) with NMR spectra data (x-axis). PLS-discriminant analysis (PLSDA), another method that commonly used, is a modification of PLS. PLS-DA is focused on
maximum separation (discrimination) rather than maximum variation [155].
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Metabolites profiling by nuclear magnetic resonance spectroscopy
Analytical tools that are available for metabolomics study are nuclear magnetic resonance
(NMR) spectroscopy, and mass spectrometry (MS) such as liquid chromatography-MS (LC-MS)
and gas chromatography-MS (GC-MS). GC-MS and LC-MS are robust and mature technology
offering superb sensitivity in detecting metabolome [146]. However, both of the latter techniques
have some drawbacks including relatively slower process, requires sample preparation/
separation (GC-MS), sample not recoverable (both LC-MS and GC-MS) and may suffer from
alteration due to sample collection and handling, hence requiring stringent quality assurance
[152]. On the other hand, NMR is more of a favorite tool for metabolomics due to its ability to
provide a high resolution spectra, requires relatively less sample preparation hence more rapid
analysis and more importantly non-destructive to the sample [146]. NMR techniques is based on
the properties of the magnetic spin of the nuclei to determine chemical structures and
concentration of a compound, thus nuclei having odd spin number such as 1H, 13C, 31P and 15N
are commonly used. However, it is important to note that, the number of metabolites detectable
using NMR techniques is relatively smaller when compared to LC-MS or GC-MS partly due to
dependency on the magnetic strength to detect the chemical shift for metabolite identification,
throughput and sensitivity [152].
Metabolomics application
Metabolomic approach has been used in various field including cancer, diabetes mellitus, and
cardiovascular diseases. In cardiovascular research, metabolomics is used predominantly in
elucidating etiology and identifying various biomarkers in the diseases pathophysiology [152].
Sebatine and colleagues demonstrated that a non-targeted approach of metabolomics were able to
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differentiate the metabolomics profiles of those who had clear-cut inducible ischemia than those
who did not (all patients underwent stress test for evaluation of possible myocardial ischemia)
[156]. This has allowed them to analyzed metabolic disturbance before and after stress testing to
identify potential novel biomarkers of coronary ischemia. Patients with clear-cut inducible
ischemia showed abnormality in the levels of gamma aminobutyric acid, uric acid, citric acid and
some other unidentified metabolites [156].
As far as ESRD patients is concerned, there are very limited studies that utilized the
metabolomics approach to study the disease process or potential biomarkers identification to help
in diagnosis and treatment. Recently, Ando and colleagues conduct an explorative study to assess
metabolic response in ESRD patients undergoing chronic HD in a time course manner - before,
during and after the HD treatment using plasma and dialysate sample using 1H NMR
spectroscopy [157]. They found a good correlation of creatinine in the plasma and dialysate
which indicating that dialysate solution could be used as a non-invasive measurement of
metabolic profile in HD patients in the future. Interestingly, they also found that additional
metabolites were formed during HD procedure [157], suggesting the catabolic effect of the HD
treatment.
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TABLE 2-1. Overview of kidney functions
Function
Waste elimination

Descriptions
•

Fluid balance

•
•

Removal of metabolic waste products (urea, creatinine, uric
acid)
Elimination and detoxification of drugs and toxins
Involve in removal and reabsorption of water to maintain fluid
balance (via action of antidiuretic hormone, atrial natriuretic
peptide, aldosterone)

Acid-base regulation

•

Involve in secretion, excretion and reabsorption of H+, HCO3-,
NH4+, PO4++ to maintain blood pH

Electrolytes balance

•

Involve in excretion and reabsorption of electrolytes such as
sodium, potassium, chloride, and bicarbonate to maintain
homeostasis.

Mineral metabolism

•

Control of mineral metabolism through endocrine synthesis
(1,25-dihydroxycholecalciferol and 24,25dihydroxycholecalciferol) and excretion of phosphorus.

Endocrine functions

•

Regulation of systemic blood pressure (renin, angiotensin,
prostaglandin, nitric oxide, sodium homeostasis)
Production of erythropoietin

•
Metabolic process

•
•

Regulation of metabolic processes (gluconeogenesis, lipid
metabolism)
Degradation and catabolism of peptide hormones (insulin,
glucagon, parathyroid hormone) and low molecular weight
protein (β2-microglobulin and light chain)

(Adapted from Himmelfarb et al 2010 [46])
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TABLE 2-2. Current CKD staging based on GFR used by KDIGO
GFR Category
G1
G2
G3a
G3b
G4
G5

GFR (ml/min/1.73 m2)
≥ 90
60-89
45-59
30-44
15-29
<15
(Source: KDIGO, 2012 [49])

Terms
Normal or high
Mildly decreased*
Mildly to moderate
Moderately to severe
Severely decreased
Kidney failure

Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate
* Relative to young adult level
In the absence of evidence kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD
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TABLE 2-3. Potential causes of protein energy wasting in CKD/ESRD population.
Causes
1. Decreased
energy intake

Notes
protein

and a.Anorexia
- Dysregulation in circulating appetite mediators
- Hypothalamic amino acid sensing
- Nitrogen-based uremic toxins
b.Dietary restrictions
c.Alterations in organs involved in nutrient intake
d.Depression
e.Inability to obtain or prepare food

2. Hypermetabolism

a.Increased energy expenditure
- Inflammation
- Increased circulating proinflammatory cytokines
- Insulin resistance secondary to obesity
- Altered adiponectin and resistin metabolism
b.Hormonal disorders
- Insulin resistance
- Increased glucocorticoid activity

3. Metabolic acidosis
4. Decreased physical activity
5. Deceased anabolism

a.Decreased nutrient intake
b.Resistance to GH/IGF-1
c.Testosterone deficiency
d.Low thyroid hormone levels

6. Comorbidities and lifestyle

Comorbidities (diabetes mellitus, CHF, depression,
coronary artery disease, peripheral vascular disease)

7. Dialysis

a.Nutrient losses into dialysate
b.Dialysis-related inflammation
c.Dialysis-related hypermetabolism
d.Loss of residual renal function
(Source: Carrero et al 2013 [12])
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TABLE 2-4. Dietary recommendations for patients undergoing chronic hemodialysis.
Nutrients
1. Calories (kcal/kg body weight)
2. Protein (g/kg body weight)
Protein (% of total calories)
3. Carbohydrate (% of total calories)
4. Fat (% total calories)

Recommended Intake
30 – 35*
1.2-1.4
15-25
50-60#
25-35

5. Cholesterol (mg/day)
6. Saturated fat (% of total calories)

<200
<7

7. Sodium (g/day)

<2.0

8. Calcium (g/day)

2.0

9. Phosphorus (g/day)

0.8 – 1.0
(Adapted from: Ikizler 2010 [85])

Note: *35 kcal/kg body weight/day if <60 years old and 30-35 kcal/kg body weight/day if >60 years old.
# Carbohydrate intake should be provided at a reduced amount for patients with hypertriglyceridemia.

	
  

47
	
  

TABLE 2-5. Potential mechanism of actions of omega-3 fatty acids on cardiovascular disease
Omega-3 fatty acids properties
1. Hypotriglyceridemic
2. Anti-inflammatory

Remarks
• Reduce fasting and postprandial TAG
• ↓ inflammatory cytokines (TNF-α, IL-1β,
IL-6, IL-8)
• ↓ generation of reactive oxygen species
• ↓ arachidonic acid derived eicosanoids

3. Antithrombogenic
4. Retard growth of the atherosclerotic plaques

• ↓ paletelet agregation
• ↓ adhesion molecules expression (e.g.
VCAM-1, ICAM-1)

5. Anti-arrhythmias

• Prevent calcium overload
• Inhibit voltage-gated sodium channel

6. Mildly hypotensive

• Unknown mechanism

(Adapted from Connor 2000 [158]; Kris-Etherthon et al 2002 [94])
Abbreviations: TAG, triacylglycerol; TNF- α, tumor necrosis factor alpha; IL-1β, interleukin 1 beta; IL-6,
interleukin 6; IL-8, interleukin 8; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular
adhesion molecule 1.
Note: This figure shows potential mechanism of omega-3 fatty acids in reducing risk for cardiovascular
diseases. This is contributed by hypotriglyuceridemic, anti-inflammatory, antithrombotic, antiarrythmias
and anti-atherosclerotic properties of omega-3.
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TABLE 2-6. Selected studies reporting the effects of omega-3 supplementation in HD patients
Study

Design

Groups

Dose

Therapy
Duration

Outcome
Measures

Khajehdehi et al
[29]

Randomized,
placebocontrolled trial

4 different treatment
groups (n=60)
1. Fish oil
2. Corn oil
3. Sesame oil
4. Placebo

1.5 g omega-3
/day

8 weeks

Ratios of
HDLC/LDLC,
TC/HDLC and
TAG/HDLC
decreased
significantly in fish
oil and corn oil
treated groups.

Kalantar-Zadeh
et al [159]

Concurrent
control

Hypoalbuminemic
HD patients:
1. intervention
(n=20)
2. control (n=20)

0.46 g EPA

4 weeks

↑ in albumin in
intervention group
Non-significant
reduction in CRP

PerunicicPekovic et al
[106]

Case-series prepost test

1. Age, sex matched
control (n=16)
2. HD patients
(n=42)

2.4 g omega-3
/day

8 weeks

↓ in IL-6, TNF-α
↑ in HDLC &
albumin

Schmitz et al
[105]

Randomized,
placebocontrolled

1. Omega-3 (n=12)
2. Placebo (n=12)

4 g omega-3
/day

12 months

↓ in TAG by 53%
Lower incidence of
thrombosis in the
treatment group
(17% vs 75%)

Saifullah et al
[108]

Randomized,
placebocontrolled

1.Omega-3 (n=18)
2.Placebo (n=9)

1.3 g omega-3
/day

12 weeks

No significance
changes in TAG
Decreased in CRP

TayyebiKhosroshahi et
al [160]

Nonrandomized,
placebocontrolled

1.omega-3 (n=37),
2.control (n=38)

3 g omega-3
/day

8 weeks

MDA significantly
reduced in omega-3
group.
No changes in
antioxidant enzymes
(SOD, FRAP)

Poulia et al[161]

Single blinded,
randomized,
cross-over trial

HD patients (n=25)

0.9g EPA +
0.8g DHA +
8mg α-TP,
OR α-TP
alone

4 weeks on
each
treatment, 2
weeks
washout
period.

No effects on serum
lipids and CRP.

Abbreviations: EPA, eicosapenthanoic acids; DHA, decosahexanoic acids; TP, tocopherols, TAG,
triacylglycerols; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α; tumor necrosis factor alpha; MDA,
malondialdehyde; SOD, superoxide dismutase; FRAP, ferric reducing ability of plasma.
	
  

49
	
  

TABLE 2-7. Potential therapeutic effects of tocotrienols.
Tocotrienols properties

Remarks

1. Antioxidant

• TTs are more potent radical scavenger and has
greater antioxidant activity again lipid peroxidation
in liposome than TPs.
• TT is more effective in the protection of
cytochrome P450 against oxidative damage when
compared to TP.
• This is due to faster cellular uptake; faster recycling
from the respective chromanoxyl radical forms in
liposomal membrane and lipoproteins; higher intermembrane mobility.

2. Anti-inflammatory

• ↓ inflammatory cytokines (CRP, TNF-α, IL-4, IL-6,
IL-8, NFκB)
• ↓ generation of reactive oxygen species
• ↓ arachidonic acid derived eicosanoids

3. Lipid altering effects

• Hypocholestrolemic effects is unique to TT not TP
• This is due to post-transcriptional suppression of
HMG-CoA
reductase
protein;
enhance
ubiquitination of HMG-CoA reductase.

4. Effects on suppression, regression • Suppression of atherosclerosis is related to
and progression of atherosclerosis
reduction in oxidative stress, total cholesterol,
increased in HDL-C; ↓ adhesion molecules
expression (e.g. VCAM-1, ICAM-1)
• Do not regress atherosclerosis in experimental
animals
• Conflicting results in progression of atherosclerosis.
5. Antithrombogenesis

• δ-TT is a potent inhibitor of platelet aggregation.
• TT reduced serum levels of thromboxane-B2 and
platelet factor 4

(Reviewed in Frank et al 2012 [116], Prasad 2011	
  [35] and Vasanthi et al 2012 [34])
Abbreviations: TT, tocotrienol; TP, tocopherols; CRP, C-reactive protein; IL, interleukin; TNF- α, tumor
necrosis factor alpha; VCAM-1, vascular cell adhesion molecule 1; ICAM-1, intercellular adhesion
molecule 1; NFκB, nuclear factor kappa B; HDLC, high density lipoprotein cholesterol.
Note: This figure shows potential mechanism of tocotrienols in reducing risk for cardiovascular diseases.
This is contributed by antioxidant, anti-inflammatory, lipid altering, anti-atherosclerotic and antithromogenic properties of tocotrienols.
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TABLE 2-8. Selected studies reporting the effects of oral vitamin E (α-tocopherol)
supplementation in HD patients
Study

Design

Groups (n)

Dose

Therapy
Duration

Outcome Measures

800IU/day

519 days
(median)

No oxidative stress
measures
↓ Cardiovascular end
points (sudden death;
myocardial
infarction)

Boaz et
al.[25]

Randomized,
double-blind
placebocontrolled

1. HD pts α-TP (97)
2. HD pts placebo (99)

Bayes et
al.[162]

Open label,
untreated healthy
control

1. HD pts (16)
2. Healthy control
untreated (30)

400mg	
  α-TP
/ dialysis
session

3 months

↓ plasma MDA
↓ autoantibodies to
oxLDL

Galli et
al.[163]

Open label,
untreated healthy
control

1. HD pts (19)
2. Healthy control
untreated (30)

800mg αtocopheryl/d

3 weeks

↓ plasma TBARS
↑ nitric oxide
↑ plasma TP
↑ plasma GSH

Giray et
al[164]

Open label,
untreated healthy
control

1. HD pts (36)
2. Healthy control
untreated (36)

600mg αTP/d

14 weeks

↓ plasma TBARS
↑ plasma GPX and
SOD activity

Badiou et
al.[165]

Open label,
treated healthy
control

1. HD pts (14)
2. Healthy control
treated (6)

500mg αTP/d

6 months

↓ plasma TBARS
↓ copper induced
oxidation
↑ plasma lipoprotein
α-TP

Diepeveen et
al.[166]

Randomized,
double-blind,
placebocontrolled
(factorial design)

1. HD pts given
artovastatin + placebo
α-TP (13)
2. HD pts given α-TP
+ placebo artovastatin
(10)
3. HD pts given
artovastatin + α-TP
(11)
4. HD pts given
placebo artovastatin +
placebo α-TP (10)

800IU
(536mg) αTP/day

12 weeks

↓ in vitro LDL
oxidazibility
No effect on plasma
oxLDL levels
↑ serum α-TP

Uzum et
al.[167]

Randomized,
placebocontrolled, with
treated PD pts,
untreated healthy
control

1. HD pts α-TP
2. HD pts placebo
3. Healthy control
untreated

300mg/day

20 weeks

↓ erythrocytes
osmotic fragility
levels in HD & PD
↓ MDA in HD
↑ serum α-TP

(Adapted from: Coombes & Fassett 2012 [24])
Note: This table shows a list of vitamin E intervention (Tocopherols) studies and their outcome measures
in hemodialysis patients.
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TABLE 2-9. Selected studies reporting the effects of tocotrienols in healthy volunteer and other
clinical population
Study

Design

Groups

Dose

Therapy
Duration

Outcome Measures

Radhakrishnan
et al. [168]

Randomized,
placebocontrolled
trial

1. Healthy
volunteer – TRF
(n=16)
2. Healthy
colunteer α-TP
(n=15)
3. Control –
placebo (n=17)

200mg of
either TRF or
α-TP

8 weeks

No different in immune
cells modulation (i.e.Thelper, NK cells, Blymphocytes, CD4:CD8
ratio)

Rasool et al.
[145]

Randomized,
blinded-end
point,
placebocontrolled
trial

Healthy
volunteer – 4
groups of dosage
(n=36)
1. Placebo
2. 80mg/d
3. 160mg/d
4. 320mg/d

Various
dosage:
80mg/d,
160mg/d,
320mg/d

8 weeks

No changes in TAS,
ASBP, TC or LDLC.
Group 160mg/d and
320mg/d showed
significant improvement
ASBP

Patel et al. [169]

Open label

Healthy
volunteer (n=80)

400mg α-TP
400mg TT

20 weeks
(mean)
1-96 weeks
(range)

TT are transported into
vital organs

Chin et al. [132]

Randomized,
placebocontrolled
trial

1. Healthy
volunteer –
placebo (n=30)
2. Healthy
volunteer TRF
(n=32)

160 mg TRF

6 months

Erythrocytes antioxidant
enzymes (SOD, GluProx)
Lipid profiles- significant
improvement in HDLC in
older adult group.

Abbreviations: TRF, tocotrienol-rich fractions; TP, tocopherols; TAS, total antioxidant status; TC, total
cholesterol; LDLC, low density lipoprotein cholesterol, ASBP, aortic systolic blood pressure; SOD,
superoxide dismutase; GluProx, glutathione peroxidase.
Note: This table shows a list of vitamin E tocotrienol intervention studies and their outcome measures in
healthy volunteer and other clinical population.

	
  

52
	
  

FIGURE 2-1. International comparisons for incidents of end-stage kidney disease.
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(Source: USRDS, 2012 [1])

Note: This figure shows incident rates of the reported ESRD cases worldwides in 2011. Mexiro reported
the highest incident rate followed by the United States, Taiwan and Japan. Rates less than 100 per million
population were reported in Scotland, Finland, Russia and Bangladesh.
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FIGURE 2-2. Different types of treatment modality option for patients with end stage kidney
disease.

A

B

C

(Source: NKUDIC, 2013; Kidney Health Australia, 2013)
Legend: A- Peritoneal dialysis, B-Hemodialysis, C-Kidney transplantation
Note: (A) Peritoneal dialysis use patient’s own peritoneum membrane to filter out fluids and other
dissolved substances. (B) In hemodialysis modality, patient’s blood is pump to pass through a dialyser
membrane allowing diffusion of fluid and other waste substance across a semipermeable membrane. This
dialysis modality is the most common in the US. (C) A new kidney from a donor is transplanted in iliac
fossa, in the recipient’s contra lateral side.
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FIGURE 2-3. Schematic diagram of the increased cardiovascular burden in ESRD.
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(Adapted from: Kalantar-Zadeh & Balakrishnan 2006 [66])
Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease; QOL, quality of life.
Note: This figure shows a proposed pathophysiology of cardiovascular disease in ESRD patients.
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FIGURE 2-4. Schematic view of the atheroma’s development

(Source: Stenvinkel et al 2003 [64])

Abbreviations: Th, T-helper cell; CRP, C-reactive protein; VCAM, vascular cell adhesion molecules;
ROS, reactive oxygen species; MMPs, matrix metalloproteinases; AngII, angiotensin II; oxLDL, oxidized
low-density lipoprotein.
Note: This figure shows atheroma’s development processes. Normal human artery is comprised of three
layers of cells – endothelial, the intima layer and the underlying tunica media. During early
artherogenesis, fatty streak is developed as a result of recruitment of inflammatory cells and foam cells
(from accumulated lipids). When dyslipidemia and inflammatory conditions persist, lipid pool grows.
Activated leukocytes secrete proteinase which caused degradation of the extracellular matrix and
ultimately cells death. Meanwhile, Th1 activity is stimulated by the present of inflammatory cytokines
that limit the synthesis of new collagen which may thin fibrous cap which make it susceptible to rapture.
Accute chronory syndrome occurs following plaque rupture due to thrombus formation from the
coagulated blood that block the circulation. On the other hand, higher Th2 activity leads to a more stable
plaque and less susceptibility to rupture.
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FIGURE 2-5. Plasma lipid transport in hypertriglyceridemia

(Source: Barter 2005 [63])
Abbreviations: CE, cholesterol ester; CETP, cholesteryl ester transfer protein; FC, free cholesterol; FFA,
free fatty acid; HDL, high density lipoprotein cholesterol, LCAT, lecithin cholesterol acyl transferase;
LDL, low density lipoprotein cholesterol; LPL, lipoprotein lipase; TAG, triacylglycerol; VLDL, very low
density lipoprotein cholesterol.
Note: This figure shows overview of lipoprotein metabolism with a highlight on dyslipidemia in
CKD/ESRD. In the normal metabolism, the liver secretes VLDLs that rich in TAG. LPL hydrolyze TAG
to FFA and promotes extrahepatic cellular uptake. In CKD/ESRD, dyslipidemia is highly prevalence
characterized by delayed TAG rich lipoproteins catabolism (i.e. ↑ VLDL/IDL) and low HDLC due
suppressed apoA1 production, increased CETP, and reduced LCAT activity.
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FIGURE 2-6. Proposed treatment strategies to treat inflammation and minimize risk for CVD in
hemodialysis patients
I. Evaluate and treat intercurrent events and co-morbidities that cause inflammation
Volume overload
Infectious complications
Periodontal disease
Inflammatory diseases
Silent ischemic heart disease

II. Evaluate and handle potential dialysis related cause of inflammation
Central dialysis catheter
Unpure dialysate
Thrombosed fistula or graft
Volume overload
Bioincompatible membrane
Infection of dialysis access

III. Consider possible anti-inflammatory treatment strategies
Non-specific Immunomodulation
Statins
Vitamin D
ACEs / ARBs

Nutritional
Intervention

Physical training

Omega-3 fatty
acids
Vitamin E
Soy Isoflavones
Genistein
(Source: Carrero & Stenvinkel 2010 [6])
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FIGURE 2-7. Omega-3 molecular structures

Abbreviations: ALA, α-linolenic acid; EPA, eicosapentanoic acid; DHA, docosahexanoic acid.
Note: This figure shows omega-3 fatty acids molecular structures – ALA (C18:3), EPA (C20:5) and DHA
(C22:6). Omega-3 fatty acids have double bond beginning at the third carbon atom from the end of the
carbon chain.
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FIGURE 2-8. Different effects of omega-3 and omega-6 in relation to eicosanoids
Arachidonic Acid
(n-6)

Eicosapentanoic Acid
(n-3)
Competition for
eicosanoid enzymes
(COX, LOX)

n-6 derived eicosanoids
(TxA2, LTA4, LTB4,
LTD4)

n-3 derived eicosanoids
(TxA3, LTB3)

Pro-inflammatory
products

Less inflammatory/
anti-inflammatory
products

•
•
•
•
•

↑ Platelet
aggregation
↑ Vascular
permeability
↑ Cytokine release
Vasoconstriction
Chemotaxis

•
•
•
•
•

↓Platelet
aggregation
↓ Cytokines
production
↓ Cytokines release
Vasodilation
↓ Chemotaxis

(Source: Friedman & Moe 2006 [92])
Abbreviations: COX, cyclooxigenasae; LOX, lipoxygenase; TxA, thromboxane; LT, leukotriene.
Note: This figure shows synthesis of eicosanoids from omega-6 and omega-3 fatty acids. Eicosanoids are
a group compounds that exert a complex control particularly in the intensity and duration of inflammatory
response. Eicosanoids derived from omega-6 are proinflammatory by promoting platelet aggregation,
vascular permeability and cytokines release. On the other hand, eicosanoids produced from omega-3 is
less inflammatory in nature. Because eicosanoids derived from omega-3 use the same enzymatic pathway
as those derived from omega-6, high concentration of EPA results in a shift towards non-inflammatory
eicosanoids.
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FIGURE 2-9. Vitamin E molecular structures

(Source: Aggarwal et al 2010 [33])
Note: This figure shows eight known vitamin E isomers, named as α-, β-, δ-, γ- tocopherol (TT) and
tocotrienols (TP) based on the number of methyl group in the chromanol ring. TT are different from TP
due to the present of unsaturated chain rather than saturated.
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FIGURE 2-10. Dietary sources of tocotrienols

(Adapted from: Aggarwal et al 2010 [33])
Note: This figure shows natural dietary sources of tocotrienol, expressed as µg per gram of the item.
Tocotrienol is abundant in palm oil, rice bran, barley, oat and wheat germ while safflower, soybean and
olive oil are minimally contain tocotrienol.
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FIGURE 2-11. The role of tocotrienols in suppression of the synthesis of pro-inflammatory
eicosanoids from arachidonic acid.
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Abbreviations: TT,
cyclooxygenase-2.
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12-HPETE,
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acid;

COX-2,

Note: This figure shows the role of tocotrienols in alleviating production of pro-inflammatory eicosanoids
from arachidonic acids. The first pathway is through inhibition glutamate-induced production of
phospholipase A2, which is the enzyme that catalyzes production of arachidonic acid from the cell
membrane phospholipids. The second pathway involved inhibition of COX-2 and c-Src kinase resulting
in reduced production of pro-inflammatory eicosanoids.
	
  

63
	
  

CHAPTER III
METHODOLOGY
General study design
This dissertation is comprised of three experiments from two different studies. General aim of
these studies is to document the effects of supplementation with anti-inflammatory, lipid altering
and antioxidant agents (i.e. omega-3 fatty acids and tocotrienols) in hemodialysis patients. These
studies were designed as randomized, double-blinded, parallel, placebo-controlled trials using
the same cohort of patients undergoing chronic hemodialysis at Great Lake Dialysis Clinic,
Detroit MI. There was seven months wash out period between the two studies (Figure 3.1).
In the first experiment (Specific Aim 1), chronic hemodialysis patients were
supplemented with omega-3 fatty acid for 24 weeks to evaluate the feasibility of the
supplementation using ‘directly observed treatment’ and to document the global effects omega-3
on nutritional, lipid profiles and inflammatory markers. Following the proven feasibility of the
study using ‘directly observed treatment’, second study (Specific Aim 2) was conducted using
similar study design but with some modification to improve compliance and delivery of effective
doses to the subjects. In the second study, HD cohort was supplemented with tocotrienols-rich
fractions (TRF) for 16 weeks to evaluate the global effects of TRF on nutritional status, lipid
profiles, inflammatory markers and oxidative status. Further investigation was carried out to
elucidate the effect of TRF on lipid metabolism following positive results on lipid profiles. In the
third experiment, the author investigated the changes in patients’ metabolomics profile following
supplementation (Specific Aim 3).
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This chapter will describe general methods that were the same between the omega-3 and
TRF studies. Specific methods/assays for each study will be described in specific chapter for the
particular study (Chapter IV, V and VI).
Ethics and human subjects issues
The Omega-3 study (Specific Aim 1) recruited 63 patients from the Great Lake Dialysis Clinic.
The protocol for the Omega-3 study was approved by the Human Investigation Committee of
Great Lake Dialysis Clinic (IRB# 00007308) and Wayne State University (HIC #125709A).
Informed written consent from the patients was obtained beforehand. Similarly, the protocol for
the TRF study (Specific Aim 2a/b) was approved by the Human Investigation Committee of
Great Lake Dialysis Clinic (IRB #00007308) and Wayne State University (IRB# 067411A). The
study recruited 81 patients of the same cohort and informed consents were obtained from the
patients before the study start. Any serious adverse events (e.g. death, inpatient hospitalization, a
life-threatening adverse experience, a persistent/significant disability) or unexpected adverse
experiences related to the use of these supplements were promptly reported to the Human
Investigation Committee using the specify form within five working days.
The Great Lake Dialysis Clinic is an outpatient dialysis facility that is affiliated with
Delta Renal Group. The dialysis facility has 24 hemodialysis stations. The hemodialysis patients
are distributed equally among seven hemodialysis shifts. Each patient attends hemodialysis
session either on Monday-Wednesday-Friday or Tuesday-Thursday-Saturday rotation at a
designated time. Each rotation day comprised of three dialysis session namely; Shift 1 runs from
5.15 am to 8.45 am, shift to from 10.15am to 1.45pm and night shift hours of operation are from
5 pm to 4.30 am. Hemodialysis patients are under exclusive care of the nephrologist and a
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certified nurse-practioner. A full time registered dietitian provides routine nutritional care and
dietary counseling to those patients. Anemia management is performed by the clinical director of
the clinic.
General aspects of collection and handling of blood samples
In general, blood was collected from the patients prior to the dialysis session into two 10mL
Vacutainer tubes with EDTA and heparin preservatives (BD, Franklin Lakes, NJ, USA). Blood
samples were transported to Wayne State University’s laboratory within 2 hours after the
collection. Additional blood was collected into tubes without anticoagulant for standard renal
profiles measurement (ser. Alb, Hb, Kt/V) and were sent to an external laboratory (Ascend
Clinical Laboratory Services, Redwood City, CA, USA). Blood samples collected in the EDTA
tubes were designated for analyses of lipid profiles and NFκB while lithium heparin tubes were
used for analyses of oxidative status and inflammatory markers. Plasma was separated by
centrifugation at 2800 rpm for 20 minutes at 4oC (GS-6KR Centrifuge, Beckman-Coulter, USA)
and aliquots were stored at -80oC until further analysis. Blood sample for nuclear factor kappa B
(NFkB) were processed immediately to obtain mononuclear cell extract using Ficoll-Paque
method (GE Health Care, Piscataway, NJ, USA), and the nuclear extract were kept at -80oC until
use.
Anthropometry measurements
The anthropometrics measurements carried out in both studies included estimated dry weight and
height at the baseline and the end of the study. Height was measured to the nearest 0.1cm (Tanita
Wall Mounted Height Rod, Tanita, USA). Body weight was measured to the nearest 0.1kg after
each HD session (Tronix Flush-Mounted In-Floor Scale, Scale-Tronix, USA). Body mass index
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(BMI) was calculated from the measurements of weight and height using Quetelet ‘s Index [
BMI (kg/m2) = weight (kg) / height (m2)][170] and compared to WHO (2000) BMI
classification chart [171].
Biochemical analyses
Biochemical analyses performed in both studies included 1) Renal profiles (ser. Alb, Hb, Kt/V)
(performed by external laboratory) 2) Lipid profiles (TC, TAG, HDL-C) and 3) Inflammatory
markers (C-RP, NFκB). Brief descriptions of each assays performed in these studies are
described as follow:
Lipid profiles
TC and TAG in the plasma was determined using commercial enzymatic assay per manufacturer
protocol (Pointe Scientific, Canton, MI). Briefly, 10µL of unhemolyzed plasma samples were
transfer into test tubes, followed by addition of 1.0mL of TC/TAG reagent (pre-warmed to 37oC)
and gently mixed by vortexing. The tubes were incubated for 10 minutes in the dark and the final
color intensity of the solution was recorded at 500nm within 30 minutes (DU 640
Spectrofotometer, Beckman-Coulter, USA). TAG concentration for each sample was calculated
by comparing to the standard absorbance (abs unknown/ abs standard X concentration standard)
and the results were expressed as mg/dL. All samples were assayed in duplicate.
HDL-C was measured in the supernatant fraction following precipitation of ApoB
containing lipoprotein using dextran sulfate and magnesium ions (Pointe Scientific Inc., Canton,
MI). In short, 150µL of plasma was transferred to microtube followed by the addition of 30µL of
Mg/Dextran Sulfate and 10 minutes incubation at room temperature. The solution was spun at
10,000 rpm for 5 minutes to precipitate ApoB containing lipoprotein. Supernatant fraction
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(50µL) was transferred to the test tubes in duplicates followed by the addition of 1.0mL of prewarmed TC reagent. After 10 minutes incubation, the color intensity was measured using
spectrophotometer at 500nm. HDL-C concentration for each sample was calculated by
comparing to the standard absorbance (abs unknown/ abs standard X concentration standard) and
the results were expressed as mg/dL. LDL-C was calculated using the Friedewald’s equation by
difference (LDLC = TC minus HDLC minus TAG/5)[174].
Inflammatory markers
CRP (Cayman Chemical, Ann Arbor, MI) levels were measured using commercial kits based on
enzyme-linked immunoabsorbent assay (ELISA) method as per the manufacturer’s protocol
(Cayman Chemical, Ann Arbor, MI). Plasma samples were diluted in the assay buffer into
1:15,000 and 100µL of each sample was placed into 96-wells microplate that has been coated
with a monoclonal antibody specific for human CRP and were incubated for an hour. The plate
was then rinsed for four times with wash buffer before addition of HRP-labeled CRP monoclonal
antibody. Two antibodies were added and formed a sandwich by binding to different location of
CRP molecule. CRP concentration in the plasma samples were measured at 450nm after addition
of chromogenic substrate TMB (tetramethylbenzidine) that formed a distinct yellow color.
Standard curve was prepared using a known concentration of CRP with data being expressed as
mg/L. A general principle of sandwich ELISA method is presented in Figure 3-2.
NFκB assay was performed based on three steps: 1) Isolation of mononuclear cells from
the blood, 2) Extraction of nuclear and cytoplasm extract, and 3) Measurement of NFκB
expression/concentration in the nuclear extract. Isolation of the mononuclear cells from the blood
was performed using Ficoll-Paque PLUS solution (GE Healthcare Life Science, Pittsburgh, PA,
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USA). Briefly, 5mL of fresh blood that were collected in EDTA tube were diluted with an equal
volume of 1 X phosphate buffer saline solution. The diluted blood were then transferred into a
15mL Corning centrifuge tube (Corning Life Science, Tewksbury, MA, USA) containing 10 mL
of Ficoll-Paque solution by carefully overlaying it using 9” Pasteur pipette (Thermo Scientific,
USA). This was followed by a centrifugation at 1,400 rpm, 20oC for 30 minutes to separate
peripheral blood mononuclear cells (PBMC). PBMC was harvested using Pasteur pipette,
transferred into a new 15mL Corning centrifuge tube, followed by an addition of three volumes
of 1 X PBS. The solution containing PBMC was centrifuge again at 1,000 rpm, at 4oC for 10
minutes to eliminate contaminant (e.g. platelet). The washing processes were done two times
before the PBMC were harvested and stored at -80oC until further use. Nuclear and cytoplasm
extract were obtained from PBMC using kits purchased from PIERCENET (Thermo Scientific,
Rockford, IL, USA) per manufacturer’s protocol. For a 40mg packed cell volume, 400µL of
cytoplasmic extraction reagent I (CER-I) was added into the cell pallet followed by a vigorous
vortexing for 15 seconds and incubation on ice for 10 minutes. CER-II solution (22 µL) was
added into the tube followed by vortex and centrifugation for 5 minutes at 16,000g, 4oC. The
cytoplasmic extract was harvested from the supernatant while the insoluble pallet was used to
extract the nuclear extract by the addition of the nuclear extraction reagent (NER). Protein
content of the nuclear extract were determined based on Bradford’s method using a commercial
reagent purchased from PIERCENET (Thermo Scientific, Rockford, IL, USA) per
manufacturer’s protocol. Upon the quantification of the protein content, each sample was
standardized for the protein concentration by a dilution with NER solution. NFκB p65 in the
nuclear extract was determined using TransAM NFκB (Active Motif, Carlsbad, CA, USA) based
on ELISA method as discussed earlier on.
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Statistical analysis
Upon the completion of the study, data were keyed-in in Microsoft Excel, checked for their
integrity and missing values before transferring into SPSS. Statistical analyses were carried out
using SPSS version 16.0 (IBM, Chicago, IL). Continues data were presented as mean±SD (in
tables) and mean±SEM (in figures), while data that were not normally distributed were presented
as median±IQR. Categorical data were presented as absolute number and percentage.
Independence t-test were applied to normally distributed continuous data to check
differences in mean between the two groups, while paired t-test were used to check differences
between time points. For continuous data that were not normally distributed, equivalent nonparametric tests were used to test differences in mean of the two groups and between the time
points. Chi-square test was used to test differences in categorical data. Pearson-correlation
coefficient test was used to evaluate correlation of the studies’ parameters.
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FIGURE 3-1. General study design.
OMEGA-3 STUDY
(n=60)

	
  

Supplementation duration:
24 weeks
(on dialysis days only –
3x/wk)

Specific aim 1 parameters:
• Nutritional indices
(Ser. Alb, Hb, MIS score)
• Inflammatory markers
(CRP, NFκB)
• Lipid profiles
(TC, TAG, HDLC)

Washout period:
24 weeks

TRF STUDY
(n=81)

Supplementation duration:
16 weeks
(on daily basis – 2x/day)

Specific aim 2 parameters:
• Nutritional indices
(Ser. Alb, Hb, 24-hr diet analysis)
• Inflammatory markers
(CRP, IL-6, TNF-α, NFκB)
• Oxidant status
(TAP, MDA)
• Lipid profiles
(TC, TAG, HDLC)
• Lipids
(CETP, ApoA1)
Specific aim 3:
• Metabolomics analysis

Abbreviations: Ser. Alb, serum albumin; Hb, hemoglobin; MIS, malnutrition-inflammation score; CRP,
C-reactive protein; NFκB, nuclear factor kappa B; IL-6, Interleukin-6; TNF-α, tumor necrosis factor
alpha; TAP, total antioxidant power; MDA, malondialdehyde; TC, total cholesterol; TAG, triacylglycerol;
HDLC, high-density lipoprotein cholesterol; CETP, cholesteryl ester transfer protein; ApoA1,
apolipoprotein A1.
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FIGURE 3-2. Principle of sandwich ELISA

(Illustration by: Genway Biotech Inc, 2013)
1. A 96-well microplate is pre-coated with desire antibody by the manufacturer (e.g. human
CRP, IL-6).
2. Plasma sample is added to the each well in the microplate in duplicate. Any antigen found in
the plasma is bound to the capture antibody.
3. Biotin labeled detection antibody is bound to the antigen.
4. HRP is added and binds the biotin labeled antibody.
5. TMB substrate is added and converted by HRP into detectable color solution. The
concentration of the antigen is quantified using spectrophotometer.
Note: This figure shows principle of sandwich ELISA that has been used to measure CRP, IL-6, TNF-α
and NFκB in this project.
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CHAPTER IV
SPECIFIC AIM 1:
EFFECTS OF PROTEIN AND OMEGA-3 SUPPLEMENTATION ON NUTRITIONAL
STATUS, LIPID PROFILES AND INFLAMMATORY INDICES
Published in: Vascular Health and Risk Management. 2012; 8:187-195 [175].
Daud ZAM, Tubie B, Adams J, Quainton T, Osia R, Tubie S, Kaur D, Khosla P, Sheyman M.

Introduction
Cardiovascular disease (CVD) represents the major source of morbidity and is a leading cause of
death in uremic patients on chronic hemodialysis [164]. From non-traditional cardio-vascular
disease risk factors in dialysis patients, a malnutrition-inflammation complex syndrome has been
postulated to play a role in the etiology of premature CVD in hemodialysis patients [7]. Thus,
there is considerable interest in finding appropriate interventions for the malnutritioninflammation complex syndrome (MICS) in this population.
Protein energy malnutrition (PEM) is highly prevalent in dialysis populations which
negatively impacts prognosis. PEM is implicated in a complex syndrome caused by nutritional
and non-nutritional factors such as deficient food ingestion secondary to uremia, dietary
restriction, chronic inflammatory state and increased catabolism related to treatment modalities,
nutrients loss in dialysate and metabolic acidosis [74]. Numerous studies have demonstrated that
protein supplementation alone may improve protein metabolism, nutritional parameters and
therefore improve clinical outcomes [176-178]. Meanwhile, causes of inflammation are
multifactorial comprising of dialysis and non-dialysis factors such as exposure of blood with

	
  

73
	
  

dialyzer membranes or tubing, infection on vascular access, reduced antioxidants and increased
oxidative stress [74, 179]. Therefore, in order for a nutritional intervention to be most effective,
it should be targeted at improving protein status and have anti-inflammatory properties to
improve inflammatory status [159].
There is a growing scientific interest on the application of omega-3 fatty acids as a means
to prevent CVD in dialysis population. Omega-3 fatty acids have been postulated to reduce a
pro-inflammatory response, confer antithrombotic properties, improve lipid levels particularly
triglycerides and improve endothelial functions in several studies [98, 104, 180, 181]. To date,
there is no well-established recommendation on omega-3 fatty acid supplementation for the
dialysis population despite the fact that the dialysis population has lower omega-3 intake [32]
and plasma levels [102]. Some of the studies published used supraphysiological doses of omega3 (>3 g/d) which required the high number of capsules and may be difficult to consumed long
term [92]. Moreover, there may be barriers to compliance with this type of nutritional
intervention especially when the study population includes non-Caucasian races, low-income
groups and unemployed [182]. Some of the clinical studies only rely on subjective method such
as pill counting to measure compliance [109, 161] which could be the important limitation for
the likely type of non-compliance population.
Therefore, we performed a pilot study to investigate the technical feasibility of “directly
observed treatment” of nutritional supplementation administered during regular dialysis sessions.
Secondary outcomes included observations on nutritional and inflammatory status of
hypoalbuminemic patients undergoing hemodialysis. We hypothesized that a combination of
protein and omega-3 supplementation would be more effective than protein supplementation
alone in improving nutritional and inflammatory status.
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Methods
Patients
One hundred-and-five patients who were undergoing routine hemodialysis treatment in the Great
Lake Dialysis Clinic in Detroit, Michigan were screened. Selection criteria for patients included
serum albumin levels not meeting the outcome goal of K/DOQI guidelines [183] (≤3.9 g/dL),
age greater than 18 years old and ongoing dialysis treatment for at least 3 months prior to the
study. Patients who were residents of nursing homes or receiving intradialytic parenteral
nutrition, tube feeding, undergoing 8 hours of dialysis treatment, nocturnal dialysis, serum
albumin > 3.9 g/dL, or fish allergies were excluded.
Study design and procedures
The present study was approved by the Human Ethics Committees of Wayne State University
and the Human Investigation Committee of Great Lakes Dialysis. Informed written consent was
obtained from all patients. Eligible subjects (n=63) were randomized into two groups - placebo
+protein supplement (Placebo, n=32) and omega 3 + protein supplement (Omega3, n=31).
Patients, care givers and investigators were blinded from group assignments. This study lasted 6
months.
Nutritional intervention and compliance
The nutritional intervention provided comprised of two components. Both treatment groups
received a blend of 30 mL liquid protein supplement (Proteinex) (Llorens Pharmaceuticals Inc,
Miami, FL) in 60 mL of apple juice providing 100 kcal, 18g protein and 8 gram carbohydrate
[specifically, 30mL of Proteinex provides 18g of protein hydrolysate (72 kcals), with 1440mg of
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L-Arginine, 540mg of L-Leucine, 420mg of L-Phenylalanine, 132mg of L-Histidine, 780mg of
L-Lysine, 360mg of L-Isoleucine, 132mg of L-Methionine and 66mg of L-Tryptophan].
Additionally, subjects were given 4 capsules of either omega-3 or placebo, formulated by Twin
Rivers Technologies (MA, USA). Each one of the omega-3 capsule contained 150 mg of DHA
and 450 mg of EPA (total DHA 600 mg, total EPA 1800 mg), while the other capsule was a
placebo comprised of olive oil. Analysis of omega-3 and placebo capsule is presented in Table 1.
Both protein and capsules were given to the patients 3 times a week after their regular dialysis
session for a total duration of 6 months. Compliance was ascertained by administering the
supplements during the patient’s dialysis session with close monitoring by nurses. Tolerability
and side effects for supplements were recorded by registered nurses and hospitalization rates
were also monitored.
Blood sampling and laboratory measures
The study flow chart is shown in Figure 1. Approximately 20 mL of fasting blood sample were
taken prior to the dialysis session. Plasma samples intended for lipid analysis were isolated from
blood by centrifugation at 3000 rpm for 20 minutes at 4oC and were kept at 4oC to be analyzed
on the following day. Blood samples for NFκB were processed immediately to obtain
mononuclear cell extract using Ficoll-Paque method [184] and the extract was kept at -80oC
until further analysis. Serum samples for common renal profiles (serum albumin, BUN,
creatinine, hemoglobin, etc) were sent to Satellite Laboratory Services (Redwood City, CA) for
analysis and were measured using standard automated laboratory techniques.
Lipids analysis
Total cholesterol, HDL cholesterol and triacylglycerol (TAG) in the plasma were determined by
enzymatic reaction using kits purchased from Pointe Scientific Inc. (Canton, MI). LDL
	
  

76
	
  

cholesterol was calculated using the Friedwald equation (LDL-C = TC minus HDL-C minus
TAG/5) [174]. LDL-C to HDL-C ratio was calculated by dividing LDL-C by HDL-C values.
Inflammatory markers
Serum CRP was analyzed by an independent laboratory (DMC Laboratory, Detroit, MI) using
immunoturbidimetric method. Activated NFκB was measured from the nuclear extracts using
TransAm chemiluminescent (p65) kit purchased from Active Motif (Carlsbad, CA) using the
procedure described by the manufacturer.
Nutritional indicators
Serum albumin was measured by bromcresol green method using standard automated laboratory
techniques. Normalized protein nitrogen appearance (nPNA) was calculated according to
K/DOQI guidelines (2000) [183]. Malnutrition-inflammation score (MIS) questionnaire [89] was
also administered prior to (baseline), during (month-2) and at the end of the study (month-6).
MIS is a quantitative scoring system that comprised of 10 components related to patients’
medical history, physical exam, body mass index and laboratory parameters, which has been
reported to be a useful tool to predict dialysis outcome, malnutrition and inflammatory status
[185-187]. MIS was performed and calculated by a single person, a registered dietitian, to
minimize inter-observer variability.
Statistical analysis
The minimum sample size for each group was n=31, which was estimated at a power of 80% and
α=0.05 for a two-arm parallel study to detect a 0.2g/dL difference in serum albumin. Results
were analyzed using intention to treat principle. All study participants were maintained in the
treatment groups to which they were randomized regardless of post-randomization withdrawal
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and any missing values reported accordingly. Categorical data are reported as number and
percentage, while continuous data are reported as mean±SD or as otherwise stated. Independent
t-test was used to determine differences in the variables of interest between the two groups at
baseline. Difference between baseline and month-2 and between baseline and month-6 for each
group were tested using paired t-test. Data that were not normally distributed were tested using
non-parametric test. Statistical significance was set at α=0.05. All statistical tests were performed
using SPSS v. 16. As there was no significant difference between baseline and the 2-month
values in any of the parameters measured, these are not discussed further (data not shown).

Results
Demographic profiles
Sixty-nine patients met the inclusion criteria, and 63 agreed to participate. Subjects were
randomized based on albumin levels, and with the exception of gender distribution, there were
no significant difference in age, duration on dialysis, BMI and prevalence of existing co-morbid
(diabetes mellitus) or indicators of dialysis adequacy (Kt/v) between the two groups (Table 2).
The study population was homogenously comprised of African-American ethnicity with no
difference in income between groups.
Tolerability, side effects and compliance
Over the course of the study, four patients passed away due to a) cerebrovascular accident (one
subject, P group), b) diabetic infection (one subject, Omega3 group) and c) CVD (two subjects,
one from each group). There were no other adverse events reported (i.e. a life-threatening
adverse experience, inpatient hospitalization or prolongation of existing hospitalization, or a
persistent or significant disability/incapacity), over the course of the study. No discernible
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“fishy” smells were reported by any of the patients with regards to capsule assignment. Two
patients complained they couldn’t swallow the pills (P group) and withdrew from the study
(Figure 1). Twenty-one patients (33%) were able to take 100% of the supplement provided (no
missing day) during the 6-month study period. Sixty-seven percent of the patients (n=22 for
Omega3 group and n=21 for P group) were able to take greater than 80% of the supplements.
The principal reason for “lack of compliance” was subjects who missed their scheduled dialysis
sessions.
Effects on lipid profiles
One subject was excluded from the analysis due to high TAG levels (478 mg/dL) as Friedwald
equation for LDL-C estimation is not reliable when TAG levels exceed 400mg/dL [188]. Total
cholesterol was significantly reduced over the 6 months intervention in both groups (p<0.001)
(Table 3). At the end of 6 months, the reduction in TC in the Omega-3 group (-37±32 mg/dL)
was approximately fifty percent greater than the reduction seen in the P group (-21±26 mg/dL,
p=0.057). While HDL-C levels were increased at month-6 compared to the baseline in both
groups (t=-4.077, p=0.000 and t=-3.410, p=0.004, respectively), there was no significant
difference between groups (p=0.531). LDL-C was reduced in both groups (Omega3 group:
t=6.083, p=0.000, P group: t=4.200, p=0.000) at month-6 as compared to the baseline, however,
no significant differences between the two groups were noted at the end of the study (p=0.092).
The LDL-C/HDL-C ratios were significantly improved in both groups as compared to baseline
(Omega3 group: t=5.875, p=0.000, P group: t=4.683, p=0.000). After 6 months, the Omega3
group had a significantly larger reduction in LDL-C/HDL-C ratios as compared to the P group (1.3±1.1 vs -0.7±0.8, p=0.043). As compared to baseline, TAG levels did not change in the P
group (p=0.561), while there was a tendency for a decline in the Omega3 group (p=0.064)
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Effects on nutritional parameters
Serum albumin and other nutritional indices are presented in Table 4. Serum albumin at the end
of the study was comparable to the values observed at baseline in both the Omega3 (t=-1.895,
p=0.070) and P (t=-0.314, p=0.756) groups. Comparison between both groups showed nosignificant difference (p=0.295). Similarly, no changes were observed in MIS score, nPNA and
BMI following the intervention within or between the groups. Additionally, hemoglobin levels
were not changed following intervention in both groups (Omega3 group: t=1.100, p=0.282, P
group: t=-0.731, p=0.471).
Effects on inflammatory indicators
The NFκB levels observed after 6 months in the Omega3 and P groups were similar to their
baseline values (Table 5). Additionally, mean differences (month-6 minus baseline) between
Omega3 and P groups were not significantly different (p=0.134). With regards to CRP levels,
mean values showed a significant elevation in CRP levels in the P group (t=-2.158, p=0.040) but
not the Omega3 group (t=-0.582, p=0.565) over the 6 months. However these differences were
not apparent when median CRP values were compared. Additionally, there was a significant
inverse association between CRP and albumin levels across both groups (r= -0.261, p=0.049).
Discussion
Our study tested the potential of a combination of protein and omega-3 supplementation to
improve nutritional and inflammatory markers in chronic hemodialysis patients. To increase
compliance the supplements were administered during patient’s routine dialysis session, three
times per week (“directly observed treatment”). Directly observed treatment allowed for 2/3rds
of the subjects to receive more than 80% of the stated overall dose over a six months period.
While compliance was excellent in patients who came in for regular dialysis sessions, the
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significant comorbidities within this patient population resulted in a large number of missed
dialysis treatments (and hence missed supplementation).
We observed that serum albumin, one of the markers of nutritional status, was not
improved significantly in either group following the intervention. This finding was in contrast to
what has been reported in previous studies [189-191]. This may be explained by the fact that
only a small number of patients were able to take all of the supplement provided to them (no
missing day) during the study course (n=21, 33.3%). Patients missed days of supplementation
mostly due to frequent hospitalization or failed to show up for their routine dialysis treatment,
ranging from 1-44 days. Therefore, this could potentially upset the effect of omega-3 and protein
supplementation per se. Further analysis on a pool of patients who substantially completed the
supplementation course (i.e. taking >80% of the supplements) showed marginal improvement in
serum albumin at month-6 as compared to the baseline (3.6±0.3 g/dL vs 3.7±0.3 g/dL, p=0.079)
but no improvement were noted in those who took <80% supplements (3.7±0.2 vs 3.7±0.4,
p=0.939). Interestingly, nPNA, an indicator of protein intake, remained constant in both group
despite protein supplementation. A similar study by Morretti et al. [192] also noted a similar
trend, in which there were no changes in nPCR despite improvement in serum albumin in the
protein group for the second 6 months.
Reduced protein intake and an increase in inflammatory response are two important
factors that lead a decrease in serum albumin [193]. However, Kaysen et al [194] had noted that
low serum albumin in dialysis population may be attributed to systemic inflammation rather than
nutritional inadequacy as a causative factor per se. In relation to that, we also observed a
significant inverse correlation between serum albumin and CRP which may indicate the
influence of inflammatory process in serum albumin levels. Friedman and Fadem [195]
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suggested that serum albumin should be taken as a marker of illnesses rather than nutrition. This
is due to the fact that serum albumin has a strong ability in predicting mortality but rather limited
prediction for nutritional status due to significant influence of non-nutrition causes (such as
inflammation).
Many of the omega-3 fatty acid supplementation studies in dialysis population have
described various potential outcomes such as attenuating dyslipidemia, inflammation and
providing cardio-protective effect. Moreover, there is substantial evidence for reducing TAG
levels [27, 28, 30] even at a dosage as low as 1.5g/day [29]. As for plasma TAG, we saw a
tendency for a reduction in TAG levels in both groups although in the O3PP group statistical
significance was marginal (p=0.064). The large variation in the difference in TAG changes
observed in the PPP group (-7±61 mg/dL, p=0.56, Table 3) could be attributed to one subject
with very high triacylglycerols concentrations. Upon removal of this subject the difference in
TAG between the 6 month and baseline value was 1±44 mg/dL, p=0.89. Thus collectively these
data suggest no change in TAG over 6 months in the placebo group, while there was a tendency
for a reduction in TAG in the Omega3 group (-20±44 mg/dL, p=0.064). Previous studies [106,
161] which administered a higher amount of omega-3 per week, with varying percentage of
EPA/DHA but with a shorter duration (4 – 8 weeks) also reported no changes in TAG levels.
However, Bouzidi et al (2010) reported that a supplementation of 2.1g omega-3 daily for 3
months among CKD patients reduced TAG levels by 48% [196]. However, it is important to note
that the baseline TAG levels in their study were much higher than the current study (275±58
mg/dL vs 123±60 mg/dL in omega-3 group). We postulate that, the baseline TAG levels (O3PP:
123±60 mg/dL and PPP group: 104±69 mg/dL) were within the normal levels and thus may not
have been sufficiently elevated to achieve a significant reduction. Skulas-Ray et al reported that
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the extent of TAG lowering with omega-3 is a function of baseline TAG levels [197]. Omega-3
supplementation resulted in better improvement in LDL-C/HDL-C ratios as compared to placebo
which appeared to be due to a greater improvement in non-HDL-C. As for inflammatory
markers, our results for CRP were inconclusive. While mean values in the P group increased
over the 6 month period, this was not the case in the Omega3 group, in which CRP levels stayed
the same. Thus Omega-3, if not effective in attenuating inflammation, may be beneficial in
preventing further increases in inflammatory status. However when the data were evaluated
using median CRP values, these differences were no longer apparent suggesting the need for a
larger sample size to definitively resolve this issue. Only a small number of studies have
investigated the effects of omega-3 on inflammatory marker in hemodialysis population. It is
important to note that, most of these studies are not comparable due to difference in study design,
supplement dosage, EPA/DHA ratios and study duration. Saifullah et al showed that, a
supplementation of 1.3 g of oral EPA and DHA daily over the period of 3 months could
modestly reduced CRP levels [108]. However, a recent study using a larger dosage (2.08g/day)
but a shorter duration (10 weeks) showed no effects on serum systemic inflammation markers
(CRP, IL-6, TNFα) and oxidative stress (MDA, TAC) [198]. In a prospective cohort study by
Noori et al (2011), the authors showed that, a lower omega-6 to omega-3 ratios (~6) was
associated with decreased inflammation and overall mortality in hemodialysis population which
indicate the importance of n-6/3 PUFA ratios in the diet [32]. However, our study was not
designed to investigate the effects of the ratio per se.
NFκB, a key player in pathogenesis of inflammation, is stimulated by pro-inflammatory
agents such as cytokines and CRP. Studies have shown that, NFκB activation and subsequent
activation of mononuclear cells trigger a process that cause myocardial inflammatory damage in
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hemodialysis patients [199, 200]. Interestingly, our data for translocation of activated NFκB to
the nucleus showed no significant changes following the intervention within and between both
groups even though we saw an increase in CRP levels in the placebo group. The latter may have
been due to the fact that the baseline CRP values in the placebo group were lower than those
assigned to the omega-3 group.
Limitations of the study
We were restricted in our patient population to one dialysis clinic for this pilot study. While the
lipid data suggested benefits of Omega3, the data for inflammatory markers was less clear-cut.
One plausible explanation for variation in inflammatory markers in the current study may be
related to insufficient dosage/frequency of Omega-3 supplementation as well as compliance (due
to frequent hospitalization resulting subjects missing dialysis sessions and therefore
supplementation). There are several similar studies that also failed to report significant changes
in inflammatory markers [161, 201-203]. Studies that demonstrated a significant effect of
omega-3 supplementation on inflammation indices are those with a higher dosage and more
frequent administration of the supplement (9.1 to 21 g/week vs 7.2g/week DHA + EPA in the
current study) as well as reported better patients’ compliance [204-207]. Another factor that
could potentially explain the contradictory finding in our study with those studies is baseline
levels of inflammatory markers. Omega-3 supplementation appears to be more effective in
studies reporting higher baseline CRP (>13.8 mg/dL) than those which did not [109, 198, 204].
Notwithstanding some of the limitations discussed above, ours is one of the few studies
to report on the use of “directly observed treatment” of oral nutritional supplementation with
protein and omega-3 in a cohort of hemodialysis patients. Our results suggest that “directly
observed treatment” is technically feasible in hemodialysis patients and does not disrupt the
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normal dialysis schedule. The relatively large number of missed dialysis sessions due to
hospitalizations, however, suggests that “directly observed treatment” should be used in the
setting of both outpatient and in-patient dialysis sessions in order to optimize compliance. In
addition, while emphasizing the huge progressive inflammatory burden in hemodialysis patients
over time; this pilot study suggests that “directly observed treatment” with a combination of
omega-3 and protein based supplement (as opposed to a pure protein supplement) could have
some benefical effects on lipid profile and CRP progression. Further studies using a combination
of out-patient “and” in-patient “directly observed treatment” of fish oil based nutritional
supplementation are warranted.

	
  

85
	
  

Tables and figures
TABLE 4-1. Selected fatty acid composition of omega-3 and placebo capsule.

C16:0
C16:1
C17:0
C17:1
C18:0
C18:1n9
C18:2n6
C18:3n3
C20:0
C20:1n9
C20:5n3
C21:5n3
C22:5n3
C22:6n3
SAFA
MUFA
PUFA
Omega-3

Omega-3
(g/100g as FA)
0.96
0.35
0.14
4.66
8.88
2.00
0.77
0.50
35.36
1.70
4.95
24.31

Placebo
(g/100g as FA)
13.86
1.44
0.07
0.11
2.73
66.64
11.42
0.69
0.43
0.26
-

7.02
15.21
77.77
67.08

17.26
70.63
12.11
0.69

Abbreviations: SAFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA,
polyunsaturated fatty acids; FA, fatty acids.
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TABLE 4-2. Clinical and demographic characteristics of the study population.
Omega-3
(n=31)

Placebo
(n=32)

P value

Demographics
Age (years)
Ethnicity
African American (n, %)
Caucasian (n, %)
Gender (males, %)
Income ($ per month)

59±13

58±13

.845

30 (97)
1 (3)
20 (62.5)
1015±576

32 (100)
0 (0)
12 (38.7)
1148±761

.059
.552

Clinical
Time on dialysis (years)
BMI (kg/m2)
Diabetes mellitus (n, %)
Kt/v
Statin usage (n, %)
C-reactive protein (mg/dL)

3.6±2.9
28.4±8.3
20 (62.5)
1.58±0.29
11(35.5)
5.8±9.2

3.3±3.8
26.9±7.8
20 (64.5)
1.63±0.32
9 (28.1)
4.9±5.6

.784
.468
.868
.536
.530
.134

Abbreviations: BMI, body mass index; Kt/v, index of dialysis adequacy.
	
  

Notes: Differences in age, time on dialysis, BMI, Kt/v and income were tested using independent t-test.
Baseline CRP levels is reported in median±interquartile range. Differences were tested using MannWhitney rank-sum test.	
   Differences in gender, Diabetes mellitus and statin treatment were tested using
chi-square. P<0.05 is considered significant.
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TABLE 4-3. Means and standard deviations of lipid profiles (TC, HDLC, LDLC, and TAG) at
baseline and month-6.
Placebo(n=26)
Baseline
Lipid profiles
TC
159±49
(mg/dL)
HDLC
44±13
(mg/dL)
LDLC
94±42
(mg/dL)
TAG
104±69
(mg/dL)
LDL-HDL 2.2±1.0
ratio

Omega 3 (n=28)

Month 6

Diff.

P

Baseline

Month 6

Diff.

P

P
overall

138±42

-21±26

.000

176±36

139±29

-37±32

.000

.057

49±11

+5±8

.004

41±14

47±16

+6±8

.000

.531

69±35

-25±27

.000

108±34

71±29

-39±33

.000

.092

96±68

-7±61

.561

123±60

102±53

-20±55

.064

.405

1.5±0.9

-0.7±0.8

.000

3.0±1.6

1.7±1.0

-1.3±1.1

.000

.043

Abbreviations: TC, total cholesterol; HDLC, high density lipoprotein cholesterol; LDLC, low density
lipoprotein cholesterol; TAG, triacylglycerides; Diff, Mean difference of month-6 minus baseline.
Notes: All values are presented as mean±SD. P values for each group derived from paired t-test between
baseline versus month-6 comparison. Overall P values derived using independent t-test, tested for mean
differences of lipid profiles parameters between omega-3 and placebo groups (bold face).
Data excludes values from 7 subjects (Placebo, n=4; Omega-3, n=3) who passed away (n=4, 2 from each
group) or were hospitalized (n=3), during the course of the study. One subject (placebo) was excluded
due to extremely high TAG levels (478mg/dL) as the Friedwald equation is not reliable when TAG levels
exceed 400mg/dL.
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TABLE 4-4. Means and standard deviations of nutritional status indicators (Ser. Alb, Hgb, MIS
score, nPNA and BMI) at baseline and month-6.
Placebo (n=27)
Baseline
Nutritional status
3.7±0.2
Ser. Alb
(g/dL)
11.0±1.0
Hgb
(g/L)

Omega-3 (n=28)

P
overall

Month 6

Diff.

P

Baseline

Month 6

Diff.

P

3.8±0.4

0.0±0.3

.756

3.6±0.3

3.7±0.3

0.1±0.3

.070

.295

11.3±1.7

0.2±1.7

.471

10.4±1.1

10.8±1.5

0.3±1.4

.282

.866

MIS
score

7.6±3.6

8.1±4.0

0.6±4.0

.215

9.0±3.6

9.1±3.4

0.4±2.2

.408

.730

nPNA

0.96±0.38

0.91±0.22

-0.01±0.23

.810

0.99±0.29

0.87±0.25

-0.07±0.45

.471

.598

BMI
(kg/m2)

25.4±5.6

25.1±6.1

0.3±1.8

.327

28.1±7.0

28.1±7.2

0.1±1.0

.699

.500

Abbreviations: Ser.Alb, serum albumin; Hgb, hemoglobin; MIS, malnutrition inflammation score;
nPNA, normalized protein equivalence of nitrogen appearance; Diff, mean difference of month-6 minus
baseline.
Notes: All values are presented as mean±SD. P values for each group derived from paired t-test between
baseline versus month-6 comparison. Overall P values derived using independent t-test, tested for mean
differences of lipid profiles parameters between omega-3 and placebo groups (bold face).
Data excludes values from 7 subjects (Placebo, n=4; Omega-3, n=3) who passed away (n=4, 2 from each
group) or were hospitalized (n=3), during the course of the study.	
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TABLE 4-5. Means and standard deviations of inflammatory indicators at baseline and month-6.
Placebo (n=27)

Omega-3 (n=28)

P overall

Baseline

Month 6

P

Baseline

Month 6

P

NFkB (fold
diff)
CRP (mg/dL)*

2.48±1.03

2.54±1.14

.703

2.52±1.19

2.15±0.4

.129

.134

6.6±8.3

11.0±13.9

.040

13.1±17.5

14.6±19.7

.565

.259

CRP (mg/dL)**

4.9±5.6

4.6±12.0

.034

5.8±9.2

6.1±14.0

.412

.326

Abbreviations: CRP, C-reactive protein; NFkB, Nuclear factor kappa-light-chain enhancer of activated B
cells.
Notes: NFkB value is presented as mean fold difference (relative to control) ±SD. CRP value is presented
as *mean±SD and **median±IQR. P values for each group derived from either paired t-test (NFkB
)/Wilcoxon rank sum test(CRP) between baseline versus month-6 comparison. Overall P values derived
using either independent t-test/Mann-Whitney rank sum test, tested for mean differences of inflammatory
parameters between omega-3 and placebo groups (bold face).
Data excludes values from 7 subjects (Placebo, n=4; Omega-3, n=3) who passed away (n=4, 2 from each
group) or were hospitalized (n=3), during the course of the study.
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FIGURE 4-1. Omega-3 study’s flow chart.
Assessed for eligibility
(n=105)

Randomization
(n=63)

Excluded (n=42)
-‐ Did not met exclusion
criteria (n=36)
-‐ Declined to participate
(n=6)

Allocated to placebo
group (n=32)

Allocated to Omega-3
group (n=31)
Baseline: blood
collection, MIS,
anthropometric data.

Month-2: blood
collection, MIS,
anthropometric data.

Passed away
(n=2)

Month-6: blood
collection, MIS,
anthropometric data.	
  

Analyzed
(including drop out)
(n=28)

Voluntary drop-out
(Unable to swallow the
capsule) (n=2)

Passed away
(n=2)

Analyzed
(including drop out)
(n=28)

Abbreviations: MIS, Malnutrition-Inflammation Score.
Notes: All patients at the Great Lake Dialysis clinic (n=105) were screened for eligibility. Sixty-nine
patients met the inclusion criteria but 6 of them declined to participate. The remaining 63 patients were
randomized into omega-3 and placebo groups and underwent intervention for 6 months. Seven additional
subjects (Placebo, n=4; Omega-3, n=3) were excluded from data analysis due to death (n=4, 2 from each
group) or hospitalization (n=3). Two patients voluntarily dropped out as they were unable to swallow the
capsules but their data were included in the analysis (intent to treat).
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CHAPTER V
SPECIFIC AIM 2:
EFFECTS OF TOCOTRIENOL-RICH FRACTION SUPPLEMENTATION ON
NUTRITIONAL INDICES, INFLAMMATORY MARKERS, OXIDATIVE STATUS AND
LIPID PROFILES IN CHRONIC HEMODIALYSIS PATIENTS
This is an expanded version of the paper published in:
Vascular Health and Risk Management. 2013; 9:747-761 [208].
Daud ZAM, Tubie B, Sheyman M, Osia R, Adams J, Quainton T, Tubie S, Khosla P.

Introduction
End-stage renal disease (ESRD) patients on chronic hemodialysis (HD) experience a higher risk
for atherosclerotic vascular disease; cardiac death accounts for approximately 50% of all-cause
mortality [209], which is 15-30 times higher than an age-matched general population [3, 5]. The
increased cardiovascular risk in this setting however cannot be exclusively explained by
traditional cardiovascular risk factors alone. Instead, a combination of various factors especially
malnutrition-inflammation complex syndrome, oxidative stress and dyslipidemia are implicated
[11, 12, 210].
Patients on HD treatment often present with malnutrition-inflammation complex
syndrome characterized by coexistence of protein-energy malnutrition and inflammation
pertaining to dialysis related factors, disease processes, various comorbidities, nutrient loss and
poor nutritional intake [74]. Chronic systemic inflammation which is commonly found in 3050% of ESRD patients exacerbates oxidant production. This is aggravated by low intake of

	
  

92
	
  

antioxidants, secondary to malnutrition and dietary restrictions in this population [211]. In fact,
low circulating plasma levels of antioxidants have been shown to correlate with carotid
atherosclerosis in ESRD patients [212]. Equally noteworthy, unadjusted analyses of 4D (Die
Deutsche Diabetes Dialyse Studie) study revealed that HD patients in the lowest plasma vitamin
E (α-tocopherol) quartile had a 79% higher risk of stroke and 31% higher risk of all-cause
mortality as compared to their counterpart in the highest quartile; however, this was confounded
by malnutrition [213].
Additionally, in ESRD patients on dialysis, dyslipidemia is highly prevalent due to
delayed catabolism of triglyceride-rich apolipoprotein B containing lipoproteins, which
subsequently leads to elevated triacylglycerol (TAG) and low plasma HDLC [15]. In a study of a
large cohort of incident dialysis patients (n= 21, 893), it has been shown that dyslipidemia
present in 82% of the population was predominantly manifest as elevated TAG (52%) and very
low density lipoprotein (VLDL) (52%), and decreased HDL (51%) [214].

Furthermore,

accumulating evidence indicates that the concentration of plasma apo-A1 and lecithin-cholesterol
acyl-transferase (LCAT) are decreased [16, 17] which in turn impedes HDL-mediated reverse
cholesterol transport [18], a process of disposing excessive cholesterol from extrahepatic tissues
and blood vessel walls. Taken together, a combination of oxidative stress, lipid disorders and
inflammation in this population is highly conducive for atherogenesis by promoting LDL
oxidation, monocyte activation, endothelial injury and consequently accumulation of lipids in the
artery wall [18].
Dietary intervention may be potentially beneficial in improving inflammatory status,
correcting oxidative stress and the observed dyslipidemia. However, there is paucity of
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information regarding the impact of dietary interventions with nutrients possessing antioxidant,
anti-inflammatory or lipid altering properties to correct these problems in the HD population.
Tocotrienols (TT) are dietary compounds that have gained increasing scientific scrutiny.
TT are members of the Vitamin E family which also includes Tocopherols (TP). Vitamin E is
comprised of 8 different isomers (four TP and four TT) designated α-, β-,γ- and δ, characterized
by a different number and position of methyl group attached on the chromanol ring. TT are the
unsaturated members of the vitamin E family, found primarily in palm fruit oil, rice bran and
annatto. In the US diet however, TP particularly γ-TP is the most abundant form of vitamin E,
derived primarily from plant seeds and vegetable oils [117].
Comparisons of antioxidant activities amongst vitamin E family members in rat liver
microsomes revealed that TT exhibited 40- to 60- fold higher activities against lipid peroxidation
(Fe2+ + ascorbate and Fe2+ + NADPH induced) and greater radical scavenging potency than TP
[129, 130]. However, in vivo, antioxidative properties of TT could be limited by physiological
process (e.g. absorption, distribution, metabolism and excretion), but TT have been found to be
as equally potent as TP [116, 215]. More importantly, TT also play a role beyond their known
antioxidant activity – i.e. they possesses an anti-inflammatory property which has been shown to
inhibit lipopolysaccharide-induced secretion of interleukin-6 (IL-6) and tumor necrosis factor
(TNF) in macrophages [37], and decreased C-reactive protein (CRP) in human volunteers [135].
Additionally, TT may also confer cardioprotective effects by improving lipid profiles (reduced
total cholesterol and TAGs) [142, 216], and lower oxidation of LDL cholesterol [137].
To our knowledge, there are no reported TT studies in HD patients, whereas 17 TP trials
have been reported, albeit with inconclusive results [24]. Majority of these studies were open
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label aimed at improving oxidative stress while only three studies used a randomized controlled
trial (RCT) design that included 95 patients cumulatively. Of the three studies, Diepeveen et
al[166] provided 800IU/day for 12 weeks (~536mg) of α-TP in combination with 40mg/day of
atorvastatin but failed to show any effects on plasma-oxidized LDL. On the other hand, Uzum et
al[167] provided 300mg TP/day for 20 weeks and showed decreased plasma oxidative stress
markers (MDA and erythrocyte osmotic fragility).
Despite the lack of TT studies in ESRD population, several studies have shown beneficial
effects of TT supplementation in the general population. Cardioprotective effects of TT in these
studies have been primarily attributed to its anti-oxidative, anti-inflammatory and lipid lowering
properties. In a study by Heng et al [135], TT supplementation in healthy volunteers resulted in
lower CRP levels, which has been regarded as a prognostic indicator for cardiovascular events
and mortality in ESRD patients [6, 7]. In addition, supplementation with TT-rich fraction from
palm oil (200mg/day for 8 weeks) plus statin in hypercholesterolemic human subjects resulted in
improved lipid profiles while minimizing the side effects of statins [142]. A recent study showed
that palm oil derived TRF increased plasma HDL-C in the elderly following 6 month of
supplementation [132]. Lipid altering effects of TT was attributed to their ability to suppress, and
stimulate ubiquitination and degradation of HMG-CoA reductase as well as to block the
processing of SREBPs as demonstrated in cell culture studies [139, 217].
Given that HD patients experience oxidative stress, chronic inflammation and
dyslipidemia and that TT are potent antioxidant and anti-inflammatory agents with the potential
to improve lipid profiles, we hypothesized that TT supplementation would be of benefit to HD
patients by improving one or more of the above conditions. The results from this pilot study form

	
  

95
	
  

the basis of the current report. To the best of our knowledge, this is the first study to report the
role of TT in HD patients.
Methods
Patients
All patients (n=118) from the Great Lake Dialysis Clinic (Detroit, MI, USA) were screened for
eligibility. Patients were eligible for enrolment if they were at least 18 years of age, and had been
on dialysis treatment for at least 3 months prior to the study. Patients who were residents of
nursing homes or receiving nutritional support (tube feeding/ intradialytic parenteral nutrition)
were excluded. None of the patients in the unit were known to have AIDS or to be on active
treatment for cancer. All patients were undergoing dialysis with the same high-flux dialyzer
membrane (Fresenius Optiflux Dialyzer, Fresenius Medical Care, Waltham, MA, USA).
Study design and procedures
The present study was approved by the Human Investigation Committees of Wayne State
University and Great Lake Dialysis, LLC. Written informed consent was obtained from all
patients. A total of 88 patients met the inclusion criteria, but, seven patients refused to participate
leading to a final number of 81. Based on the final number of participants, randomization was
made in blocks in order to keep the sizes of the treatment groups similar and groups were
uniformly distributed by key-outcome measures. Block sizes were randomly selected to reduce
the potential for selection bias. This process was performed using the Random Allocation
Software version 1.0 [218]. A total of 81 patients were randomly allocated into TRF (n=41) and
placebo (n=40) groups. All clinical investigators and laboratory personnel as well as the study
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participants were blinded from group allocation and treatment until the end of the study. A
summary of the study’s flowchart is shows in Figure 5-1.
Nutritional intervention and compliance
TRF and placebo capsules were formulated by Carotino Sdn. Bhd. (Johor, Malaysia). TRF soft
gel capsules used were commercially available, each consisted of 90mg TT (comprising 30.18
mg α-, 5.30 mg β-, 41.66 mg γ-, and 12.86 mg δ-TTs) and 20.00 mg α-TP. Placebo capsules
contained negligible amounts of TT (0.12 mg α-, 0.06 mg β-, and 0.06 mg γ-TT) and TP (0.29
mg α-, 0.04 mg β-, and 0.11 mg γ-TP-) (Table 5-1). Patients were provided with two TRF or
placebo capsules during each of three weekly dialysis sessions. They were also supplied with a
pill organizer that contained TRF or placebo capsules for non-dialysis days. Patients were
instructed to consume two capsules during main meals (one during lunch and one during dinner).
Compliance was ascertained by “directly observed treatment” [175] – which involved nurses
directly observing patients taking their supplement capsules during designated days of dialysis.
Supplementation adherence on the non-dialysis days was measured by pill counting as described
elsewhere [219]. Briefly, patients returned the pill organizer each week and received refills - the
left over soft capsules in the pill organizer were counted and recorded.

Potential changes in diet

pattern were ascertained by collecting 24-hour diet recalls from all subjects (at baseline and week
16) by the same Registered Dietitian. Energy, macro- and micronutrients intake were analyzed
using Nutritionist-Pro (First Databank, Chicago, IL) based on the USDA database. Because TT
were not included in USDA database, their content was estimated based on published values
[115, 220, 221].
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Anthropometry, blood sampling and laboratory measures
Anthropometry measurements comprised height and weight. Patients’ weights were recorded to
the nearest 0.1kg (Tronix Flush-Mounted In-Floor Scale, Scale-Tronix, White Plains, NY, USA)
after each HD session to determine estimated dry body weight. Height was measured to the
nearest 0.1cm using a Tanita Wall Mounted Height Rod (Tanita, Arlington Heights, IL, USA).
BMI was calculated based on the Quetelet’s Index [170].
Approximately 15mL of fasting (for ~10 hrs) midweek predialysis blood samples were
collected from existing access sites of each study participant into two blood collection tubes.
Blood samples were collected into tubes (Becton Dickson, Franklin Lakes, NJ, USA) containing
either EDTA (for lipid analyses) or lithium heparin (for inflammatory markers and oxidative
status analyses) at baseline and wks-8 (lipid analyses only), 12 and 16. Plasma was isolated by
centrifugation at 2800rpm for 20 minutes at 4oC, divided into aliquots and immediately stored at
-80oC until further analysis. Serum samples for standard renal profiles (serum albumin, BUN,
creatinine) were analyzed using standard automated laboratory techniques by an external
laboratory (Ascend Clinical Laboratory Services, Redwood City, CA, USA).
Plasma Total cholesterol (TC), and TAG was determined by enzymatic reaction (Pointe
Scientific Inc., Canton, MI, USA). HDLC was measured in the supernatant after precipitation of
apoB-containing lipoproteins by dextran sulfate and magnesium ions (Pointe Scientific Inc.,
Canton, MI). LDLC was calculated using the Friedewald equation by difference (LDLC = TC
minus HDLC minus TAG/5).
CRP levels were measured using commercial kits based on enzyme-linked
immunoabsorbent assay (ELISA) method as per the manufacturer’s protocol (Cayman Chemical,
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Ann Arbor, MI, USA). Plasma samples were diluted in the assay buffer into 1:15,000 and
100µL of each sample was placed into a 96-well microplate that had been coated with a
monoclonal antibody specific for human CRP and incubated for an hour. The plate was then
rinsed four times with wash buffer before addition of horseradish peroxidase-labeled CRP
monoclonal antibody. Two antibodies were added and formed a sandwich by binding to different
locations on the CRP molecule. CRP concentration in the plasma samples were measured at
450nm after addition of chromogenic substrate tetramethybenzidine that formed a distinct yellow
color. IL-6 (Thermo Scientific, Rockford, IL, USA) , ApoA1 (Immunology Consultants Lab.
Inc., Portland, OR, USA) and TNFα in the plasma was also measured using similar principles per
manufacturers’ protocol. NFκB p65 levels were measured in the nuclear extract of peripheral
blood mononuclear cells as described in details in Chapter III.
Total antioxidant power (TAP) of the plasma was measured using commercial kits based
on a cupric reducing antioxidant capacity spectrophotometric method (Oxford Biomedical,
Oxford, MI, USA). Briefly, 200µL of diluted plasma samples (1:40 of plasma/dilution buffer)
were placed in a 96-well microplate followed by the addition of copper solution (50µL) and stop
solution (50µL). The reduction potential in the plasma sample converts Cu2+ into a reduced form
of copper (Cu1+) which in turn formed a stable 2:1 complex with the chromogenic reagent. This
color complex was quantified with an absorption maximum at 450nm. Standard curve was
prepared using a known concentration of trolox with data being expressed as mM trolox
equivalents.
Malondialdehyde (MDA) in the plasma was measured indirectly based on the reaction of
a chromogenic reagent, 2-thiobarbituric acid with MDA using a spectrophotometric method
(Oxford Biomedical, Oxford, MI, USA). Plasma samples were deprotinized with trichloroacetic
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acid (Fisher Scientific, Fair Lawn, NJ, USA) and the supernatant was obtained by centrifugation.
Total MDA in the deprotinized plasma samples were determined by the addition of indicator
solution followed by incubation at 65oC for 30 mins and the color complex was quantified with
an absorption maximum at 540nm. Standard curve was prepared using a known concentration of
MDA stock solution supplied in the kit.
Statistical Analysis
All results were analyzed using intention-to-treat principle in which all data were counted
regardless of post-randomization withdrawal and any missing values were reported accordingly.
Statistical analyses were carried out using SPSS v.16 (IBM, Chicago, IL, USA). Data for
categorical variables were reported as number and percentage, while continuous data were
reported as mean±standard deviation or median±interquartile range for skewed variables.
Between group difference in the change in parameters at particular time points were tested using
independence t-test (or respective non-parametric test for non-normality distributed variables).
One way repeated measures ANOVA were used to test time effects (the change from baseline)
for variables of interest in each group. χ2 statistics was used to evaluate differences in categorical
variables. Correlations between selected variables were calculated using Pearson’s correlation
coefficients test. P values of <0.05 is regarded as statistically significant.
Results
Characteristics of the study population
A total of 81 patients were randomized into placebo (n=40) and TRF (n=41) groups and were
provided either TRF or placebo capsules for 16 weeks. Two patients in the placebo group died
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due to cardiac arrest during the course of the study. An additional two patients (1 placebo; 1
TRF) were excluded due to transplantation and catheter dysfunction, respectively.
Table 5-2 shows the clinical and demographics characteristics of the study population.
There were no significant differences in all demographic and clinical variables at baseline. Our
study population was homogenously comprised of African-American ethnicity. Average body
mass index for placebo (28.7±8.2 kg/m2) and TRF (30.3±8.1 kg/m2) groups were in the category
of overweight based on WHO (2000) classification [171]. Over 60% of the patients in both
placebo and TRF groups had diagnosed Diabetes Mellitus. Moreover, ten patients (5 placebo; 5
TRF) was positive for hepatitis C antibody test (RIBA Reflex Siemens Centaur
chemiluminescent assay). Lipid lowering drugs (statins) were used by 28 patients (11 in placebo;
17 in TRF), aspirin were prescribed to 47 patients (22 placebo; 25 TRF) and 69 patient were
prescribed one or more type of antihypertensive drugs (35 placebo; 34 TRF). However, there
were no differences in term of drug distribution between the two groups based on χ2 test. In term
of dialysis parameters, both placebo and TRF groups had comparable dialysis treatment
adequacy as measured by Kt/V (K – dialyzer clearance of urea, t- dialysis time, and V- volume
of distribution of urea). In term of vascular access route, both groups had a similar proportion of
patients using either an arteriovenous fistula (18 placebo; 15 TRF), an arteriovenous graft (13
placebo; 16 TRF) or venous catheter (9 placebo, 10 TRF).
Dietary intake, tolerability, side effects and compliance
Dietary analysis based on 24-hr dietary recall during baseline and wk-16 of the study showed
that there were no changes in energy and macronutrients, between the two groups at a given
particular time point. There were no differences in vitamin E (TP and TT) intake at baseline and
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wk-16.

Similar results were also seen in vitamin C, β-carotene and other micronutrients

(potassium, phosphorus) intake within and between the groups (Table 5-3). Meanwhile, a total
of 62% of our study population [58% placebo (n=23) and 66% TRF (n=27)] were taking dietary
supplements that comprised of Renalcaps (18% placebo; 18% TRF), Nephrocaps (3% placebo;
3% TRF), vitamin C (0% placebo; 2% TRF) and multivitamins (2% placebo; 2% TRF).
Nephrocaps and Renalcaps comprised of 100mg vitamin C, 1.5mg Thiamine, 1.7mg Riboflavin,
20mg Niacin, 10mg Vitamin B6, 1 mg Folate, 6µg vitamin B12, 150µg Biotin and 5mg
pantothenic acid (Figure 5-2).
TRF and placebo supplements were well tolerated by the subjects. During the first week
of the study, one patient from the placebo group reported of diarrhea but this was not related to
supplementation and subsequently resumed the study. No other adverse effects were reported
from subjects in either groups to justify removal from the study. In the current study, compliance
was ascertained by direct and real-time observation of subjects taking the supplements during
dialysis sessions (three times a week) as well as pill counting method on non-dialysis days.
Compliance during non-dialysis days was more than 70% for each week except during wk-14
and wk-15 due to holidays (Thanksgiving). There were no differences in capsule consumption
(% of capsule disappearance) between placebo and TRF groups during the course of study
(Figure 5-3). Compliance of supplementation at home was relatively good considering that the
study population was comprised of low income and low literacy group which typically is
associated with poor compliance [175, 222].
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Effects on nutritional, inflammatory and oxidative markers
Nutritional, inflammatory and oxidative indices are presented in Table 5-4. Data for CRP and
IL-6 are reported in median±IQR because they were skewed. Median CRP levels at baseline was
16.6±28.8 and 13.0±20.5mg/L for the placebo and TRF group, respectively. There were no
difference in CRP levels between TRF and placebo at each time point. No significant changes
were noted in the CRP levels in both groups per repeated measures one-way ANOVA. Similarly,
there was no difference in mean IL-6 between or within groups at all time points.
Similarly, there were no significant changes (repeated measures one-way ANOVA)
observed in NFκB p65 levels over the time in both groups. It is important to note that, at
baseline, NFκB p65 levels in TRF group is significantly higher than placebo (91.7±9.8 vs
54.2±10.5 pg/µL, p<0.05, respectively). Upon normalization into the baseline value (week-12
minus baseline), TRF group showed marginal difference (p=0.08) when compared to placebo (16.7±13 vs 15.1±11 pg/µL) (Figure 5-4).

Another inflammatory marker, TNFα, also

demonstrated similar results in which there were no significant difference noted within and
between groups as measured at baseline and week-12 of the intervention (Figure 5-5).
Measurement of TAP showed that the TRF group had significantly higher TAP (p<0.05)
at wk-12 as compared to placebo (626±98 vs 564±95 mM Trolox equivalent). However, no
changes were observed within the TRF and placebo groups when compared to the baseline.
This was also in concert with indirect measurement of MDA, a marker for oxidative stress, in
which TRF group had a marginally lower MDA (2.60±2.28 µM MDA) at week-12 as compared
to placebo group (4.68±5.72 µM MDA) (p=0.055). There were no significant changes in MDA
values within the TRF and placebo groups when compared to the baseline. In terms of nutritional
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indicators (serum albumin, hemoglobin, BMI), no changes were observed within or between
groups.
Effects on lipid profiles
Plasma TAG levels was significantly reduced in TRF group after 12 weeks of supplementation
as compared to baseline values (144±91 vs 113±47 mg/dL plasma, p<0.05) and remained
significantly reduced at wk-16 (144±91 vs 103±45 mg/dL plasma, p<0.05). In contrast, TAG
levels remained the same in the placebo group. Interestingly, both groups showed a progressive
decline in plasma TC and a significant improvement in HDLC when compared to the baseline
values starting at wk-8. Hence, this also resulted in a reduction of LDL-C and the ratio of
TC/HDLC (Table 5-5).
As TAG levels were somewhat higher in the TRF group at baseline, values were
normalized to these baseline values. Normalized plasma TAG were reduced in the TRF group as
compared to placebo at wk-12 (-33±84 vs 6±66 mg/dL, p=0.032), and at wk-16 (-36±79 vs 8±47 mg/dL, p=0.072) (Figure 5-6). Plasma HDLC was significantly higher in the TRF group as
compared to placebo at both wk-12 (22±15 vs 9±11 mg/dL, p<0.0001) and wk-16 (16±14 vs
10±9 mg/dL, p<0.05, respectively) (Figure 5-7).
Measurement of ApoA1 concentration in the plasma, a major protein component of HDL
particles, revealed that it was significantly higher in TRF group as compared to placebo at wk12 (1.56±0.59 vs 1.27±0.34 mg/mL, p<0.05, respectively) consistent with the higher HDL-C
concentrations (Figure 5-10). However, no difference was noted between groups at wk-16.
Measurement of CETP activity, a plasma protein that facilitates the transfer of cholesteryl
ester from HDL in exchange for triacylglycerols from TAG-rich lipoprotein, was significantly
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lower in the TRF group at wk-16 as compared to placebo (96±18 vs 129±43 pmol/mL plasma/hr,
p<0.001, respectively), which reflected the higher HDL-C value in TRF group. Interestingly,
CETP activity was slightly higher in TRF group during wk-12 (95±19 vs 84±19 pmol/mL
plasma/hr, p<0.05, respectively). Pearson’s correlation test between HDL-C levels and ApoA1
concentration during wk-12 and wk-16 showed a significant correlation between the two
variables. Similarly, significant correlations were observed between plasma TAG and CETP
(Figure 5-11).
Correlation between biochemical parameters
Table 5-6 depicted Pearson’s correlation coefficient test between nutritional indicators,
inflammatory markers and oxidative status parameters based on pool data (baseline + week-12 +
week-16). MDA as indicator of oxidative stress has an inverse relationship with TAP (r= -0.273,
p<0.01) indicating that higher total antioxidant capacity in the plasma confers some protective
effect against the reactive species – MDA. Moreover, MDA levels were also significantly
correlated with CRP (r=0.501, p<0.01), exemplifies the complex relationship of inflammation
and oxidative stress as discussed in Chapter II. Serum albumin was also positively correlated
with TAP suggesting the antioxidant role of albumin (by localized thiol moieties) as previously
reported elsewhere [11]. Furthermore, serum albumin was inversely correlated with CRP levels
(r= -0.163, p<0.05) due to the fact that it is a negative-acute phase protein while CRP is the
positive-acute phase protein. Increased in CRP is therefore lead to a decreased in serum albumin.
The summary of Pearson’s correlation coefficient test between lipid profiles (TC, TAG,
HDLC, LDLC and TC-HDLC ratios) is presented in Table 5-7. In brief, CRP was positively
correlated with TAG (r= 0.159, p<0.05) while had an inverse relationship with HDLC (p= -
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0.163, p<0.05) suggesting the protective role of HDLC. Similarly, LDLC showed a positive
relationship with MDA (r= 0.138, p<0.05). Interestingly, when compared to dietary intake
parameters, total fat and cholesterol intake were inversely correlated with HDLC, while
cholesterol and vitamin E intake had a positive relationship with TAG levels.
Discussion
The present study, to the best of our knowledge, is the first to report the extent of vitamin E
tocotrienol-rich fraction supplementation effects on inflammatory markers, oxidative status and
lipid profiles in HD subjects. This study highlights some important findings especially in the
lipid altering properties of TT which could potentially have clinical implications. Patients in both
placebo and TRF group had comparable demographics, percentage of smoking cigarettes,
dialysis and clinical parameters distribution. In addition, baseline inflammatory markers,
oxidative status and lipid profiles in both groups were not statistically different. Thus any
potential comorbidities and confounding factors were minimized by being randomly distributed
across the two groups.
In this study, we observed that baseline median CRP levels in both groups were relatively
higher as compared to commonly reported values in the literatures [223, 224]. However, this is in
accordance with our previous results [175] despite methodological differences between the two
studies. The fact that gradual increments in CRP levels were seen in both groups might suggest a
progressive inflammatory burden in this population. Results from the present study indicated that
short term TRF administration was unable to improve CRP levels in HD patients. This is in
contrast with recent TRF trial that has been conducted in healthy volunteers which showed
reduction in CRP levels in older subjects [135]. We speculate that this is partially due to high
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interindividual variability in CRP levels, which is often associated with transient intercurrent
clinical events and the dynamic response of immune system [225]. Despite the high predictive
power of mortality in a single CRP measurement [73], given the fact that CRP fluctuates
dramatically upon acute inflammation [226] or even in the absence of changes in other
biochemical measures or health status [226-228], CRP measurement alone may not adequately
capture immunomodulatory changes following therapeutic intervention, thus necessitating
measurement of other inflammatory biomarkers. Similar observations were also seen in IL-6,
NFκB p65 and TNFα values. In term of oxidative status parameters, no significant improvements
were seen in TAP and MDA values in either TRF or placebo group over time, but the TRF group
had higher TAP and marginally lower MDA at week-12 but these was not seen at week-16.
Taken together, TRF supplementation failed to improve inflammatory and oxidative status
markers in the current study.
Interestingly, TRF supplementation resulted in improvement in plasma TAG and HDLC.
The improvement in lipid profiles was less anticipated due to mixed results in previous human
trials. For example, Mustad et al [144] administered 200mg TT/day for 28 days in healthy
hypercholestrolemic volunteers but failed to show any effects on blood lipids. Similarly,
supplementation with a TT-rich vitamin E concentrate (140mg TT, 80mg TP per day) to 20 men
for 42 days showed no improvement in lipoprotein profiles despite changes in plasma
tocopherols and tocotrienols concentration [143]. We speculate that the earlier studies in human
volunteer did not show a positive result in blood lipids due to a shorter duration, a smaller dose
and sample size. A recent study which administered TT for a longer period (6 months) in healthy
older adults showed significant improvement in lipid profiles (increased HDL-C and improved
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TC/HDLC ratios) [132], which strengthen the speculation that TT effects on blood lipids could
be a function of time and may depend on subject’s clinical status.
Because dyslipidemia is implicated in the pathogenesis of cardiovascular diseases,
therefore, it has become more common for dialysis patients with dyslipidemia to receive statin
treatment [229], albeit with conflicting evidence [69]. In our study population, 11 patients in
placebo group and 17 patients in TRF group were on statin treatment. Statin induced inhibition
of HMG CoA reductase leads to depletion of hepatic cholesterol pools and subsequently
decreases production of apoB-containing VLDL particles and upregulates LDL receptors.
Because VLDLs are the major TAG-trafficking lipoprotein in fasting plasma, therefore statins
reduce TAG by enhancing clearance of VLDL and reuptake of LDL via LDL receptors. In the
present study, TAG levels were significantly reduced in TRF groups at wk-12 but not at wk-16
(p=0.07) partly due to high variability in both groups. We postulated that this variability may
partly be due to statin users in the placebo group. Additional analysis among statin users revealed
that the TAG reduction observed in the placebo group was indeed due to statin administration
(Figure 5-8). Interestingly, in TRF group, both the statin and non-statin users showed a
reduction trend in TAG, which strengthens the speculation that TRF may be directly involved in
the TAG reduction process. Similar findings has been shown in a randomized, placebocontrolled clinical trial by Zaiden et al [140] in which supplementation with 120mg of γ-,δtocotrienols (γ-,δ-T3) for 8 weeks resulted in an ~ 28% reduction in TAG as compared to
baseline. This improvement in TAG was partly explained by suppression of the upstream
regulators of lipid homeostasis as demonstrated in an in-vitro study [140].
The increase in HDL-C levels in the plasma can be attributed in part to increased
production of HDL particles, delayed catabolism of HDL particles or higher cholesterol contents
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in HDL particles. To elucidate the mechanism of TT effects on TAG and HDL-C during wk-12
and wk-16, ApoA1 and CETP were measured. Our results showed that the ApoA1 level was
significantly higher in the TRF group during wk-12, which coincided with higher HDL-C in the
TRF group. Because ApoA1 is the major protein component of HDL particles (70%), increased
HDL-C levels at wk-12 in the TRF group may be explained by an increase in HDL particles
(mirrored by higher ApoA1 concentration). Pearson’s correlation test between HDL-C levels and
ApoA1 concentration during wk-12 and wk-16 confirmed significant correlation between the
two variables.
Animal studies have established that about one third of ApoA1 is catabolized by the
kidney and the rest by the liver - humans are assumed to have similar pathway of ApoA1
catabolism [230, 231]. In the context of ESRD patients, because kidney functions are impaired,
this also hypothetically leads to reduction of ApoA1 catabolism. Conversely, a recent study
showed that ESRD patients on HD have higher prevalence of autoantibodies to ApoA1 (antiApoA1 IgG) which correlates with dialysis vintage [232]. Similarly, in a comparative study
between healthy control and hemodialysis patients, Pahl et al [233] found that plasma HDL-C is
markedly reduced in HD patients which was mirrored by reduced ApoA1 plasma concentration.
Taken together, these may partially explain low HDL-C observed in ESRD/HD patients.
In the context of our study, the TRF supplemented group had significant increase in
HDL-C which was reflected by higher plasma ApoA1 concentration. In concert with the current
study, Heng et al [135] demonstrated that supplementation with 150mg/day TRF in a healthy
population resulted in increased expression of ApoA1 precursor. The effect on ApoA1 may not
be unique to TT per se because α-TP supplementation also increased pro apoA1 and apoA1
concentration [234]. Literature on molecular explanation of TRF effects on ApoA1 expression is
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scarce, thus further investigation in this area is warranted. It is possible that TRF and tocopherol
exhibit antioxidant like mechanism which implicates several transcription factors such as MAP,
PPARα and PPARγ in the upregulation of proapoA1 [234].
CETP activity was lower in TRF group during wk-16, consistent with the higher HDLC
value.

CETP mediates the transfer of cholesterol ester from HDL to VLDL remnants in

exchange for triacylglycerols [18]. Because HD patients usually experience delayed catabolism
of TAG rich lipoprotein, therefore, we speculate that CETP activity may be increased to facilitate
TAG-Cholesterol transfer between HDL and apoB100 lipoproteins. A recent study that
compared HDL-associated enzymes in HD vs healthy control subjects confirmed that HD
patients have higher CETP as compared to control [71], while another study reported no changes
in CETP [18]. In our study Pearson’s correlation test between CETP activity and TAG
concentration during wk-12 and wk-16 confirmed significant correlation between the two
variables.
Hemodialysis patients are frequently hospitalized due to concurrent comorbidities. In the
current study, we monitored missed dialysis sessions for each patient and the primary reason was
recorded. Cumulative numbers of missed dialysis session for each group were calculated (Figure
5-12). The total days of hospitalization was 122 vs 180 days for the TRF and placebo groups,
respectively. This is an intriguing observation. It should be noted that in a recent study in end
stage liver disease (ESLD) patients Patel et al reported that supplementation with 400mg TT/day
in ESLD patients slowed the rise in MELD scores (a standardized scoring system that is
clinically used to determine severity of liver failure and priority for transplantation) in 50% of
the patients receiving TT supplementation [169]. Coupled with our initial observation, it is
possible that TT therapeutics may provide benefit due to their ability to penetrate vital organ
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tissues. However, this hypothesis is purely speculative at present and warrants further
investigation in a larger cohort.
It is important to emphasize that the comparisons here are made to the studies that either
used α-TP in HD patients or studies that used TT/TRF in healthy volunteers of different clinical
population. Given that TT possesses the distinct functions from TP in the context of its
antioxidant and anti-inflammatory properties; therefore there are no comparable vis-a-vis studies
in HD patients.
Limitations of the study
The present study highlights beneficial treatment effects of TRF on lipids. Nevertheless, the
results of this study should be interpreted with caution. Firstly, the study was homogenously
comprised of a single race, and the majority of the patients were in low-income, low-literacy
group. Therefore, the positive outcome of TRF on lipids may not be generalizable to a more
diverse HD population. Secondly, compliance may have been a factor. However our study
design enabled us to directly monitor and observe patients taking their supplement during regular
dialysis days, while we were able to estimate consumption on non-dialysis days by the pill
counting method. Dietary changes were monitored by a single 24-hr dietary recall at baseline and
at the end of the study. We acknowledge the limitation of this method to adequately capture
dietary changes, however given the fact that diet monotony of dialysis patients plus limited
contribution of TT-rich food sources to our patients’ diet, we believe that variation in dietary
contribution of TT is clinically less important in contributing to the outcome of the present study.
Finally, the number of subjects in our cohort did not allow us to separate the effects of the
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various medication regimens (e.g. statins, anti-hypertensive drugs, aspirin) from the effects of TT
per se.
We did not measure TT in the blood, as the focus of the study was to observe the global
effects following oral supplementation, and not to look at the pharmacokinetics of tocotrienol
supplementation per se. It is known that TT are transported in circulating lipoproteins,[124, 235,
236] albeit with a short half-life[123] but recent data shows that they are indeed delivered to vital
organs.[169] Correlating plasma TT following supplementation in HD patients will be of
importance in the future as dose-escalation studies are contemplated to ascertain the optimal dose
of TT required in this population.
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Tables and figures
TABLE 5-1. TRF and placebo capsule composition
Content (mg)
Tocopherol (TP)
α-TP
β-TP
δ-TP
γ-TP
Tocotrienol (TT)
α-TT
β-TT
δ-TT
γ-TT

TRF

Placebo

20.00
-

0.29
0.04
0.11

30.18
5.30
41.66
12.86

0.12
0.06
0.06

Notes: TRF capsules were formulated from oil palm fruits while placebo capsules from wheat germ oil.
Other ingredients include the same amount of medium chain triglycerides in both capsules.
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TABLE 5-2. Baseline clinical and demographic characteristics of the study population.

Demographics
Age (yrs)
Age > 65 yrs (n, %)
Ethnicity
African American (n, %)
Gender (males, %)
Smoking cigarettes (n, %)
Clinical
Diabetes Mellitus (n, %)
Hepatitis C (n, %)
Time on dialysis (months)
BMI (kg/m2)
Systolic B/P (mmHg)
Diastolic B/P (mmHg)
Kt/v
Statins (n, %)
Aspirin (n, %)
Anti-hypertensive, one or more type
(n,%)
Vascular access
Arteriovenous fistula (n, %)
Arteriovenous graft (n, %)
Venous catheter (n, %)

Placebo
(n=40)

TRF
(n=41)

P value

58±13
12 (30)

59±12
14 (34)

0.565
0.689

40 (100)
23 (57.5)
10 (25.0)

40 (97.5)
20 (48.8)
10 (24.3)

0.432

26 (65)
5 (12.5)
37±18
28.7±8.2
150±24
81±15
1.48±0.26
11 (27.5)
22 (55.0)

25 (61)
5 (12.2)
34±19
30.3±8.1
153±23
83±14
1.45±0.20
17 (41.4)
25 (61.0)

0.708
0.967
0.446
0.768
0.651
0.506
0.516
0.124
0.297

35 (87.5)

34 (82.9)

0.562

18 (45)
13 (32.5)
9 (22.5)

15 (36.6)
16 (39)
10 (24.4)

0.732

Abbreviations: BMI= Body Mass Index; B/P=blood pressure; Kt/V=Index of Dialysis Adequacy.
Note: Data are reported as mean±SD for continuous variables and number (percentage) for categorical
variables. P values are comparison between groups at baseline obtained from independent t-test or
Pearson χ2 test wherever appropriate,

	
  

114
	
  

TABLE 5-3. Energy, macronutrients and micronutrients intake during the course of the study.
All
(n=81)

Baseline
Placebo
TRF
(n=40)
(n=41)

P
value

All
(n=71)

Week-16
Placebo
TRF
(n=34)
(n=37)

P
value

Energy
(kcal/day)
Protein
(gm/day)
Carbohydrate
(gm/day)
Fat
(gm/day)
Vit A
(IU/day)
Vit C
(mg/day)
Vit E
(mg/day)

1995±977

2132±1243

1868±633

N.S.

1544±580

1505±545

1580±616

N.S>

94±59

99±80

88±31

N.S.

75±40

75±36

76±44

N.S.

209±106

204±100

213±111

N.S.

178±79

177±71

180±85

N.S.

90±68

105±90

76±37

N.S.

60±32

57±23

63±39

N.S.

7371 ±
19372

5524 ±
7415

9172 ±
26273

N.S.

6015 ±
9645

6377 ±
12115

5718 ±
7193

N.S.

98±84

89±82

108±86

N.S.

90±105

102±112

80±98

N.S.

9±10

9±9

10±12

N.S.

6±4

5±3

6±5

N.S.

Tocotrienols
(mg/day)
Potassium
(mg/day)
Phosphorus
(mg/day)

2.5±3.8

2.3±3.8

2.6±3.8

N.S.

1.6±2.3

1.6±1.5

1.6±2.8

N.S.

2350±872

2329±1266

2371±2334

N.S.

2015±919

1962±961

2058±894

N.S.

1183±652

1181±722

1186±585

N.S.

996±469

953±431

1031±500

N.S.

Abbreviations: N.S., not significant
Note: Energy, macronutrients and micronutrients intake were estimated based on 24-hr dietary recall.
Reported tocotrienols values are from diet only and does not include contribution from supplementation.
All values are presented as mean±SD. P values derived using independent t-test, tested for mean
differences of micronutrients intake between TRF and Placebo groups between baseline and wk-16.
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TABLE 5-4. Inflammatory, oxidative and nutritional markers during baseline, week-12 and
week-16.

Inflammatory markers
C-reactive protein (CRP) (mg/L)
Baseline
Week-12
Week-16
Interleukin-6 (IL-6) (pg/mL)
Baseline
Week-12
Week-16
Oxidative Status
TAP (mM Trolox equivalent)
Baseline
Week-12
Week-16
TBARS (µM MDA)
Baseline
Week-12
Week-16
Nutritional indicators
Serum albumin (g/dL)
Baseline
Week-12
Week-16
Hemoglobin (g/L)
Baseline
Week-12
Week-16
Body Mass Index (kg/m2)
Baseline
Week-12
Week-16

Placebo
(n=38)

TRF
(n=40)

16.6±28.8
25.1±36.5
17.9±39.5

13.0±20.5
15.5±18.0
14.3±28.0

4.6±5.9
5.2±3.5
5.2±2.1

4.9±3.5
4.9±2.3
5.9±3.1

640±207
564±95a
697±166

669±127
626±98b
759±246

3.39±5.12
4.68±5.72
3.85±3.90

3.01±4.65
2.60±2.28
2.89±3.65

3.9±0.3
3.9±0.3
4.0±0.4

3.9±0.3
3.9±0.3
3.9±0.5

10±2
10±1
10±1

10±2
10±2
10±2

28.7±8.2
29.1±8.1
29.1±8.3

30.3±8.1
30.4±8.2
30.5±8.2

Abbreviations: TAP,total antioxidant power; TBARS, thiobarbituric acid reactive substances; MDA,
malondialdehyde.
Note: Values are reported as median±IQR (CRP, IL-6) or mean±SD (TAP, TBARS, Alb, Hb, BMI).
Statistical analysis were conducted using one-way repeated measures ANOVA to test the difference in the
parameters overtime as compared to the baseline in each group – significant difference (p<0.05) for this
test denoted as *symbol. Independent t-test (TAP, TBARS, Alb, Hb, BMI) and Mann-Whitney U test
(CRP, IL-6) were used to test the mean differences between TRF and placebo groups at particular time
point – significant difference (p<0.05) for these tests denoted as different alphabetical letters. At week-12,
there was marginal difference (p=0.055) in TBARS (µM MDA) between placebo and TRF groups.
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TABLE 5-5. Lipid profiles of the subjects at baseline, week-8, week-12 and week-16.
Placebo
(n=38)

TRF
(n=40)

Triacylglycerols (mg/dL)
Baseline
Week-8
Week-12
Week-16

109±63
106±51
100±57
95±48

144±91
139±86
113±47*
103±45*

Total cholesterol (mg/dL)
Baseline
Week-8
Week-12
Week-16

179±42
153±32*
140±31*
149±38*

183±49
158±36*
142±43*
145±45*

High-density lipoprotein cholesterol (mg/dL)
Baseline
Week-8
Week-12
Week-16

44±12
51±14*
54±13*a
54±12*

42±13
51±15*
63±18*b
58±18*

Low-density lipoprotein cholesterol (mg/dL)
Baseline
Week-8
Week-12
Week-16

112±38
81±31*
70±32*
75±34*

112±46
79±35*
58±38*
66±42*

4.25±1.36
3.19±1.08
2.80±1.13
2.88±1.07

4.59±1.80
3.29±1.07
2.38±0.87
2.66±1.03

TC/HDLC ratio
Baseline
Week-8
Week-12
Week-16

Note: Values are reported as mean±SD. TAG, TC and HDLC were measured using standard enzymatic
assay, whilst LDLC were calculated by different using Fridewald equation. One-way repeated measures
ANOVA was used to test the difference in the parameters overtime as compared to the baseline in each
group – significant difference (p<0.05) for this test denoted as *symbol. Independent t-test was used to
test the mean differences between TRF and Placebo groups at particular time point – significant
difference (p<0.05) for these tests denoted as different alphabetical letters.
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TABLE 5-6. Pearson correlation coefficient between selected nutritional, inflammatory and
oxidative status markers based on pool data (baseline + week 12 + week-16).

TAP
MDA
IL-6
CRP
TNFα
NFκB
Alb
Hgb
Ferr

Oxidative
Status
TAP
MDA
1
-.273**
1
n.s.
n.s.
n.s.
.501**
n.s.
n.s.
n.s.
n.s.
.144*
n.s.
n.s.
n.s.
n.s.
n.s.

IL-6

Inflammatory
Markers
CRP
TNFα

1
.148*
n.s.
n.s.
n.s.
n.s.
n.s.

1
n.s.
n.s.
-.163*
n.s.
n.s.

1
n.s.
n.s.
n.s.
n.s.

NFκB

1
n.s.
n.s.
n.s.

Nutritional
Indicators
Alb
Hgb
Ferr

1
n.s.
.190*

1
-.168*

1

Abbreviations: TAP, total antioxidant power; MDA, malondialdehyde; IL-6, interleukin-6; CRP, Creactive protein; TNFα, tumor necrosis factor alpha; NFκB, nuclear factor kappa B; Alb, serum albumin;
Hgb, hemoglobin; Ferr, ferritin; n.s., not significant.
Notes: This figure shows Pearson correlation coefficients of selected nutritional, inflammatory and
oxidative status markers based on pool data (n=155 for TNFα and NFκB; n=226 for all other). Data are
presented as Pearson correlation r values. Symbol * and ** indicates correlation is significant (p<0.05 and
p<0.01, respectively).
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TABLE 5-7. Pearson correlation coefficient between lipid profiles and selected nutritional,
inflammatory and oxidative status markers based on pool data (baseline + week
12 + week-16).

Oxidative Status
TAP
MDA
Inflammatory Markers
CRP
IL-6
TNFα
NFκB
Nutritional Indices
Alb
Hgb
Ferr
Calorie/kg body weight
Protein/kg body weight
Fat intake (g)
Cholesterol intake (mg)
Vitamin E intake (mg/day)

TC

TAG

Lipid Profiles
HDLC

n.s.
.148*

.146*
n.s.

n.s.
n.s.

n.s.
.138*

n.s.
n.s.

n.s.
n.s.
n.s.
n.s.

.159*
n.s.
n.s.
n.s.

-.163*
n.s.
n.s.
n.s.

n.s.
n.s.
n.s.
n.s.

n.s.
n.s.
n.s.
n.s.

n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.

n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
.306*
.226**

n.s.
n.s.
n.s.
n.s.
n.s.
-.194*
-.208*
n.s.

n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.

n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
.183*
n.s.

LDLC

TC/HDLC

Abbreviations: TAP, total antioxidant power; MDA, malondialdehyde; IL-6, interleukin-6; CRP, Creactive protein; TNFα, tumor necrosis factor alpha; NFκB, nuclear factor kappa B; ALB, serum albumin;
HGB, hemoglobin; FERR, ferritin; n.s., not significant; TC, total cholesterol; TAG, triacylglycerol;
HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol.
Notes: This figure shows Pearson correlation coefficients between lipid profiles and selected nutritional,
inflammatory and oxidative status markers based on pool data (n=155 for TNFα, NFκB and dietary data;
n=226 for all other). Data are presented as Pearson correlation r values. TC, TAG and HDLC were
measured in the plasma using commercial kit while LDLC were calculated by difference using
Friedewald formula. Dietary data (calorie/kg body weight, protein/kg body weight, fat, cholesterol and
vitamin E intake were estimated based on two 24-hr diet recall (baseline and wk-16). Symbol * and **
indicates correlation is significant (p<0.05 and p<0.01, respectively).
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FIGURE 5-1. TRF study’s flow chart.

Screened for eligibility
(n=118)
Excluded (n=37)
• Did not met inclusion criteria
(n=30)
• Declined to participate (n=7)

Randomization
(n=81)

Allocated to TRF
(n=41)
Excluded (catheter
dysfunction) (n=1)

Allocated to Placebo
(n=40)

Week 1
Week 3

Week 12

Analyzed
(including drop out)
(n=40)

Died (n=1)
(Cardiac arrest)
Underwent
transplantation (n=1)

Died (n=1)
(Cardiac arrest)

Analyzed
(including drop out)
(n=37)

Note: All patients (n=118) were screened for eligibility. A patient was excluded if he/she was <18 years
age, undergoing dialysis treatment <3 months, resident of nursing homes, undergoing 8 hours of dialysis
treatment or receiving intradialytic parenteral/enteral feeding. Data were analyzed according intention-totreat regardless of post-randomization withdrawal.
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FIGURE 5-2. Dietary supplements intake among study’s subjects.

Note: This figure shows dietary supplements intake as reported by the study’s subjects. Values are
presented as percentage of patients taking particular supplements during the study period. Neprhocaps and
Renalcaps (generic) contain the same amount of vitamins as follow: 100mg vitamin C, 1.5mg Thiamine,
1.7mg Riboflavin, 20mg Niacin, 10mg Vitamin B6, 1 mg Folate, 6µg vitamin B12, 150µg Biotin and
5mg pantothenic acid.
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FIGURE 5-3. Percent of capsule ‘consumption’ in placebo (n=38) and TRF (n=40) group during
the course of the study.

Note: This figure shows percent of capsule consumption (disappearance) for non-dialysis days, measured
by pill counting method for 16 weeks of the study. Values are expressed as mean±SEM. No significant
differences for each week between the two groups were noted as tested by independent t-test.

	
  

122
	
  

FIGURE 5-4. NFκB p65 value at baseline and week-12.

Abbreviations: NFκB, nuclear factor kappa B; Diff, mean difference in [NFκB] (wk-12 minus baseline).
Note: This figure shows NFκB p65 concentration measured in the nuclear extract using ELISA-based kit.
Values are reported as mean±SEM. Independent t-test was used to test the mean differences between
TRF and Placebo groups at each time point (baseline, wk-12, diff). Symbol * indicates significant
difference (p<0.05) while # indicates marginal difference (p=0.08) when compared to the placebo group.
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FIGURE 5-5. TNFα value at baseline and week-12.

Abbreviations: TNFα, tumor necrosis factor alpha; Diff, difference.
Note: This figure shows TNFα concentration measured in the plasma using ELISA-based kit. Values are
reported as mean±SEM. Independent t-test was used to test the mean differences between TRF and
Placebo groups at each time point (baseline, wk-12, diff). No different was noted between placebo and
TRF groups at all time points.
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FIGURE 5-6. Mean changes in plasma TAG normalized to the baseline.

Abbreviations: TAG, triacylglycerols.
Note: Values are presented as mean±SEM. TAG data are calculated by different from baseline values.
Symbol * indicates significant difference (p<0.05) as compared to placebo at each time point based on
independent t-test. At week-16 the there was a marginal different between TRF and placebo groups
(p=0.072).
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FIGURE 5-7. Mean changes in plasma HDLC normalized to the baseline.

Abbreviation: HDLC, high-density lipoprotein cholesterol
Note: Values are presented as mean±SEM. HDLC data are calculated by different from baseline values.
Symbol * indicates significant difference (p<0.05) as compared to placebo at each time point based on
independent t-test.
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FIGURE 5-8. Change in TAG levels among statin and non-statin users in placebo and TRF
groups.

Note: Changes in TAG and HDLC were calculated by deducting baseline values. Data are reported as
mean±SEM. Difference alphabet denote marginal difference (p<0.08), tested by independent t-test.
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FIGURE 5-9. Comparison of ApoA1 (A) and CETP activity (B) during week-12 and week-16.

A

B

*	
  
*	
  

*	
  

*	
  

Abbreviations: ApoA1, apolipoprotein A1; CETP, cholesteryl ester transfer protein
Note: Data are presented as mean±SEM. Symbol * indicates significant difference (p<0.05) as compared
to placebo at each time point, tested by independent t-test. Figure A shows plasma ApoA1 concentration
during week-12 and week-16 in both groups as measured by ELISA method. Figure B shows CETP
(cholesteryl ester transfer protein) activity during week-12 and week-16in both groups as measured in the
plasma using flourometric assay kit.
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FIGURE 5-10. Pearson’s correlation coefficient in lipid parameters during week-12 and week16.

B

A

TRF
Placebo

r=0.375, p<0.002

C

r=0.359, p<0.04

D

r=0.260, p<0.03

r=0.475, p<0.001

Abbreviations: HDLC, high-density lipoprotein cholesterol; ApoA1, apolipoprotein A1; TAG,
triacylglycerols; CETP, cholesteryl ester transfer protein.
Note: (A) (B) Correlation between ApoA1(mg/mL plasma) and HDLC (mg/dL plasma) at wk-12 and wk16, respectively. (C) (D) Correlation between CETP activity (pmol/µL plasma/hr) and TAG (mg/dL
plasma) at wk-12 and wk-16, respectively.
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FIGURE 5-11. Cumulative days of missed treatment in placebo (n=38) and TRF (n=40) group
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Note: This figure is for illustrative purpose only. Data are presented as absolute number of days of missed
dialysis session during each month of study course. The total number of days missed was 122 vs 180
days for the TRF and placebo groups, respectively.
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CHAPTER VI
SPECIFIC AIM 3:
CHANGES IN METABOLOMIC PROFILES FOLLOWING TRF
SUPPLEMENTATION
Introduction
ESRD patients on chronic HD have alarmingly higher risk for cardiovascular mortality when
compared to the age-matched general population (i.e. 15-30 times higher risk) [3, 5]. In fact,
cardiac death account for more than 50% of all-cause mortality in this population [209]. It is
believed that malnutrition-inflammation complex syndrome, oxidative stress and dyslipidemia
are implicated in the pathogenesis of cardiovascular diseases in this population [11, 12, 210].
Therefore, it is of interest to examine dietary impact of nutrients possessing antioxidant, antiinflammatory or lipid altering properties to alleviate these problems in the HD population. One
of the dietary compounds that have gained increasing scientific scrutiny is tocotrienols (TT). TT
have been shown to confer cardio protection via its antioxidative, lipid-lowering, antiinflammatory and anti-atherosclerotic properties in animal model as well as in human [34, 35,
37, 114].
However, the impact of such dietary intervention in a diverse clinical population is
challenging to interpret partly due to intra- and inter-individual variability in response to the
intervention, underlying comorbidities and the implication of compliance/non-compliance to the
overall study’s results. Moreover, the nature of traditional biomarkers such as lipid profiles
(plasma levels of total cholesterol, triglycerides, and high-density lipoprotein cholesterol) may
not adequately provide a complete picture of a disease progression because they are restricted to
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a known pathophysiologic pathway or reflect only on a specific aspect of the disease process
[152]. Fortunately, with the emerging of ‘omics’ technology especially metabolomics, an
unbiased approach to study the breadth of metabolite disturbance following a disease state has
become possible [39, 40]. The omics approach has allowed scientists to characterize a complex
myriad of metabolic pathways involving lipids, sugars, organic acids, amino acids and other
small molecule analytes that are the substrates or byproducts of metabolism, or have been
ingested [152].
However, given the infancy age of the omics approach, there are relatively few literatures
pertinent to HD patients. Metabolomics has been used to identify potential cardiovascular risk
biomarkers in several groups [152, 237]. For example, Senn and colleagues studied a large
cohort of patients undergoing coronary angiography and found that several metabolites such as
trimethylamine-N-oxide (TMAO), choline and betaine had a dose-dependent relationship with
regards to the presence of CVD and the severity of atherosclerotic heart diseases [152].
Interestingly, in CKD patients not on dialysis, NMR studies of plasma and urine indicates
accumulation of aliphatic amines including TMAO [238]. In a recent study, Fujiwara and
colleagues utilized metabolomics for pattern recognition analysis to differentiate plasma
metabolic profile of pre- versus post- HD treatment. They found that the NMR spectral pattern of
plasma between pre and post HD treatment was clearly discriminated. Upon identification and
quantification of the metabolites, they found that significant fluctuations were seen in the levels
of creatinine, TMAO, glucose, lactate and acetate when comparing pre- and post- HD plasma
metabolites [239].
In Chapter V, we reported that TT administration in the form of TT-rich fraction (TRF)
in a randomized, double-blinded, placebo-controlled, parallel trial for 16 weeks improved lipid
	
  

132
	
  

profiles in patients undergoing chronic HD as characterized by lower TAG and higher HDLC in
the TRF group when compared to the placebo group. This was correlated with higher ApoA1,
the main protein component of HDLC, while CETP activity, the plasma protein that facilitates
the transport of cholesterol and TAG between lipoprotein was lower in TRF group. Although
there were some reduction trends in inflammatory markers and oxidative status parameters, none
of these achieved statistical significance. Interestingly, TRF group also had relatively less
hospitalization days when compared to the placebo groups. We speculate that no significant
changes were seen in inflammatory markers due to high intra and inter-individual variability of
these markers due to a dynamic response of the immune system, in-concert with other studies
[224, 226]. Hence, such study requires a relatively bigger sample size to increase the statistical
power in order to detect the difference [240]. Therefore, the objective of this specific aim was to
determine whether the TRF supplementation led to overall changes in patients’ metabolomics
profile and whether the observed changes in plasma lipids correlate with their metabolomics
profile. In order to achieve this specific aim, 1H nuclear magnetic spectroscopy (1H NMR) was
utilized to simultaneously analyze numerous metabolites detectable in patients’ plasma sample,
to provide an insight in metabolomics shift overtime and their differences between treatment and
placebo groups. A powerful multivariate data analysis (MVDA) using statistical model such as
principal component analysis (PCA) and partial least square (PLS) was used to analyze this data
set.
Methods
Subjects and study design
This experiment is a subset of the previously reported study (Chapter VI and Daud et al 2013
[208]). The study was approved by the Human Investigation Committees of Wayne State

	
  

133
	
  

University and Great Lake Dialysis, LLC. Procedures for patient selection and randomization
were as reported in Chapter VI. Patients were randomly allocated into treatment group (TRF) or
placebo, and received the respective supplementation for 12 weeks. The study was extended for
another 4 weeks (for a total of 16 weeks) to confirm some substantial changes observed in week12. All of our patients were undergoing dialysis with the same high-flux dialyzer membrane
(Fresenius Optiflux Dialyzer, Fresenius Medical Care, Waltham, MA, USA). Both groups had a
comparable dialysis adequacy (Kt/V) (placebo 1.45±0.20; TRF 1.48±0.26, p=0.516) as estimated
by single-pool model.
Blood sample collection and preparation for NMR analysis
Approximately 5mL of fasting (for ~10 hrs) midweek predialysis blood samples were collected
from existing access sites of each study participant into blood collection tubes containing
lithium heparin (Becton Dickson, Franklin Lakes, NJ, USA) at baseline and week-12. Plasma
was isolated by centrifugation at 2800rpm for 20 minutes at 4oC, divided into aliquots and
immediately stored at -80oC until further analysis.
For NMR analysis, plasma samples were thawed and equilibrated at room temperature.
Upon thawing, plasma samples were centrifuged at 10,000 rpm for 2 minutes to remove solid
debris. An aliquot of 400µL of plasma supernatant were transferred into an assembled Amicon
Ultra 0.5mL 3kDa filter device (Sigma-Aldrich, St. Louis, MO, USA) that had been pre-washed
three times with deionized water (450µL deionized water, spun for 13,800 rpm for 5 minutes
each wash). The filter devices containing plasma were centrifuged for 30 minutes, 13,800 rpm at
room temperature. The ‘filtrates’ were subsequently transferred into new microtubes and were
diluted with deuterium oxide (D2O) (Cambridge Isotope Inc., Andover, MA, USA) in 1:1 ratio
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(300µL filtrate + 300µL D2O). NMR cocktail containing 5mmol/L 3-(trimehylsilyl)-1
propanesulfonic acid (TMS) (Sigma-Aldrich, St Louis, MO, USA) and 10mmol/L Imidazole
(ACROS Organics, Thermo Fisher Scientific, NJ, USA) was added to the diluted plasma samples
in 9:1 ratio. The prepared samples were subsequently transferred to 5mm NMR tubes (8 inches
long) (Sigma-Aldrich, St. Louis, MO, USA). The summary of sample preparation for NMR
analysis is illustrated in Figure 6-1.
Proton 1H NMR acquisition
One dimensional 1H NMR spectra were acquired using a 600MHz Agilent spectrometer,
performed at a temperature of 27oC. The free induction decays (FIDs) were collected into 32K
datapoint, for a total of 64 scans, with a spectrum width of 10 ppm, and an acquisition time of 4
seconds. The water signal was suppressed by a presaturation and set the flip angle to 90o.
Spectral processing
FIDs were processed with ACD software version 12.0 (Advance Chemistry Development, Inc.,
Toronto, ON, Canada) by stacking together as a group, followed by Fourier transformation, autophasing and auto-baseline correction. The whole spectra were divided into 1000 equal bins using
intelligent binning option. The spectra were digitized into a table of common integrals containing
a non-negative value and exported as a text file for multivariate data analysis. Figure 6-2
summarized the spectral processing procedure using ACD software.
Multivariate data analysis
Multivariate data analysis was performed using SIMCA-P 12.0+ (Umetrics, Umea, Sweden).
Briefly, the data text file was imported into the software and transposed. Given that, each row
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represents a case (i.e. a patient) while each column represents a variable (i.e. 1000 binned
spectra) (Figure 6-3).

Data was statistically analyzed using three types of mathematical

algorithm, namely 1) principle component analysis (PCA), 2) partial least square (PLS) and 3)
PLS-discriminant analysis (PLS-DA).

PCA is an unsupervised statistical procedure that is

designed to display the systematic variation in the data matrix X – this is achieved by showing
related observations and deviations/similarities in the data set via a score plot and a loading plot.
PCA is often used for exploratory analysis of the data set. The score plot provides visual
information regarding the similarities/differences in the data while the corresponding loading
plot provides information regarding the variables (the part of spectrum) that is responsible for the
difference/similarities observed in the score plot [151]. PLS and PLS-DA is a supervised method
of analyses. PLS is basically an extension of PCA in which Y variable(s) is added to connect
with the information provided by X variables. In addition, PLS-DA identify the model that
separates the classes of observation based on X variables and hypothetical Y variables.

All x

variables were Pareto’s scaled before multivariate data analysis.
Metabolites identification and quantification
Loading plot of PCA provides a visual indication on the part of the spectra and corresponding
metabolites that are responsible for the differences in metabolic profile between the two groups.
These metabolites were identified and quantified using Chenomx NMR 7.1 suite (Edmonton,
Alberta, Canada). Briefly, FID files were first processed in the Chenomx Processor to adjust for
pH, assign chemical shift indicator and remove line shape distortion by autophasing, autospline
baseline correction and reference deconvolution. The processed spectra were then exported into
Chenomx Profiler for identification and quantification of the metabolites. There were 313 known
metabolites in the Chenomx Profiler (using 600Mhz magnet database) that is specific for
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different magnetic strength and pH ranges. Each metabolite and their corresponding peak
clusters were matched to the existing database and the area under the peak dictates the
concentration of that particular metabolites (Figure 6.4). Data on these quantified metabolites
were exported into SPSS for statistical analysis.
Statistical analysis
Apart from multivariate data analyses as explained above, statistical analyses for the identified
metabolites were carried out using SPSS v.16 (IBM, Chicago, IL, USA). Independence t-test was
applied to test the difference in the metabolites concentration between TRF and placebo groups.
P values of <0.05 is regarded as statistically significant.
Results
Metabolomics profile at baseline
PCA was conducted at baseline to investigate whether the metabolomics profiles between TRF
and placebo groups were different.

The PCA-X score plot at baseline indicates that

metabolomics profiles between the two groups were not different as evident by the scattered and
random scores from both groups in the eclipse. There was no particular pattern observed at this
point (Figure 6-5).
Metabolomics profile at week-12
The same analysis (PCA) was performed at week-12 to investigate the difference in
metabolomics profiles at week-12. PCA-X plot indicates that there was some pattern of scores
between the two groups; however, no clear separation was observed (Figure 6-6). Further
analysis using PLS-DA indicates that there was a clear separation between TRF and placebo
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groups in the PLS-DA score plot by the principal component 1 (Figure 6-7). Hence, this is
suggesting that TRF supplementation induced specific metabolomics pattern change resulting in
different profiles.
Correlation of metabolomics profiles with other parameters
Two-dimensional PLS plots were also performed to investigate predictive effects of plasma
metabolome in relation to known biomarkers. Figure 6-9 shows correlation between
metabolomics profile (x-axis) and inflammatory markers (CRP, IL-6) (y-axis) of the two groups
at week-12. There was a weak correlation (R2=0.38) between metabolomics profile and
inflammatory markers. In other words, the PLS regression between the plasma metabolome from
NMR and plasma inflammatory markers indicate that 38% of the variations in the inflammatory
markers can be predicted by the treatment conditions (placebo vs TRF).
Similarly, the PLS analysis between plasma metabolomics profiles and plasma oxidative
status (TAP and MDA) revealed a weak correlation (R2=0.26) (Figure 6-10). This may indicate
that plasma TAP and MDA have less predictive power towards the changes in metabolomics
profile.
Meanwhile, plasma HDLC (Figure 6-11) and lipid profiles (TC + TAG + HDLC)
(Figure 6-12) were also moderately correlated with plasma metabolomics profile (R2=0.49 and
R2=0.60, respectively) indicating that the observed change in plasma HDLC and lipid profiles
were reflected in the change in concentration of metabolites present in the plasma. Based on this
result, 60% of the variations in the lipid profiles can be predicted by the treatment group
allocation. This is also in concert with the fact that most changes in lipid profile were seen at
week-12 of the intervention.
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Metabolites identification and quantification
PCA loading plot (Figure 6-8) provides a guide on the part of the spectra that is responsible for
the differences observed between TRF and placebo groups at week-12. By using Chenomx NMR
Suite software, a total of 33 metabolites were identified and quantified. These metabolites were
significantly different (p<0.05) or approached significance (0.05<p<0.10). However as the
metabolites were analyzed from 4 subjects per treatment – the fact that some metabolites were at
the lower limit of detection in one or two subjects per treatment, invariably skewed group means
in certain cases. Regardless, some of these metabolites included various compound classes such
as amino acids (e.g. histidine, methionine), carbohydrates (e.g. galactose, lactose), organic acids
(e.g. lactate) and phospholipids related compound. Some of the metabolites that have been
previously shown to be implicated in CKD included 2-Hydroxyglutarate, 3-Hydroxy-3methylglutarte, Betaine, Cadaverine, Glycerate, Mandelate, Proline and 2-Hydroxy-3methylvalerate as well as Citrate, N-acetylaspartate, N-acetylcysteine and Ribose. However until
analyses from more subjects is completed no definitive statement or conclusion can be made.
Discussion
In this experiment, we showed that plasma metabolomic profiles of HD patients between TRF
and placebo group did not show any different at baseline. After 12 weeks of supplementation,
initial analysis using unsupervised PCA of the plasma metabolic profiles did not indicate obvious
treatment related effects, with only some pattern of separation at principle component 1.
However, by using PLS-DA modeling, TRF group’s plasma metabolomic profile was clearly
discriminated from the placebo group. The fact that plasma metabolomic profiles were different
between the two groups after 12 weeks of intervention may indicate 1) real effects of TRF that
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induced metabolic changes reflected in the plasma metabolic profiles, or 2) potential
confounders such as medications, dietary intake and life style, that could influence metabolic
changes. To complicate things, there are also lines of evidence reporting the impact of gut
bacteria on the metabolome [148].
It is unlikely that dietary intake/pattern of a stable chronic dialysis patient had changed
partly because of diet monotony due to dietary restrictions, which have been consistently
reported in the literature [32, 241, 242]. However, it is possible that diversity in medication
profiles of HD patients may contribute to variations in metabolic profiles, resulting in artifact
and misinterpretation. Given the significant co-morbidity experience by HD patients, many of
our patients were on a handful of medication such as anti-hypertensive drugs (e.g. atenolol,
amlodipine, losaratan), blood-thinning medication (e.g. aspirin), diuretics (e.g. furosemide),
lipid-lowering drug (e.g. statins), and phosphate binders (e.g. calcium acetate). It is almost
impossible to control on this aspect given the ‘intention to treat’ nature of the clinical study. In
order to overcome such variations, one may require a relatively larger sample size as compared
to animal, or cell metabolomics studies [150], but this may not be feasible. Therefore, the
preferred strategy to overcome this variability is to perform a small-scale untargeted approach as
outlined by Mamas and colleagues:
“In metabolomic studies of the general population, the preferred strategy is to perform two
independent small-scale holistic studies (defined as discovery and validation) where the
number of samples is typically 10–100s and where many potential confounders (e.g. age, BMI,
gender) are controlled so that the only ‘random’ variable between classes is the disease or
drug treatment. These studies define potential biomarkers or disease pathophysiology”

Mamas et al. (2011) [150].
Given limited funding and time constraints, we streamlined this experiment in order to
evaluate the actual effects of TRF by selected patients with similar medication and demographic
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profiles. As discussed earlier, we found that the metabolomic profiles of TRF and placebo groups
were clearly discriminated at week-12 but not at baseline; suggesting TRF induced metabolic
pattern change. Furthermore, based on two-dimensional PLS analysis, metabolomic profile of the
patients at week-12 was significantly correlated with lipid profiles in-concert with the changed in
lipid profile measurements. Interestingly, PLS tests also indicate that plasma metabolomics
profiles were correlated with serum albumin and inflammatory markers. This is an intriguing
observation given the fact that we did not see any difference in serum albumin and inflammatory
markers [208] which may suggest the need for a bigger sample size due to high variability in
these traditional biomarkers. However, the correlation between metabolomics profiles and
inflammatory biomarkers may need to be viewed in relation to anti-inflammatory properties of
aspirin due to the fact that all subjects in this subset analysis were prescribed aspirin
(acetylsalicylic acid). Interestingly, removal of aspirin peak clusters (2.32, 7.13, 7.145, 7.35,
7.37, 7.50, 7.51, 7.52, 7.67, 7.68ppm) in the spectra database from the SIMCA software prior to
MVDA analysis did show the same pattern of discrimination, suggesting the minimal effects of
aspirin as anti-inflammatory agent.
Based on the preliminary metabolites identification data, several metabolites that were
identified appear to be involved in CKD. Betaine is a metabolite of choline and recent evidences
indicate that increased levels of choline, betaine and TMAO are associated with increased risk
for cardiovascular diseases [152, 243]. 3-hydroxy-3-methylglutarate (HMG),	
   is	
   a metabolite that
accumulates in the urine of patients affected by 3-Hydroxy-3-methylglutaric aciduria. Recent
evidence indicates that accumulation of HMG in the plasma is associated with lipid and protein
oxidative damage as well as reduce enzymatic antioxidant defense in rat cerebral cortex [244]. It
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is postulated that the accumulation of HMG in ESRD patients may be due to residual uremia
because dialysis does not effectively remove uremic toxins.
Cadaverin and some other polyamines have been reported to increase in the late stage of
CKD and in HD patients [245]. Accumulation of cadaverin is associated with suppression of
erythropoiesis [246] leading to hyporensponsive of

anemia treatment by Epogen (human

erythropoietin produced via recombinant DNA technology), resulting in higher dosage
requirement [245, 247]. This is exemplify by the fact that patients on peritoneal dialysis
treatment are generally less anemic than those on HD [248, 249] due to a more efficient middle
molecules removal [245, 248] and frequent dialysis (four times daily vs three times a week). It is
interesting that recent publication indicate that supplementation with vitamin E improved
Epogen responsiveness in HD patients [250], suggesting a potential target of vitamin E on
uremic toxins that contribute to erythropoiesis suppression. Cruz et al reported that the use of
vitamin E coated membranes in 172 maintenance HD patients leads to reduction of Epogen
dosage and improved hemoglobin levels [251].
Because kidney plays an important role in the metabolism of protein and amino acids,
kidney failure results in alteration of plasma amino acids (AA). It has been found that plasma
concentration of citrulline, cysteine and taurine are increased in the early stage of CKD [252].
On the other hand, most plasma AA in the late stage of CKD and in ESRD undergoing HD
treatment showe a decreased except for proline, asparagine, citrulline, asymmetric
dimethylarginine and hydroxykynuerenine that show an increase in their levels [253]. This
increased is hypothesized to be due to uremic retention and/or systemic over production. It has
also been reported that the changes in plasma AA are associated with disease severity as
indicated by the significant correlation in eGFR in a multivariate model [253].
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Some other metabolites of interest in the initial anlayses include N-acetylcysteine and Nacetylaspartate. It is interesting that, levels of N-acetylaspartate and N-acetylaspartylglutamate
(based on magnetic resonance spectroscopy of the brain) have been found to be reduced in
dialysis patients, and these are associated with attention deficit, as well as disturbances in
memory and learning activity [254]. This phenomenon has been postulated to be related to the
accumulation of neurotoxic metabolites, hormonal disturbance and an imbalance in excitatory
and inhibitory neurotransmitters following kidney failure [254, 255]. On the other hand, Nacetylcysteine confers antioxidant effect due to the presence of thiol groups in its molecular
structure. N-acetylcysteine has been used as adjunct treatment during chemotherapy for the
cancer treatment [256] and in the management of anemia and oxidative stress in HD patients
[257]. Thus a complete analysis from the current sample set will yield important and exciting
clues on the metabolic effects of TRF supplementation
Literature pertaining to metabolomics application in HD/ESRD patient is very scarce,
therefore no direct comparisons are available. Only a few studies have explored the utilization of
this technology especially for diagnostic purposes. For example, Sato et al [258] explored
metabolomics analysis of plasma sample of pre- and post- HD treatment, and subsequently
identified potential novel biomarkers that can be used as alternatives to urea and creatinine to
determine dialysis dose adequacy. Fujiwara et al [239] utilized metabolomics approach for
pattern recognition analysis and found that NMR spectra between pre and post HD treatment was
clearly discriminated due to fluctuation in the levels of creatinine, TMAO, glucose, lactate and
acetate. Interestingly, both of the studies did not report their patients’ medication profiles.

	
  

143
	
  

Future directions
Based on the multivariate data analysis of the plasma metabolomics profile to date, it is now
understood that supplementation with TRF triggers some metabolic changes which appear to be
reflected in the plasma metabolites. Preliminary metabolite identification and quantification
revealed several metabolites that responsible for the differences between TRF and placebo
groups. These metabolites however need to be firstly confirmed and secondly, validated with
biochemical assays for confirmation. Upon validating these metabolites, they should be
compared to known biochemical pathways to examine their relevance in the disease process as
well as in diagnostic and treatment aspects in relation to TRF supplementation.
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Table and Figures
TABLE 6-1. Characteristics of the samples for metabolomic analysis.

Demographics
Age (yrs)
African American (n, %)
Gender (males, %)
Clinical
Diabetes Mellitus (n, %)
Time on dialysis (months)
BMI (kg/m2)
Kt/v
Statins (n, %)
Aspirin (n, %)
Anti-hypertensive, one or more type
(n,%)

Placebo
(n=9)

TRF
(n=8)

P value

54
9 (100)
5 (55.6)

59
8 (100)
5 (62.5)

N.S.
N.S.
N.S.

6 (66.7)
32
29.3
1.48
0 (0)
9 (100)

5 (62.5)
35
27.9
1.45
0 (0)
8 (100)

N.S.
N.S.
N.S.
N.S.
N.S.
N.S.

9 (100)

8 (100)

N.S.

Note: Data are reported as mean for continuous variables and number (percentage) for categorical
variables. P values are comparison between groups obtained from independent t-test or Pearson χ2 test
wherever appropriate.
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FIGURE 6-1. Sample preparation for NMR analysis
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Note: This figure illustrates steps during sample preparation for NMR analysis: 1) Blood sample were
collected into lithium heparin tubes, 2) Plasma was obtained by centrifugation, 3) Plasma was transferred
into a clean micro tube for storage, 4) Sample was stored at -80oC until use, 5) Frozen plasma was thawed
at room temperature, 6) High molecular weight compound was removed via 3kDa ultracentrifugation
device, 7) ‘Filtrate’ was used for NMR analysis. During this step, sample was spiked with the internal
standard (TMS) and pH indicator was added. 8) A total of 600µL sample (diluted 1:1 in deuterium oxide)
was used for NMR FID acquisition.
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FIGURE 6-2. Illustration for processing of NMR spectra using ACD software v. 12.0

1	
  	
  

All FID files acquired from 600 MhZ
1
H NMR were imported into ACD
software. The x-axis represents the
time domain.

2	
  
	
  
The
FID
files
were
Fourier
transformed followed by auto-phasing
and auto adjustment for baseline.
Reference peak (TMS) were also set at
0 ppm. The x-axis represents chemical
shift (ppm).

3	
  
	
  
The spectra were divided into 1000
equal bins. Each bin represents one
variable.

4	
  	
  
The values from each bin are digitized
into a non-negative numbers as a table
of common integrals (TOCI). TOCI is
then exported to SIMCA P+ software
as a text file.
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FIGURE 6-3. Multivariate data analysis processes using SIMCA-P 12.0+ software

Note: This figure shows a screen capture of multivariate data analysis (MVDA) processes from SIMCAP 12.0+ software (Umetrics, Umea, Sweden). Upon importing table of common integral from ACD
software, the data was transposed so that each column represents a variable while each row represents an
observation (subject). The primary ID column (dark yellow) represents the particular subjects while the
secondary ID dictates their group allocation. The data was further edited by removing corresponding
variables that did not contain any peak on the spectrum (i.e. <0.5ppm and >8.0ppm), prior to running
MVDA.
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FIGURE 6-4. Metabolites identification and quantification using Chenomx software.

Note: This figure shows one of the processes of metabolites identification and quantification
using Chenomx NMR Suite 7.7. The processed NMR file (following phasing, baseline correction
and reference deconvolution) was exported into Chenomx Profiler. Each peak cluster in the
NMR spectrum was manually matched with the database. In this example, lactate comprised of
two peak clusters (i.e. at 4.1 and 1.3 ppm). Each peak cluster needs to be matched with the
pattern of peak cluster in the database. The software will calculate the concentration of the
particular metabolite based on the matched peak clusters area.
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FIGURE 6-5. PCA score plot for NMR spectra obtained from plasma samples of HD patients at
baseline.
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SIMCA-P+ 12 - 2014-01-16 12:34:20 (UTC-5)

Abbreviations: PCA, principal component analysis; PLA, placebo; TRF, tocotrienol-rich fraction.
Note: This figure depicts PCA-X score plot indicating metabolomics profile between the two groups at
baseline. The eclipse represents the 95th percentile of confidence interval, while any score outside of the
eclipse is consider as an outlier. One outlier score was excluded from the analysis. Water peaks region
(4.5 – 5.0 ppm) were removed from the data prior to analysis. The score for TRF and placebo groups were
scattered indicating that the metabolomics profiles between the two groups were similar.
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FIGURE 6-6. PCA score plot for NMR spectra obtained from plasma samples of HD patients at
week-12.
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Abbreviations: PCA, principal component analysis; PLA, placebo; TRF, tocotrienol-rich fraction.
Note: This figure depicts PCA-X score plot indicating metabolomics profile between the two groups at
week-12. The eclipse represents the 95th percentile of confidence interval, while any score outside of the
eclipse is considered as an outlier. One outlier score was excluded from the analysis. Water peaks region
(4.5 – 5.0 ppm) were removed from the data prior to analysis. The score plot shows there was separation
trend indicating that metabolomics profiles of the two groups were discriminated.
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FIGURE 6-7. PLS-DA score plot for NMR spectra obtained from plasma samples of HD
patients at week-12.
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Abbreviations: PLS-DA, partial least square – discriminant analysis; PLA, placebo; TRF, tocotrienol-rich
fraction.
Note: This figure shows PLS-DA score plot depicting metabolomics profile of the two groups at week-12.
The eclipse represents the 95th percentile of confidence interval, while any score outside of the eclipse is
considered as an outlier. One outlier observation was excluded from the analysis. Water peaks region
(4.5 – 5.0 ppm) were removed from the data prior to analysis. Metabolomics profile of the two groups
was clearly discriminated as indicated by a clear separation trend.

	
  

152
	
  

FIGURE 6-8. PCA-X loading plot for NMR spectra obtained from plasma samples of HD
patients at week-12.
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Abbreviations: PCA, principal component analysis.
Note: This figure shows the corresponding PCA-X loading plot for Figure 6-6. The loading plot provides
information regarding the part of the spectrum that was different or common between the two groups. The
dense, dark area represents common metabolites (part of spectrum) that are shared between the two
groups while the isolated plots indicate the part of the spectrum that responsible for the difference (yellow
circles).
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FIGURE 6-9. PLS score plot for correlation between metabolomics profile and inflammatory
markers at week-12.
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Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; CRP, C-reactive
protein; IL-6, interleukin-6.
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and
inflammatory markers (CRP, IL-6) (y-axis) of the two groups at week-12. There was a moderate
correlation (R2=0.38) between metabolomics profile and inflammatory markers. This result indicates that
there are some metabolites in the plasma sample that are correlated with the inflammatory markers.
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FIGURE 6-10. PLS score plot for correlation between metabolomics profile and oxidative status
biomarkers (TAP, MDA) at week-12.
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Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; TAP, total
antioxidant power; MDA, malondialdehyde.
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and
total antioxidant capacity (y-axis) of the two groups at week-12. There was a moderate correlation
(R2=0.26) between metabolomics profile and TAP. This result indicates that there are some metabolites in
the plasma sample that are correlated with the TAP.
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FIGURE 6-11. PLS score plot for correlation between metabolomics profile and plasma HDLC
at week-12
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Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; HDL-C, highdensity lipoprotein cholesterol.
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and
total antioxidant capacity (y-axis) of the two groups at week-12. There was a moderate correlation
(R2=0.49) between metabolomics profile and HDL-C. This result indicates that there are some
metabolites in the plasma sample that are correlated with the HDL-C.
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FIGURE 6-12. PLS score plot for correlation between metabolomics profile and plasma lipid
profiles (TC, TAG, HDLC) at week-12
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Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction; TC, total
cholesterol; TAG, triacylglycerols; HDL-C, high-density lipoprotein cholesterol.
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and
plasma lipid profiles (TC, TAG, and HDL-C) (y-axis) of the two groups at week-12. There was a
moderate correlation (R2=0.60) between metabolomics profile and lipid profiles. This result indicates that
there are some metabolites in the plasma sample that are correlated with the lipid profiles.
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FIGURE 6-13. PLS score plot for correlation between metabolomics profile and serum albumin
at week-12.
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Abbreviations: PLS, partial least square; PLA, placebo; TRF, tocotrienol-rich fraction
Note: This figure shows PLS score plot depicting correlation between metabolomics profile (x-axis) and
serum albumin levels (as a marker of nutritional status) (y-axis) of the two groups at week-12. There was
a moderate correlation (R2=0.65) between metabolomics profile and lipid profiles. This result indicates
that there are some metabolites in the plasma sample that are correlated with the serum albumin levels.
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CHAPTER VII
CONCLUSION AND RECOMMENDATIONS
Conclusion
The aim of the first study was to evaluate the effects of omega-3 combined with hydrolyzed
protein supplementation on the nutritional status, inflammatory markers and lipid profiles in
chronic HD patients. The study was designed in such way that supplementation intake can be
directly monitored in real-time in order to maximize the compliance given the fact that our study
population was mainly comprised of low-income and low-literacy group which often associated
with poor compliance. We found that omega-3 group had significant improvement in
LDLC/HDLC ratio while TAG was marginally improved. However, no significant different were
seen in nutritional and inflammatory parameters between placebo and omega-3 groups after 6months of supplementation. While compliance was excellent in patients who attended the
treatment session, significant numbers of patients missed the treatment due to hospitalization,
thus also missed their supplementation – this potentially had an impact on the overall study
results. Results from this study support the hypothesis that the combination of omega-3 and
protein supplementation improve lipid profiles but fail to show significant effect on
inflammatory and nutritional indicators.
Following a successful ‘directly observed treatment’ approach in omega-3 study, a
second study was administered using vitamin E tocotrienols (TRF), a nutritional agent that
exhibit antioxidant, anti-inflammatory with a potential lipid altering effects in the same cohort of
the patients. Given the significant comorbidities experienced by these patients that resulted in
significant hospitalization and missed dialysis treatment in the first study, therefore additional
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steps were taken in order to improve compliance in administering the supplements. Patients were
provided with capsule organizer for supplement supply during non-dialysis days and compliance
were monitored via pill counting method and ‘directly observed treatment’. Additional
monitoring on dietary changes (through 24-hr diet recalls) was also implemented. The results
showed that TRF supplemented group had significant improvement in lipid profiles as indicated
by a lower TAG, and higher HDLC at week-12 and week-16 of the study when compared to the
placebo group. Interestingly, TRF group also exhibit less total hospitalization days as compared
to the placebo group. However, TRF supplementation did not significantly impact any
nutritional, inflammatory and oxidative status biomarkers.
Following the unexpected outcomes in lipids, we sought to investigate further on several
key components of lipid metabolism namely, CETP and ApoA1. We found that the change in
TAG and HDLC seen in TRF group were related to a higher ApoA1 concentration and lower
CETP activity, indicating a potential increase in HDL particle in TRF group. As a conclusion,
further study in a larger cohort of patients (multi-center) is needed to confirm this observation.
Furthermore, an increased in sample size will allow sub-group analyses to elucidate the
cofounding effect of various medications and underlying diseases in this population.
Given the limitation of the traditional biomarkers to provide information on a global
impact of TRF supplementation, the metabolomics approach was used to elucidate whether the
TRF supplementation lead to overall changes in patients’ metabolomics profile and whether the
observed changes in plasma lipids correlates with their metabolomics profile. Based on the
multivariate data analysis (PCA, PLS-DA), it was shown that metabolomics profiles of TRF
group were different from placebo group at week-12 of the intervention. Moreover,
metabolomics profile in both TRF and placebo group was correlated with inflammatory markers
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and lipid profiles suggesting that some plasma metabolite could predict/ responsible for the
changes in lipid profiles and inflammatory markers. Preliminary results from metabolites
identification and quantification revealed that TRF supplementation triggered metabolic changes
leading to either reduction or increased in several metabolites that have been reported otherwise.
These

include

reduction

in

2-Hydroxyglutarate,

3-Hydroxy-3-methylglutarte,

Betaine,

Cadaverine, Glycerate, Mandelate, Proline and 2-Hydroxy-3-methylvalerate. On the other hand,
metabolites that were significantly higher in TRF group include Citrate, N-acetylaspartate, Nacetylcysteine and Ribose. Further study is needed to validate the respective metabolites that
contribute to the different metabolomics profile in TRF group with biochemistry test.

Recommendations and future directions
The first study added to the known knowledge regarding omega-3 fatty acids effects on lipid
profiles, particularly in reducing TAG. However, additional study in a larger scale is needed to
confirm omega-3 fatty acids effects on inflammatory markers since literature in this area is still
ambiguous, partly due to high variability in the inflammatory markers. Such study should also
include measurement of plasma fatty acids together with dietary records to confirm compliance.
The second study has provided exploratory data on the benefit of tocotrienol
supplementation particularly in improving lipid profiles. However, given the shortcomings of the
study and the fact that it was conducted in a homogenous population, the impact of TRF in a
diverse dialysis population is unknown and yet to be recommended. Therefore, the precedent
study should consider a multi-center approach to confirm the current observation, improve the
study’s power and enable subgroup analysis (e.g. diabetic vs non-diabetic; statin vs non-statin
users). Future study should incorporate more robust measurements for lipids and inflammatory
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parameters (e.g. LCAT, lipoprotein particle size, cytokines and pro-inflammatory eicosanoids) to
understand the mechanism of action. Moreover, a dose escalation study should also be
considered to identify optimum dosage and duration to achieve the target lipid and inflammatory
parameters as well as to recognize adverse effects (if there is any, especially at higher dosage).
It would also be of interest to investigate synergistic effects of omega-3 and TT in this
population. Finally, intervention aimed at improving inflammatory biomarkers would require a
large study population and extensive funding due to a substantial variability in these biomarkers.
However, with the use of metabolomics approach, overall understanding of cardiovascular
disease states beyond traditional biomarkers will facilitate discovery of novel biomarkers and
metabolic pathways.
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APPENDIX A: 24-HOUR DIETARY RECALL FORM
Name:

Date:

Time /
Meals

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

Food eaten

	
  

Quantity /
portion size /
amount/ numbers
	
  

Remarks
(if appropriate – add additional
information)
(e.g. how prepared?, brand
name?, added cream/sugar, where
eaten?)
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APPENDIX B: EXAMPLE OF DIETARY ANALYSIS PERFORMED USING
NUTRITIONIST PRO
Menu Template Nutrient Analysis
Total Days: 1
Total Foods: 16

Avg. Daily Kcals: 2186.680
Nam e:
20b

Nutrient

Value Unit

Weight
Kilocalories
Protein

1914.2 g
2186.7 kcal
111.4 g

Carbohydrate
Fat, Total
Alcohol
Cholesterol
Saturated Fat

224.9
95.0
0.0
719.9
27.9

g
g
g
mg
g

Goal

%

2000.0
50.0

109 %
223 %

300.0
65.0

75 %
146 %

300.0
20.0

240 %
140 %

Nutrient

Value Unit

Phosphorus
Iodine
Magnesium

1365.460 mg
218.531 mg

Zinc
Copper
Manganese
Selenium
Fluoride

10.774
0.847
1.340
139.567
265.774

mg
mg
mg
µg
µg

Goal

%

1000.000
150.000
400.000

137 %

15.000
2.000
2.000
70.000

72 %
42 %
67 %
199 %

Nutrient Goal Tem plate
DAILY VALUES/RDI - ADULT
Analyzed by

55 %

Zul

Percentage of Kcals
Protein
Carbohydrate

20.2%
40.9%

Fat, total

0.389

Alcohol

Monounsaturated Fat
Polyunsaturated Fat
MFA 18:1, Oleic
PFA 18:2, Linoleic

37.1
21.1
32.4
14.6

g
g
g
g

Chromium
Molybdenum
Dietary Fiber, Total
Soluble Fiber
Insoluble Fiber
Crude Fiber
Sugar, Total
Glucose
Galactose
Fructose
Sucrose

PFA 18:3, Linolenic
PFA 20:5, EPA
PFA 22:6, DHA
Trans Fatty Acid
Sodium
Potassium
Vitamin A (RE)

1.5
0.0
0.0
0.0
4279.4
3377.7
651.8

g
g
g
g
mg
mg
RE

Vitamin A (IU)
Vitamin A (RAE)
Beta-Carotene
Alpha-Carotene
Lutein (+ Zeaxanthin)
Beta-Cryptoxanthin
Lycopene
Vitamin C
Calcium
Iron
Vitamin D (ug)
Vitamin D (IU)
Vitamin E (mg)
Vitamin E (IU)
Alpha-Tocopherol
Thiamin
Riboflavin
Niacin
Pyridoxine (Vitamin B6)
Folate (Total)
Folate (DFE)
Cobalamin (Vitamin B12)
Biotin
Pantothenic Acid
Vitamin K

3773.9
505.6
1680.4
274.5
1943.0
0.0
1210.0
490.1
561.7
14.6
1.2
49.6
6.1
9.1
1.4
3.9
2.2
24.5
1.7
245.2
259.9
3.7
24.1
4.2
27.7

IU
µg
µg
µg
µg
µg
µg
mg
mg
mg
µg
IU
mg
IU
mg
mg
mg
mg
mg
µg
µg
µg
µg
mg
µg

Tuesday, October 01, 2013

2400.0
3500.0

178 %
97 %

5000.0

75 %

60.0
1000.0
18.0
10.0
400.0
20.0
30.0

817 %
56 %
81 %
12 %
12 %
30 %
30 %

1.5
1.7
20.0
2.0
400.0

263 %
127 %
122 %
86 %
61 %

6.0
300.0
10.0
80.0

62 %
8%
42 %
35 %

0.074
185.911
12.958
0.000
0.000
4.369
21.292
4.864
0.000
4.314
8.605

mg
µg
g
g
g
g
g
g
g
g
g

0.120
75.000
25.000

62 %
248 %
52 %

0.0%

Exchanges
Bread/Starch
Fat
Fruit
Meat-High Fat
Meat-Medium Fat
Other Carbohydrate
Vegetable

6
6.50
6.50
0.50
11.00
0.50
4.00

Lactose
0.000 g
Maltose
0.495 g
Sugar Alcohol
Other Carbohydrate
Tryptophan
1239.329 mg
Threonine
4535.460 mg
Isoleucine
4730.796 mg
Leucine
8138.050 mg
Lysine
8166.761 mg
Methionine
2613.008 mg
Cystine
1531.321 mg
Phenylalanine
4439.847 mg
Tyrosine
3507.970 mg
Valine
5309.381 mg
Arginine
6189.328 mg
Histidine
3439.898 mg
Alanine
5737.192 mg
Aspartic Acid
9574.290 mg
Glutamic Acid
16841.620 mg
Glycine
4990.013 mg
Proline
4971.783 mg
Serine
4830.367 mg
Moisture
972.189 g
Ash
19.200 g
Caffeine
137.460 mg
Page

First DataBank Nutritionist Pro™

Note: Example of the output from analysis of energy and nutrients intake from one subject using
Nutritionist Pro.
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APPENDIX C: COMPLIANCE MONITORING FORM
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APPENDIX D: QUANTITATIVE ANALYSIS OF TOCOTRIENOL LEVELS BY
EXTERNAL LABORATORY
Introduction
In this study HPLC was used for separation, determination and quantification of individual
tocotrienol levels in human plasma after the oral administration of TRF (fasting plasma samples).
Materials and Methods
Sample Preparation
Human plasma samples were stored at -80oC until use. For extraction, 150 µL of plasma was
added to a glass tube with screw cap and kept on ice. To this 2 mL of 1% ascorbic acid in ethanol
(w/v), 900µL of deionized water, 25 µL of 1% BHT (w/v) in ethanol and 2 mL of hexane were
added. The tubes were screw capped and contents were mixed by hand inversion followed by
centrifugation at 1000rpm for 4 min. After the phase separation, supernatant hexane layer was
taken into a new labeled test tube which consists of lipophilic tocopherols and tocotrienols. The
extraction was repeated by adding 2 mL of hexane and mixing it by hand inversion followed by
centrifuigation at 1000 rpm for 4 min. The supernatant hexane layer was added to the previous
extract and dried under vacuum with centrifugal evaporator. The residue obtained is suspended
in 200 µL of mobile phase and placed in deactivated glass auto-injector insert for analysis.
Chromatographic conditions
Analysis of tocotrienols was performed according to the method described below. An aliquot of
20 µL was injected into HPLC system (Dionex) coupled to Dionex RF 2000 floerescene
detector. The pump was run at a flow rate of 1.8ml/min and the mobile phase used was
composed of methanol, isopropanol, NaClO4 (85.10.5). Mobile phase was filtered through 0.2
µm nylon membrane before use. The total run time was 18 min and chromatographic separation
was carried out by a phenomenex reversed phase column (5µm, 4.6mm x 250mm). The eluate
was monitored for peaks by fluorescence detector set at excitation wavelength of 296nm and
emission wavelength of 330nm. Calibrations were linear for the determination of α-tocopherol
and γ-tocotrienol.
Standard curve and linearity
Stock solution of γ-tocotrienol and α-tocopherol (1mM) were prepared in mobile phase. For
standard curve, γ-tocotrienol was diluted by mobile phase to give concentration of 0.05, 0.1,
0.25, 0.5, 1 and 2 µM and α-tocopherol was diluted to 0.1, 0.25, 0.5, 1, 2.5 and 5 µM. The
retention time for γ-tocotrienol and α-tocopherol were found to be 7.1min and 14.2 min (appox.).
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Results
All the standard and test samples were run for analysis and images are shown below. Individual
tocotrienols were shown in following Table.
Sample #
Placebo 1
Placebo 2
Placebo 3
Placebo 4
Placebo 5
TRF1
TRF2
TRF3
TRF4
TRF5
ND

	
  

ND

ND

ND

γ-tocotrienol
Peak
Conc.
area
(ng in
100µL)
ND
ND
ND
ND
ND
ND
ND
ND
12114
0.24
144047
0.14
197457
0.4
ND
ND
ND
ND
ND

α-tocotrienol
Peak
Conc.
area
(ng in
100µL)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND

δ-tocotrienol
Peak
Conc.
area
(ng in
100µL)
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
3225131

α-tocopherol
Peak area Conc.
(ng in
100µL)
1921577
157
1576941
103
1172591
100.2
1137831
52.7
635672
209
1576941
134.6
3019545
226.5
2273772
203.9
3548170
270.9
269.2
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ABSTRACT
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Mortality rate in patients undergoing chronic hemodialysis (HD) in the United States
remain unacceptably high despite improvement in dialysis technology. Cardiovascular disease
(CVD) account for more than 50% of the premature death in this population. Evidences indicate
that the accelerated CVD are attributed to by malnutrition, inflammation, dyslipidemia and
oxidative stress. Dietary intervention using nutrients with antioxidant, anti-inflammatory, and
potential lipid altering properties to correct the aforementioned problems remain inconclusive.
Furthermore, such nutritional intervention trial is often hampered by poor compliance related to
medical and socioeconomic barriers. Therefore, a series of randomized, double-blind, placebocontrolled, parallel trials were undertaken to document the technical feasibility of ‘directly
observed treatment’ and the global impact of several nutrients namely omega-3 and vitamin E
tocotrienols on nutritional and oxidative indicators, inflammatory markers and lipid profiles in a
cohort of chronic HD patients.
The objective of the first study was to evaluate the impact of omega-3 plus liquid protein
supplement on serum albumin, plasma lipids and other indicator of nutrition and inflammation.
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markers. The study recruited 63 subjects and they were randomized into placebo+protein (n=32)
and omega-3+protein (n=31) groups. The two intervention groups received 30mL of a liquid
protein plus 2.4g omega-3 or placebo, three times per week after their routine dialysis session for
6 months. Directly observed nutritional supplement resulted in significant improvement in the
LDLC/HDLC ratio in the omega-3 group as compared to the placebo group (P=0.043). In the
omega-3 group, serum albumin was also marginally higher after 6 months as compared to the
baseline (P=0.07). The observed increase in CRP levels in the placebo group over 6 months was
not apparent in the omega-3 group, although there was no significant difference between groups.
NFκB, MIS, nPNA, BMI and hemoglobin were unaffected by the intervention. Therefore, it is
conclude that ‘directly observed treatment’ with an omega-3 based supplement (as opposed to a
pure protein supplement) showed beneficial effects on lipid profile, and CRP levels. Further
studies using a combination of outpatient and inpatient ‘directly observed treatment’ is
warranted.
Given a proven feasibility of directly observed treatment in the first study, we conducted
a second study using tocotrienol rich fractions (TRF) by incorporating the same design to
maximize compliance but with additional take home supplements. Vitamin E tocotrienols have
been reported to confer anti-inflammatory, antioxidant and a potential of lipid altering benefits in
vitro, in vivo and in some other clinical population. However, the impact of this nutrient in HD
population is unknown. Subjects were provided daily with capsules containing either vitamin E
tocotrienol-rich fraction (TRF) (180 mg tocotrienols, 40 mg tocopherols) or placebo (0.48 mg
tocotrienols, 0.88 mg tocopherols). For the results, TRF supplementation did not impact any
nutritional, inflammatory, or oxidative status biomarkers over time when compared with the
baseline within the group (one-way repeated measures analysis of variance) or when compared
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with the placebo group at a particular time point (independent t-test). However, the TRF
supplemented group showed improvement in lipid profiles after 12 and 16 weeks of intervention
when compared with placebo at the respective time points. Normalized plasma triacylglycerols
(cf baseline) in the TRF group was reduced by 33 mg/dL (P=0.032) and 36 mg/dL (P=0.072)
after 12 and 16 weeks of intervention but no significant improvement was seen in the placebo
group. Similarly, normalized plasma high-density lipoprotein cholesterol was higher (P<0,05) in
the TRF group as compared with placebo at both week 12 and week 16. The changes in the TRF
group at week 12 and week 16 were associated with higher plasma apolipoprotein A1
concentration (P<0.02) and lower cholesteryl-ester transfer protein activity (P<0.001).	
   As a
conclusion, TRF supplementation improved lipid profiles in the study of maintenance HD
patients. A multi-centered trial is warranted to confirm these observations.
Finally, following a positive impact of TRF supplementation on lipid profiles, we
undertook a metabolomics approach to investigate whether the TRF supplementation lead to
overall changes in patients’ metabolomics profile and whether the observed changes in plasma
lipids correlates with their metabolomics profile. Based on the principal component analysis
(PCA), there was a separation pattern between the TRF and placebo groups at week-12. After
applying partial least square-discriminant analysis (PLS-DA), there was a clear separation
between the two groups indicating different metabolomics profiles. In addition, metabolomics
profile in both TRF and placebo group was correlated with inflammatory markers and lipid
profiles suggesting that some plasma metabolite could predict/ responsible for the changes in
lipid profiles and inflammatory markers.
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